Список литературы

Номер в рекоменд. Ссылка 1. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sexspecific mortality for 282 causes of death in 195 countries and territories, 1980- 2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1736-1788. doi: 10.1016/S0140-6736(18)32203-7. Epub 2018 Nov 8 2. Townsend N, Kazakiewicz D, Wright FL, et al. Epidemiology of cardiovascular disease in Europe. Nat Rev Cardiol. 2022 Feb;19(2):133-143. doi: 10.1038/s41569-021-00607-3. Epub 2021 Sep 8 3. Townsend N, Wilson L, Bhatnagar P, et al. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J. 2016 Nov 7;37(42):3232-3245 4. Российский статистический ежегодник. 2021: Стат.сб./Росстат. – М., 2021 – 692 с 5. Демографический ежегодник России. 2021: Стат.сб./ Росстат. - M., 2021. – 256 c 6. Бойцов С.А. Грипп, новая коронавирусная инфекция и сердечно-сосудистые заболевания. Кардиологический вестник. 2021;16(1):5‑9 7. Погосова Н. В., Оганов Р. Г., Суворов С. В. Почему в Москве смертность от сердечно-сосудистых заболеваний ниже, чем в других регионах Российской Федерации? Кардиоваскулярная терапия и профилактика, 2015; 14(2): 4–12 8. Pogosova N, Oganov R, Saner H, et al. Potential and limitations of health policy to improve coronary heart disease prevention and to reduce the burden of disease: A Russian experience. Eur J Prev Cardiol. 2018 Nov;25(16):1725-1734. doi: 10.1177/2047487318768030. Epub 2018 Apr 11 9. Калинина А. М., Ипатов П. В., Кушунина Д. В., и соавт. Результаты выявления болезней системы кровообращения при диспансеризации взрослого населения: опыт первых 2 лет. Терапевтический архив. 2016;88(1): 46-52 10. С. А. Бойцов, А. Д. Деев, С. А. Шальнова. Смертность и факторы риска неинфекционных заболеваний в России: особенности, динамика, прогноз. Терапевтический архив. 2017;89(1): 5-13 11. Болотова Е.В., Концевая А.В., Ковригина И.В. Динамика факторов риска сердечно-сосудистых заболеваний в зависимости от статуса диспансерного наблюдения за трехлетний период. Фундаментальная и клиническая медицина 2020; 5(2):39-47. https://doi.org/10.23946/2500-0764-2020-5-2-39- 47 12. Калинина А.М., Соколов Г.Е., Горный Б.Э., Драпкина О.М. Оценка качества диспансеризации как организационной технологии медицинской профилактики в первичном звене здравоохранения: в фокусе сердечнососудистые заболевания. Профилактическая медицина.2021;24(1):26 34 13. Алекян Б.Г., Григорьян А.М., Стаферов А.В., Карапетян Н.Г. Рентгенэндоваскулярная диагностика и лечение заболеваний сердца и сосудов в Российской Федерации. Специальный выпуск журнала "Эндоваскулярная хирургия". 2021. Т. 8. С. 233 259 14. Алекян Б.Г., Бойцов С.А, Маношкина Е.М., Ганюков В.И. Реваскуляризация миокарда в Российской Федерации при остром коронарном синдроме в 2016-2020 гг. Кардиология 2021; 61(12): 4-15 https://doi.org/10.18087/cardio.2021.12.n1879 15. Погосова Н.В., Оганов Р.Г., Бойцов С.А. и соавт. Анализ ключевых показателей вторичной профилактики у пациентов с ишемической болезнью сердца в России и Европе по результатам российской части международного многоцентрового исследования EUROASPIRE V. Кардиоваскулярная терапия и профилактика 2020; 19(6): 67-78 https://doi.org/10.15829/1728-8800-2020-2739 16. Погосова Н.В., Бойцов С.А., Аушева А.К. и соавт. Медикаментозная терапия и приверженность к ней пациентов с ишемической болезнью сердца: результаты российской части международного многоцентрового исследования EUROASPIRE V. Кардиология. 2021;61(8):4-13. https://doi.org/10.18087/cardio.2021.8.n1650 17. Загребельный А.В., Марцевич С.Ю., Лукьянов М.М. и соавт. Качество гиполипидемической терапии в амбулаторно-поликлинической практике: данные регистра РЕКВАЗА. Профилактическая медицина. 2016;19(1):9‑14. https://doi.org/10.17116/profmed20161919-14 18. Khavjou O, Phelps D, Leib A. Prepared for Sue Nelson. November 2016. Projections of Cardiovascular Disease Prevalence and Costs: 2015–2035. 2016 Technical Report. https://www.heart.org/-/media/Files/GetInvolved/Advocacy/CVD-Predictions-Through-2035.pdf 19. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in mortality from coronary heart disease in the United States between 1980 and 2000. N Engl J Med 2007; 356: 2388-2398 doi: 10.1056/NEJMsa053935 pmid: 17554120. 20. Jousilahti P, Laatikainen T, Peltonen M, et al. Primary prevention and risk factor reduction in coronary heart disease mortality among working aged men and women in eastern Finland over 40 years: population based observational study. BMJ. 2016;352:i721. Published 2016 Mar 1. doi:10.1136/bmj.i721 21. Бойцов СА, Погосова НВ, Бубнова МГ и соавт. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018; 6:7–122. https://doi.org/10.15829/1560- 4071-2018-6-7-122. 22. Баланова Ю.А., Шальнова С.А., Куценко В.А., и соавт. Вклад артериальной гипертонии и других факторов риска в выживаемость и смертность в российской популяции. Кардиоваскулярная терапия и профилактика. 2021;20(5):3003. https://doi.org/10.15829/1728-8800-2021-3003 23. Ference B.A., Ginsberg H.N., Graham I., et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017. 38(32): 2459-2472. doi: 10.1093/eurheartj/ehx144. 24. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681. doi:10.1016/S0140-6736(10)61350-5 260 25. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-590. doi:10.1016/S0140-6736(12)60367-5 26. Метельская В.А., Шальнова С.А., Деев А.Д., и соавт. Анализ распространенности показателей, характеризующих атерогенность спектра липопротеинов, у жителей Российской Федерации (по данным исследования ЭССЕ-РФ). Профилактическая медицина. 2016;19(1):15-23 DOI: 10.17116/profmed201619115-23 27. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627-2642. doi:10.1016/S0140-6736(17)32129-3 DOI: 10.1530/ey.15.13.20 28. Emerging Risk Factors Collaboration, Wormser D, Kaptoge S, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011;377(9771):1085-1095. doi:10.1016/S0140-6736(11)60105-0 29. Sun YQ, Burgess S, Staley JR, et al. Body mass index and all cause mortality in HUNT and UK Biobank studies: linear and non-linear mendelian randomisation analyses. BMJ. 2019;364:l1042. Published 2019 Mar 26. doi:10.1136/bmj.l1042 30. Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju ShN, et al. Body-mass index and all-cause mortality: individual-participant-data metaanalysis of 239 prospective studies in four continents. Lancet. 2016;388(10046):776-786. doi:10.1016/S0140-6736(16)30175-1 31. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ. 2004;328(7455):1519. doi:10.1136/bmj.38142.554479.AE 32. Prescott E, Hippe M, Schnohr P, Hein HO, Vestbo J. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ. 1998;316(7137):1043-1047. doi:10.1136/bmj.316.7137.1043 33. Huxley R.R., Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. The Lancet. 2011. 378(9799): 1297-1305. doi: 10.1016/s0140-6736(11)60781-2. 34. Gupta R, Gupta S, Sharma S, Sinha DN, Mehrotra R. Risk of Coronary Heart Disease Among Smokeless Tobacco Users: Results of Systematic Review and Meta-Analysis of Global Data. Nicotine Tob Res. 2019;21(1):25-31. doi:10.1093/ntr/nty002 35. Lv X, Sun J, Bi Y, et al. Risk of all-cause mortality and cardiovascular disease associated with secondhand smoke exposure: a systematic review and metaanalysis. Int J Cardiol. 2015;199:106-115. doi:10.1016/j.ijcard.2015.07.011 36. Баланова Ю.А., Шальнова С.А., Деев А.Д., и соавт. Распространенность курения в России. Что изменилось за 20 лет? Профилактическая медицина. 2015;18(6):47-52. DOI: 10.17116/profmed201518647-52 37. Hoek AG, van Oort S, Mukamal KJ, Beulens JWJ. Alcohol Consumption and Cardiovascular Disease Risk: Placing New Data in Context. Curr Atheroscler Rep. 2022;24(1):51-59. doi:10.1007/s11883-022-00992-1 261 38. Larsson SC, Burgess S, Mason AM, Michaëlsson K. Alcohol Consumption and Cardiovascular Disease: A Mendelian Randomization Study. Circ Genom Precis Med. 2020;13(3):e002814. doi:10.1161/CIRCGEN.119.002814 39. Zhang HZ, Shao B, Wang QY, et al. Alcohol Consumption and Risk of Atrial Fibrillation: A Dose-Response Meta-Analysis of Prospective Studies. Front Cardiovasc Med. 2022;9:802163. Published 2022 Feb 24. doi:10.3389/fcvm.2022.802163 40. Шальнова С.А., Максимов С.А., Баланова Ю.А., и соавт. Потребление алкоголя и зависимость от социально-демографических факторов у лиц трудоспособного возраста (по данным исследования ЭССЕ-РФ). Профилактическая медицина. 2019;22(5):45-53 DOI: 10.17116/profmed20192205145 41. Wahid A, Manek N, Nichols M, et al. Quantifying the Association Between Physical Activity and Cardiovascular Disease and Diabetes: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2016;5(9):e002495. Published 2016 Sep 14. doi:10.1161/JAHA.115.002495 42. Barbiellini Amidei C, Trevisan C, Dotto M, et al. Association of physical activity trajectories with major cardiovascular diseases in elderly people. Heart. 2022;108(5):360-366. doi:10.1136/heartjnl-2021-320013 43. Jingjie W, Yang L, Jing Y, Ran L, Yiqing X, Zhou N. Sedentary time and its association with risk of cardiovascular diseases in adults: an updated systematic review and meta-analysis of observational studies. BMC Public Health. 2022;22(1):286. Published 2022 Feb 12. doi:10.1186/s12889-022-12728-6 44. Забина Е.Ю., Зиновьева В.А., Шальнова С.А., и соавт . Сравнение уровня физической активности в трех крупных индустриальных центрах Российской Федерации с применением Глобального опросника по физической активности (GPAQ) Профилактическая медицина. 2017;17(6):56-61 DOI: 10.17116/profmed201720656-61 45. Евстифеева С.Е., Капустина А.В., Никонов Е.Л., и соавт. от имени участников исследования ЭГИДА-Москва. Возрастные и гендерные характеристики поведенческих факторов риска и приверженности здоровому образу жизни у москвичей. Кардиоваскулярная терапия и профилактика. 2020;19(5):2670. https://doi.org/10.15829/1728-8800-2020-2670 46. Баланова Ю.А., Капустина А.В., Шальнова С.А., и соавт . Поведенческие факторы риска в российской популяции: результаты обследования по модифицированной методологии STEPS. Профилактическая медицина. 2020;23(5):56-66. DOI: 10.17116/profmed20202305156 47. Chareonrungrueangchai K, Wongkawinwoot K, Anothaisintawee T, Reutrakul S. Dietary Factors and Risks of Cardiovascular Diseases: An Umbrella Review. Nutrients. 2020;12(4):1088. Published 2020 Apr 15. doi:10.3390/nu12041088 48. Rodríguez-Monforte M, Flores-Mateo G, Sánchez E. Dietary patterns and CVD: a systematic review and meta-analysis of observational studies. Br J Nutr. 2015;114(9):1341-1359. doi:10.1017/S0007114515003177 49. Федеральная служба государственной статистики. Выборочное наблюдение рациона питания населения. Итоги. [Electronic resource]. 2018. URL: https://gks.ru/free_doc/new_site/food18/index.html (accessed: 07.04.2020). 262 50. Whelton SP, McEvoy JW, Shaw L, et al. Association of Normal Systolic Blood Pressure Level With Cardiovascular Disease in the Absence of Risk Factors. JAMA Cardiol. 2020;5(9):1011-1018. doi:10.1001/jamacardio.2020.1731 51. Баланова Ю.А., Шальнова С.А., Имаева А.Э., и соавт. Распространенность артериальной гипертонии, охват лечением и его эффективность в Российской Федерации (данные наблюдательного исследования ЭССЕ-РФ2). Рациональная Фармакотерапия в Кардиологии. 2019;15(4):450-466. https://doi.org/10.20996/1819-6446-2019-15-4-450-466 52. Aune D, Sen A, Prasad M, et al. BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. BMJ. 2016;353:i2156. Published 2016 May 4. doi:10.1136/bmj.i2156 53. Баланова Ю.А., Шальнова С.А., Деев А.Д., и соавт. Ожирение в российской популяции — распространенность и ассоциации с факторами риска хронических неинфекционных заболеваний. Российский кардиологический журнал. 2018;(6):123-130. https://doi.org/10.15829/1560-4071-2018-6-123- 130 54. Жернакова Ю.В., Железнова Е.А., Чазова И.Е., и соавт. Распространенность абдоминального ожирения в субъектах Российской Федерации и его связь с социально-экономическим статусом, результаты эпидемиологического исследования ЭССЕ-РФ // Терапевтический архив. - 2018. - Т. 90. - №10. - C. 14-22. doi: 10.26442/terarkh201890104-22 55. Дедов И.И., Шестакова М.В., Майоров А.Ю., и соавт. Сахарный диабет 2 типа у взрослых. Сахарный диабет. 2020;23(2S):4-102. https://doi.org/10.14341/DM12507 56. Peters S.A.E., Huxley R.R., Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775 385 individuals and 12 539 strokes. The Lancet. 2014. 383(9933): 1973-1980. doi: 10.1016/s0140-6736(14)60040-4. 57. Шестакова М.В., Викулова О.К., Железнякова А.В., и соавт. Эпидемиология сахарного диабета в Российской Федерации: что изменилось за последнее десятилетие? Терапевтический архив. - 2019. - Т. 91. - №10. - C. 4-13. doi: 10.26442/00403660.2019.10.000364 58. Жернакова Ю.В. Чазова И.Е., Ощепкова Е.В., и соавт. Распространенность сахарного диабета в популяции больных артериальной гипертонией. По данным исследования ЭССЕ-РФ //Системные гипертензии. 2018; 15(1): 56- 62. DOI: 10.26442/2075-082X_15.1.56-62 59. Stringhini S, Carmeli C, Jokela M, et al. Socioeconomic status and the 25 × 25 risk factors as determinants of premature mortality: a multicohort study and metaanalysis of 1·7 million men and women [published correction appears in Lancet. 2017 Mar 25;389(10075):1194] [published correction appears in Lancet. 2017 Mar 25;389(10075):1194]. Lancet. 2017;389(10075):1229-1237. doi:10.1016/S0140-6736(16)32380-7 60. Pogosova N, Saner H, Pedersen SS, et al. Psychosocial aspects in cardiac rehabilitation: From theory to practice. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation of the European Society of Cardiology. Eur J Prev Cardiol. 2015;22(10):1290-1306. doi:10.1177/2047487314543075 263 61. Gan Y, Gong Y, Tong X, et al. Depression and the risk of coronary heart disease: a meta-analysis of prospective cohort studies. BMC Psychiatry. 2014;14:371. Published 2014 Dec 24. doi:10.1186/s12888-014-0371-z 62. de Miranda Azevedo R, Roest AM, Hoen PW, de Jonge P. Cognitive/affective and somatic/affective symptoms of depression in patients with heart disease and their association with cardiovascular prognosis: a meta-analysis. Psychol Med. 2014;44(13):2689-2703. doi:10.1017/S0033291714000063 63. Karlsen HR, Matejschek F, Saksvik-Lehouillier I, Langvik E. Anxiety as a risk factor for cardiovascular disease independent of depression: A narrative review of current status and conflicting findings. Health Psychol Open. 2021;8(1):2055102920987462. Published 2021 Jan 13. doi:10.1177/2055102920987462 64. Celano CM, Millstein RA, Bedoya CA, Healy BC, Roest AM, Huffman JC. Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis. Am Heart J. 2015;170(6):1105-1115. doi:10.1016/j.ahj.2015.09.013 65. Nyberg ST, Fransson EI, Heikkilä K, et al. Job strain and cardiovascular disease risk factors: meta-analysis of individual-participant data from 47,000 men and women. PLoS One. 2013;8(6):e67323. Published 2013 Jun 20. doi:10.1371/journal.pone.0067323 66. Taylor JL, Makarem N, Shimbo D, et al. Gender Differences in Associations Between Stress and Cardiovascular Risk Factors and Outcomes. Gend Genome. 2018;2 (4):111-122. doi:10.1177/2470289718820845 67. Berntson J, Patel JS, Stewart JC. Number of recent stressful life events and incident cardiovascular disease: Moderation by lifetime depressive disorder. J Psychosom Res. 2017; 99: 149-154. doi:10.1016/j.jpsychores.2017.06.008 68. Rozanski A, Bavishi C, Kubzansky LD, Cohen R. Association of Optimism With Cardiovascular Events and All-Cause Mortality: A Systematic Review and Metaanalysis. JAMA Netw Open. 2019;2(9):e1912200. Published 2019 Sep 4. doi:10.1001/jamanetworkopen.2019.12200 69. Cohen R, Bavishi C, Rozanski A. Purpose in life and its relationship to all-cause mortality and cardiovascular events: a meta-analysis. Psychosom Med. 2016; 78: 122–133. doi: 10.1097/PSY.0000000000000274 70. Оганов Р.Г., Ольбинская Л.И., Смулевич А.Б., и др. Депрессии и расстройства депрессивного спектра в общемедицинской практике. Результаты программы КОМПАС. Кардиология 2004; 1: 48 – 54 71. Погосова Н.В., Бойцов С.А., Оганов Р.Г., и соавт. Клиникоэпидемиологическая программа изучения психосоциальных факторов риска в кардиологической практике у больных артериальной гипертонией и ишемической болезнью сердца (КОМЕТА): первые результаты российского многоцентрового исследования. Кардиология. 2018;58(9):47-58. https://doi.org/10.18087/cardio.2018.9.10171 72. Schultz WM, Kelli HM, Lisko JC, et al. Socioeconomic Status and Cardiovascular Outcomes: Challenges and Interventions. Circulation. 2018;137(20):2166-2178. doi:10.1161/CIRCULATIONAHA.117.029652 73. Khaing W, Vallibhakara SA, Attia J, et al. Effects of education and income on cardiovascular outcomes: A systematic review and metaanalysis. Eur J Prev Cardiol 2017;24:10321042. doi: 10.1177/2047487317705916 264 74. Долгалев И.В., Иванова А.Ю., Карпов Р.С. Влияние уровня образования на риск общей и сердечно-сосудистой смертности по результатам 27-летнего проспективного когортного исследования. Профилактическая медицина. 2020;23(6):22-27. DOI: 10.17116/profmed20202306122 75. Концевая А.В., Шальнова С.А., Баланова Ю.А. и др. Социальноэкономические градиенты поведенческих факторов риска в Российской популяции (по результатам исследования ЭССЕ-РФ). Кардиоваскулярная терапия и профилактика. 2015;14(4):59-67. doi:10.15829/1728-8800-2015-4- 59-67 76. Zhang Y.,Chen Ch., Pan X., et al. Associations of healthy lifestyle and socioeconomic status with mortality and incident cardiovascular disease: two prospective cohort studies. BMJ 2021;372:n604. doi: 10.1136/bmj.n604. 77. Wilder ME, Zheng Z, Zeger SL et al. Relationship Between Social Determinants of Health and Antihypertensive Medication Adherence in a Medicaid Cohort. Circ Cardiovasc Qual Outcomes. 2022;15(2):e008150. doi: 10.1161/CIRCOUTCOMES.121.008150. 78. Moledina A, Tang KL. Socioeconomic Status, Mortality, and Access to Cardiac Services After Acute Myocardial Infarction in Canada: A Systematic Review and Meta-analysis. CJC Open. 2021;3(7):950-964.doi: 10.1016/j.cjco.2021.02.006. 79. Garland A, Jeon SH, Stepner M, et al. Effects of cardiovascular and cerebrovascular health events on work and earnings: a population-based retrospective cohort study. CMAJ. 2019;191(1):E3-E10. doi:10.1503/cmaj.181238 80. Концевая А.В., Драпкина О.М., Баланова Ю.А., и соавт. Экономический ущерб от сердечно-сосудистых заболеваний в Российской Федерации в 2016 году. Рациональная Фармакотерапия в Кардиологии. 2018;14(2):156- 166. https://doi.org/10.20996/1819-6446-2018-14-2-156-166. 81. Концевая А.В., Муканеева Д.К., Мырзаматова А. О., и соавт. Экономический ущерб факторов риска, обусловленный их вкладом в заболеваемость и смертность от основных хронических неинфекционных заболеваний в Российской Федерации в 2016 году. Кардиоваскулярная терапия и профилактика. 2020;19(1):2396. doi:10.15829/1728-8800-2020-1-2396. 82. Feigin V.L., Brainin M., Norrving B. et al. What Is the Best Mix of Population-Wide and High-Risk Targeted Strategies of Primary Stroke and Cardiovascular Disease Prevention? J Am Heart Assoc. 2020;9:e014494. DOI: 10.1161/JAHA.119.014494 83. Saving lives, spending less: the case for investing in noncommunicable diseases. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. https://www.who.int/publications/i/item/9789240041059 84. McConnachie A, Walker A, Robertson M, et al. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. Eur Heart J. 2014;35(5):290-298. doi:10.1093/eurheartj/eht232 85. Mistry H, Morris S, Dyer M, et al. Cost-effectiveness of a European preventive cardiology programme in primary care: a Markov modelling approach. BMJ Open. 2012;2(5):e001029. Published 2012 Oct 11. doi:10.1136/bmjopen-2012-001029 86. De Smedt D, Kotseva K, De Bacquer D, et al. Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health 265 economics project. Eur Heart J. 2012;33(22):2865-2872. doi:10.1093/eurheartj/ehs210 87. Сметнева Н.С., Погожева А.В., Васильев Ю.Л., и соавт. Роль оптимального питания в профилактике сердечно-сосудистых заболеваний // Вопросы питания. 2020. Т. 89, № 3. С. 114–124. DOI: 10.24411/0042-8833-2020-10035 88. Rose G. Sick individuals and sick populations. Int J Epidemiol. 1985;14(1):32-38. doi:10.1093/ije/14.1.32 89. Бойцов С.А., Драпкина О.М. Современное содержание и совершенствование стратегии высокого сердечнососудистого риска в снижении смертности от сердечно-сосудистых заболеваний. Терапевтический архив. 2021; 93 (1): 4– 6. DOI: 10.26442/00403660.2021.01.200543 90. Chamnan P, Simmons RK, Khaw KT, Wareham NJ, Griffin SJ. Estimating the population impact of screening strategies for identifying and treating people at high risk of cardiovascular disease: modelling study. BMJ. 2010;340:c1693. Published 2010 Apr 23. doi:10.1136/bmj.c1693 91. Jørgensen T, Jacobsen RK, Toft U, Aadahl M, Glümer C, Pisinger C. Effect of screening and lifestyle counselling on incidence of ischaemic heart disease in general population: Inter99 randomised trial. BMJ. 2014;348:g3617. Published 2014 Jun 9. doi:10.1136/bmj.g3617 92. Ebrahim S, Taylor F, Ward K, Beswick A, Burke M, Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev. 2011;(1):CD001561. Published 2011 Jan 19. doi:10.1002/14651858.CD001561.pub3 93. Kennedy O, Su F, Pears R, Walmsley E, Roderick P. Evaluating the effectiveness of the NHS Health Check programme in South England: a quasi-randomised controlled trial. BMJ Open. 2019;9(9):e029420. Published 2019 Sep 20. doi:10.1136/bmjopen-2019-029420 94. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database Syst Rev. 2019;1(1):CD009009. Published 2019 Jan 31. doi:10.1002/14651858.CD009009.pub3 95. Si S, Moss JR, Sullivan TR, Newton SS, Stocks NP. Effectiveness of general practicebased health checks: a systematic review and meta-analysis. Br J Gen Pract. 2014;64(618):e47-e53. doi:10.3399/bjgp14X676456 96. Приказ МЗ РФ от 27 апреля 2021 года N 404н "Об утверждении Порядка проведения профилактического медицинского осмотра и диспансеризации определенных групп взрослого населения (с изменениями на 1 февраля 2022 года)". 97. Patel R, Barnard S, Thompson K, et al. Evaluation of the uptake and delivery of the NHS Health Check programme in England, using primary care data from 9.5 million people: a cross-sectional study. BMJ Open. 2020;10(11):e042963. Published 2020 Nov 5. doi:10.1136/bmjopen-2020-042963 98. Mehta S, Wells S, Grey C, et al. Initiation and maintenance of cardiovascular medications following cardiovascular risk assessment in a large primary care cohort: PREDICT CVD-16. Eur J Prev Cardiol. 2014;21(2):192-202. doi:10.1177/2047487312462150 266 99. Dorresteijn JA, Visseren FL, Ridker PM, et al. Estimating treatment effects for individual patients based on the results of randomised clinical trials. BMJ. 2011;343:d5888. Published 2011 Oct 3. doi:10.1136/bmj.d5888 100. Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24(11): 987-1003 101. Кухарчук В. В., Ежов М. В., Сергиенко И. В., и соавт. Кухарчук В. В. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр //Атеросклероз и дислипидемии. 2020. №. 1. С. 7-40. https://jad.noatero.ru/index.php/jad/article/view/274/271 102. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42, 3227-3337. doi:10.1093/eurheartj/ehab484. 103. Приказ Министерства Здравоохранения РФ от 15 марта 2022 г. N 168н "Об утверждений порядка проведения диспансерного наблюдения за взрослыми" 104. Kaasenbrood L, Boekholdt SM, van der Graaf Y, et al. Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population. Circulation. 2016;134(19):1419-1429. doi:10.1161/CIRCULATIONAHA.116.021314 105. De Bacquer D, Ueda P, Reiner Z, et al. , EUROASPIRE IV and V National Coordinators. Prediction of recurrent event in patients with coronary heart disease: the EUROASPIRE Risk Model. Eur J Prev Cardiol 2020:[Online ahead of print]. 106. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377(14):1319-1330. doi:10.1056/NEJMoa1709118 107. Bhatt D.L., Steg P.G., Miller M., et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine. 2019. 380(1): 11-22. doi: 10.1056/nejmoa1812792. 108. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020;383(19):1838-1847. doi:10.1056/NEJMoa2021372 109. Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019;381(26):2497-2505. doi:10.1056/NEJMoa1912388 110. Sattar N, Rawshani A, Franzén S, et al. Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks. Circulation. 2019;139(19):2228-2237. doi:10.1161/CIRCULATIONAHA.118.037885 111. Kengne AP, Patel A, Marre M, et al. Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. Eur J Cardiovasc Prev Rehabil. 2011;18(3):393-398. doi:10.1177/1741826710394270 112. Cersosimo E, Johnson EL, Chovanes C, Skolnik N. Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach. Diabetes Obes Metab. 2018;20(3):497-507. doi:10.1111/dom.13108 113. Rodbard HW, Visco VE, Andersen H, Hiort LC, Shu DH. Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full 267 basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial [published correction appears in Lancet Diabetes Endocrinol. 2014 Jan;2(1):e3]. Lancet Diabetes Endocrinol. 2014;2(1):30-37. doi:10.1016/S2213- 8587(13)70090-1 114. Rawshani A., Sattar N., Franzén S., et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. The Lancet. 2018. 392(10146): 477-486. doi: 10.1016/s0140-6736(18)31506-x. 115. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339-352. doi:10.1016/S0140-6736(13)60595-4 116. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with allcause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073-2081. doi:10.1016/S0140- 6736(10)60674-5 117. Kivimäki M, Steptoe A. Effects of stress on the development and progression of cardiovascular disease. Nat Rev Cardiol. 2018;15(4):215-229. doi:10.1038/nrcardio.2017.18 118. Higueras-Fresnillo S, Cabanas-Sánchez V, Lopez-Garcia E, et al. Physical Activity and Association Between Frailty and All-Cause and Cardiovascular Mortality in Older Adults: Population-Based Prospective Cohort Study. J Am Geriatr Soc. 2018;66(11):2097-2103. doi:10.1111/jgs.15542 119. Rozanski A. Behavioral cardiology: current advances and future directions. J Am Coll Cardiol. 2014;64(1):100-110. doi:10.1016/j.jacc.2014.03.047 120. Afilalo J, Alexander KP, Mack MJ, et al. Frailty assessment in the cardiovascular care of older adults. J Am Coll Cardiol. 2014;63(8):747-762. doi:10.1016/j.jacc.2013.09.070 121. Singh M, Stewart R, White H. Importance of frailty in patients with cardiovascular disease. Eur Heart J. 2014;35(26):1726-1731. doi:10.1093/eurheartj/ehu197 122. Jha MK, Qamar A, Vaduganathan M, Charney DS, Murrough JW. Screening and Management of Depression in Patients With Cardiovascular Disease: JACC Stateof-the-Art Review. J Am Coll Cardiol. 2019;73(14):1827-1845. doi:10.1016/j.jacc.2019.01.041 123. Vaccarino V, Badimon L, Bremner JD, et al. Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation [published correction appears in Eur Heart J. 2020 May 1;41(17):1696]. Eur Heart J. 2020;41(17):1687-1696. doi:10.1093/eurheartj/ehy913 124. Lin JS, Evans CV, Johnson E, Redmond N, Coppola EL, Smith N. Nontraditional Risk Factors in Cardiovascular Disease Risk Assessment: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018;320(3):281-297. doi:10.1001/jama.2018.4242 125. Peters SA, den Ruijter HM, Bots ML, Moons KG. Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review. Heart. 2012;98(3):177-184. doi:10.1136/heartjnl-2011-300747 268 126. SCOT-HEART Investigators, Newby DE, Adamson PD, et al. Coronary CT Angiography and 5-Year Risk of Myocardial Infarction. N Engl J Med. 2018;379(10):924-933. doi:10.1056/NEJMoa1805971 127. Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine [published correction appears in J Am Soc Echocardiogr. 2008 Apr;21(4):376]. J Am Soc Echocardiogr. 2008;21(2):93-190. doi:10.1016/j.echo.2007.11.011 128. Den Ruijter HM, Peters SA, Anderson TJ, et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis [published correction appears in JAMA. 2013 Oct 23;310(16):1739]. JAMA. 2012;308(8):796-803. doi:10.1001/jama.2012.9630 129. Shaw LJ, Iskandrian AE. Prognostic value of gated myocardial perfusion SPECT. J Nucl Cardiol. 2004;11(2):171-185. doi:10.1016/j.nuclcard.2003.12.004 130. Albus C, Waller C, Fritzsche K, et al. Significance of psychosocial factors in cardiology: update 2018 : Position paper of the German Cardiac Society. Clin Res Cardiol. 2019;108(11):1175-1196. doi:10.1007/s00392-019-01488-w 131. Schnohr P, Marott JL, Kristensen TS, et al. Ranking of psychosocial and traditional risk factors by importance for coronary heart disease: the Copenhagen City Heart Study. Eur Heart J. 2015;36(22):1385-1393. doi:10.1093/eurheartj/ehv027 132. Kim JM, Stewart R, Kang HJ, et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychol Med. 2021;51(6):964-974. doi:10.1017/S003329171900388X 133. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099. Published 2017 May 23. doi:10.1136/bmj.j2099 134. Karmali KN, Persell SD, Perel P, Lloyd-Jones DM, Berendsen MA, Huffman MD. Risk scoring for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017;3(3):CD006887. Published 2017 Mar 14. doi:10.1002/14651858.CD006887.pub4 135. Stewart MA. Effective physician-patient communication and health outcomes: a review. CMAJ. 1995 May 1;152(9):1423-33. 136. Zolnierek KB, Dimatteo MR. Physician communication and patient adherence to treatment: a meta-analysis. Med Care. 2009;47(8):826-834. doi:10.1097/MLR.0b013e31819a5acc 137. Riedl D, Schüßler G. The Influence of Doctor-Patient Communication on Health Outcomes: A Systematic Review. Z Psychosom Med Psychother. 2017;63(2):131- 150. doi:10.13109/zptm.2017.63.2.131 138. Świątoniowska-Lonc N, Polański J, Tański W, Jankowska-Polańska B. Impact of satisfaction with physician-patient communication on self-care and adherence in patients with hypertension: cross-sectional study. BMC Health Serv Res. 2020;20(1):1046. Published 2020 Nov 16. doi:10.1186/s12913-020-05912-0 139. Spiegelhalter D, Pearson M, Short I. Visualizing uncertainty about the future. Science. 2011;333(6048):1393-1400. doi:10.1126/science.1191181 269 140. Zipkin DA, Umscheid CA, Keating NL, et al. Evidence-based risk communication: a systematic review. Ann Intern Med. 2014;161(4):270-280. doi:10.7326/M14- 0295 141. Lie HC, Juvet LK, Street RL Jr, et al. Effects of Physicians' Information Giving on Patient Outcomes: a Systematic Review. J Gen Intern Med. 2022;37(3):651-663. doi:10.1007/s11606-021-07044-5 142. Howick J, Moscrop A, Mebius A, et al. Effects of empathic and positive communication in healthcare consultations: a systematic review and metaanalysis [published correction appears in J R Soc Med. 2018 Oct;111(10):383]. J R Soc Med. 2018;111(7):240-252. doi:10.1177/0141076818769477 143. Mentrup S, Harris E, Gomersall T, Köpke S, Astin F. Patients' Experiences of Cardiovascular Health Education and Risk Communication: A Qualitative Synthesis. Qual Health Res. 2020;30(1):88-104. doi:10.1177/1049732319887949 144. Rossello X, Dorresteijn JA, Janssen A, et al. Risk prediction tools in cardiovascular disease prevention: A report from the ESC Prevention of CVD Programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP). Eur J Prev Cardiol. 2019;26(14):1534-1544. doi:10.1177/2047487319846715 145. Hoffmann M, Nilsson PM, Ahlner J, et al. Do patients or their physicians more accurately assess long-term risk associated with hypertension? A populationbased study. Scand J Prim Health Care. 2020;38(2):166-175. doi:10.1080/02813432.2020.1753345 146. Damman OC, Vonk SI, van den Haak MJ, van Hooijdonk CMJ, Timmermans DRM. The effects of infographics and several quantitative versus qualitative formats for cardiovascular disease risk, including heart age, on people's risk understanding. Patient Educ Couns. 2018;101(8):1410-1418. doi:10.1016/j.pec.2018.03.015 147. Cooney MT, Vartiainen E, Laatikainen T, et al. Cardiovascular risk age: concepts and practicalities. Heart. 2012;98(12):941-946. doi:10.1136/heartjnl-2011- 301478 148. Cuende JI, Cuende N, Calaveras-Lagartos J. How to calculate vascular age with the SCORE project scales: a new method of cardiovascular risk evaluation. Eur Heart J. 2010;31(19):2351-2358. doi:10.1093/eurheartj/ehq205 149. US Preventive Services Task Force, Davidson KW, Mangione CM, et al. Collaboration and Shared Decision-Making Between Patients and Clinicians in Preventive Health Care Decisions and US Preventive Services Task Force Recommendations. JAMA. 2022;327(12):1171-1176. doi:10.1001/jama.2022.3267 150. Turkson-Ocran RN, Ogunwole SM, Hines AL, Peterson PN. Shared Decision Making in Cardiovascular Patient Care to Address Cardiovascular Disease Disparities. J Am Heart Assoc. 2021;10(20):e018183. doi:10.1161/JAHA.120.018183 151. Stacey D, Légaré F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2017;4(4):CD001431. Published 2017 Apr 12. doi:10.1002/14651858.CD001431.pub5 152. Yen RW, Smith J, Engel J, et al. A Systematic Review and Meta-Analysis of Patient Decision Aids for Socially Disadvantaged Populations: Update from the 270 International Patient Decision Aid Standards (IDPAS). Med Decis Making. 2021;41(7):870-896. doi:10.1177/0272989X211020317 153. Wändell PE, de Waard AM, Holzmann MJ, et al. Barriers and facilitators among health professionals in primary care to prevention of cardiometabolic diseases: A systematic review. Fam Pract. 2018;35(4):383-398. doi:10.1093/fampra/cmx137 154. Astin F, Lucock M, Jennings CS. Heart and mind: behavioural cardiology demystified for the clinician. Heart. 2019;105(11):881-888. doi:10.1136/heartjnl2016-310750 155. Navar AM, Wang TY, Li S, et al. Patient-Perceived Versus Actual Risk of Cardiovascular Disease and Associated Willingness to Consider and Use Prevention Therapy. Circ Cardiovasc Qual Outcomes. 2021;14(1):e006548. doi:10.1161/CIRCOUTCOMES.120.006548 156. Lee WW, Choi KC, Yum RW, Yu DS, Chair SY. Effectiveness of motivational interviewing on lifestyle modification and health outcomes of clients at risk or diagnosed with cardiovascular diseases: A systematic review. Int J Nurs Stud. 2016;53:331-341. doi:10.1016/j.ijnurstu.2015.09.010 157. Zulman DM, Haverfield MC, Shaw JG, et al. Practices to Foster Physician Presence and Connection With Patients in the Clinical Encounter [published correction appears in JAMA. 2020 Mar 17;323(11):1098]. JAMA. 2020;323(1):70-81. doi:10.1001/jama.2019.19003 158. Miller WR, Rose GS. Toward a theory of motivational interviewing. Am Psychol. 2009;64(6):527-537. doi:10.1037/a0016830 159. Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6:42. Published 2011 Apr 23. doi:10.1186/1748-5908-6-42 160. Ambrosetti M, Abreu A, Corrà U, et al. Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol. 2020 Mar 30:2047487320913379. doi: 10.1177/2047487320913379. Epub ahead of print. PMID: 32223332. 161. Duffy EY, Ashen D, Blumenthal RS, et al. Communication approaches to enhance patient motivation and adherence in cardiovascular disease prevention. Clin Cardiol. 2021;44(9):1199-1207. doi:10.1002/clc.23555 162. Martin SS, Sperling LS, Blaha MJ, et al. Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA Guidelines. J Am Coll Cardiol. 2015;65(13):1361-1368. doi:10.1016/j.jacc.2015.01.043 163. Rubak S, Sandbaek A, Lauritzen T, Christensen B. Motivational interviewing: a systematic review and meta-analysis. Br J Gen Pract. 2005;55(513):305-312. 164. Artinian NT, Fletcher GF, Mozaffarian D, et al. Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart Association. Circulation. 2010;122(4):406-441. doi:10.1161/CIR.0b013e3181e8edf1 165. Balady GJ, Williams MA, Ades PA, et al. Core components of cardiac rehabilitation/secondary prevention programs: 2007 update: a scientific statement from the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils on 271 Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism; and the American Association of Cardiovascular and Pulmonary Rehabilitation. Circulation. 2007;115(20):2675-2682. doi:10.1161/CIRCULATIONAHA.106.180945 166. Piepoli MF, Corrà U, Benzer W, et al. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil. 2010;17(1):1-17. doi:10.1097/HJR.0b013e3283313592 167. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-2381. doi:10.1093/eurheartj/ehw106 168. Auer R, Gaume J, Rodondi N, Cornuz J, Ghali WA. Efficacy of in-hospital multidimensional interventions of secondary prevention after acute coronary syndrome: a systematic review and meta-analysis. Circulation. 2008;117(24):3109-3117. doi:10.1161/CIRCULATIONAHA.107.748095 169. Janssen V, De Gucht V, Dusseldorp E, Maes S. Lifestyle modification programmes for patients with coronary heart disease: a systematic review and meta-analysis of randomized controlled trials. Eur J Prev Cardiol. 2013;20(4):620-640. doi:10.1177/2047487312462824 170. Hazelton G, Williams JW, Wakefield J, Perlman A, Kraus WE, Wolever RQ. Psychosocial benefits of cardiac rehabilitation among women compared with men. J Cardiopulm Rehabil Prev. 2014;34(1):21-28. doi:10.1097/HCR.0000000000000034 171. Burell G, Granlund B. Women's hearts need special treatment. Int J Behav Med. 2002;9(3):228-242. doi:10.1207/s15327558ijbm0903_05 172. World Health Organization - Noncommunicable diseases country profiles 2018, https://www.who.int/publications/i/item/ncd-country-profiles-2018, Последнее обращение: 07.10.2021 173. GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [published correction appears in Lancet. 2019 Jan 12;393(10167):132] [published correction appears in Lancet. 2019 Jun 22;393(10190):e44]. Lancet. 2018;392(10159):1923- 1994. doi:10.1016/S0140-6736(18)32225-6 174. WHO report on the global tobacco epidemic 2021: addressing new and emerging products. 27 July 2021, World Health Organization, Geneva, Switzerland 175. Федеральные статистические наблюдения по социально-демографическим проблемам. Итоги Выборочного наблюдения состояния здоровья населения в 2019, 2020, 2021гг., Федеральная служба государственной статистики. https://rosstat.gov.ru/itog_inspect 272 176. Самородская ИВ, Бойцов СА. Повторный инфаркт миокарда: оценка, риски, профилактика. Российский кардиологический журнал 2017; 6(146): 139-145. https://doi.org/10.15829/1560-4071-2017-6-139-145 177. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004;43(10):1731-1737. doi:10.1016/j.jacc.2003.12.047 178. Banks, E., Joshy, G., Korda, R.J., et al. Tobacco smoking and risk of 36 cardiovascular disease subtypes: fatal and non-fatal outcomes in a large prospective Australian study. BMC Med 17, 128 (2019). https://doi.org/10.1186/s12916-019-1351-4 179. Шальнова С.А., Деев А.Д., Оганов Р.Г. Факторы, влияющие на смертность от сердечно-сосудистых заболеваний в российской популяции. Кардиоваскулярная терапия и профилактика, 2005, 4, 1: 4-9 180. Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol. 2014;34(3):509-515. doi:10.1161/ATVBAHA.113.300156 181. Papathanasiou G., Mamali A., Papafloratos S., et al. Effects of smoking on cardiovascular function: the role of nicotine and carbon monoxide. Health Sci J. (2014) 8:274–90., Available online at: https://www.hsj.gr/abstract/effects-ofsmoking-on-cardiovascular-function-the-role-of-nicotine-and-carbon-monoxide2732.html 182. Hahad O, Arnold N, Prochaska JH, et al. Cigarette Smoking Is Related to Endothelial Dysfunction of Resistance, but Not Conduit Arteries in the General Population-Results From the Gutenberg Health Study. Front Cardiovasc Med. 2021;8:674622. Published 2021 May 19. doi:10.3389/fcvm.2021.674622 183. Middlekauff HR. Cardiovascular impact of electronic-cigarette use. Trends Cardiovasc Med. 2020 Apr;30(3):133-140. doi: 10.1016/j.tcm.2019.04.006. Epub 2019 Apr 25. PMID: 31072697 184. Barua RS, Ambrose JA. Mechanisms of coronary thrombosis in cigarette smoke exposure Arterioscler Thromb Vasc Biol 2013;33:1460-67. 10.1161/ATVBAHA.112.300154 185. Levin MG, Klarin D, Assimes TL, et al. Genetics of Smoking and Risk of Atherosclerotic Cardiovascular Diseases: A Mendelian Randomization Study. JAMA Netw Open. 2021;4(1):e2034461. Published 2021 Jan 4. doi:10.1001/jamanetworkopen.2020.34461 186. Hackshaw Allan, Morris Joan K, Boniface Sadie, Tang Jin-Ling, Milenković Dušan. Low cigarette consumption and risk of coronary heart disease and stroke: metaanalysis of 141 cohort studies in 55 study reports BMJ 2018 и :j5855, 360 187. Lubin JH, Couper D, Lutsey PL, et al. Risk of cardiovascular disease from cumulative cigarette use and the impact of smoking intensity. Epidemiology 2016;27:395-404. 10.1097/EDE.0000000000000437 188. Frey PF, Ganz P, Hsue PY, et al. The exposure-dependent effects of aged secondhand smoke on endothelial function. J Am Coll Cardiol 2012;59:1908-13. 10.1016/j.jacc.2012.02.025 189. Oono IP, Mackay DF, Pell JP. Meta-analysis of the association between secondhand smoke exposure and stroke. J Public Health (Oxf) 2011;33:496-502. 10.1093/pubmed/fdr025 273 190. Alzahrani T, Pena I, Temesgen N, et al. Association between electronic cigarette use and myocardial infarction. Am J Prev Med 2018;55(4):455–61 191. Middlekauff HR, Gornbein J. Association of electronic cigarette use with myocardial infarction: persistent uncertainty. Am J Prev Med 2019;56(1):159–60 192. Taylor, D.H. Jr; Hasselblad, V.; Henley, S.J.; Thun, M.J.; Sloan, F.A. Benefits of smoking cessation for longevity. Am. J. Public Health 2002, 92, 990-996 193. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003;290:86_97 194. Anthonisen NR, Skeans MA, Wise RA, et al, Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142:233_239 195. Iestra JA, Kromhout D, van der Schouw YT, et al. Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review. Circulation. 2005, Aug 9;112(6):924-34. doi: 10.1161/CIRCULATIONAHA.104.503995. PMID: 16087812 196. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2004;1:CD003041 197. Chow CK, Jolly S, Rao-Melacini P, et al. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation 2010;121:750–758 198. Balfour D., Benowitz N., Fagerstrom K., et al. Diagnosis and treatment of nicotine dependence with emphasis on nicotine replacement therapy. A status report. European Heart Journal (2000) 21, 438–445 199. Hu Y, Zong G, Liu G, et al. Smoking Cessation, Weight Change, Type 2 Diabetes, and Mortality. N Engl J Med 2018;379:623_632 200. Hartmann-Boyce J, Chepkin SC, Ye W, et al. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev 2018;5:CD000146 201. Lindson N, Chepkin SC, Ye W, et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2019;4:CD013308 202. Woolf KJ, Zabad MN, Post JM, et al. Effect of nicotine replacement therapy on cardiovascular outcomes after acute coronary syndromes. Am J Cardiol 2012;110:968_970 203. Suissa K, Lariviere J, Eisenberg MJ, et al. . Efficacy and Safety of Smoking Cessation Interventions in Patients With Cardiovascular Disease: A Network Meta-Analysis of Randomized Controlled Trials., Circ Cardiovasc Qual Outcomes 2017;10:e002458 204. Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2016;2016(5):CD006103. Published 2016 May 9. doi:10.1002/14651858.CD006103.pub7 205. Приказ Минздрава РФот 26.10.2017 N869н «Об утверждении порядка проведения диспансеризации определенных групп взрослого населения», Приказ Минздрава от 26 февраля 2021г. №140н «Об утверждении Порядка оказания медицинской помощи взрослому населению по прекращению потребления табака или никотинсодержащей продукции, лечению табачной (никотиновой) зависимости, последствий потребления, табака или 274 никотинсодержащей продукции. http://www.consultant.ru/document/cons_doc_LAW_379416/ 206. Драпкина О. М., Концевая А. В., Калинина А. М., и др. Профилактика хронических неинфекционных заболеваний в Российской Федерации. Национальное руководство. Кардиоваскулярная терапия и профилактика. 2022;21(4):3235. doi:10.15829/1728-8800-2022-3235 207. Borland, R., Yong, H. H., O'Connor, R. J., Hyland, A., & Thompson, M. E. (2010). The reliability and predictive validity of the Heaviness of Smoking Index and its two components: findings from the International Tobacco Control Four Country study., Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 12 Suppl(Suppl 1), S45–S50. https://doi.org/10.1093/ntr/ntq038 208. Гамбарян М.Г., Драпкина О.М. Алгоритмы оказания помощи курящим в системе здравоохранения. «Позвольте спросить: Вы курите?» // Профилактическая медицина.— 2019.— 22, 3.- 57-72 209. West R, Raw M, McNeill A, et al. (2015). Health-care interventions to promote and assist tobacco cessation: A review of efficacy, effectiveness and affordability for use in national guideline development. Addiction. 110. 10.1111/add.12998 210. Lancaster T, Stead LF, Individual behavioural counselling for smoking cessation (Review) The Cochrane Library 2008, Issue 4 211. Wang MP, Suen YN, Li WH, et al. Intervention With Brief Cessation Advice Plus Active Referral for Proactively Recruited Community Smokers:, A Pragmatic Cluster Randomized Clinical Trial JAMA Intern Med. 2017 Dec 1;177(12):1790- 1797. doi: 10.1001/jamainternmed.2017.5793 212. Stead LF, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev. 2012 Oct 17; 10.1002/14651858.CD008286.pub2., 10:CD008286 213. Stead LF, Koilpillai P, Lancaster T. Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation. Database Syst Rev. 2015 Oct 12; 10.1002/14651858.CD009670.pub3., (10):CD009670 214. Cahill K, Lindson-Hawley N, Thomas KH, et al. Nicotinereceptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2016:CD006103 215. Stead LF, Perera RC, Mant D, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Systematic Review 2012, Issue 4. Art.No.: CD000146. DOI: 10.1002/14651858.CD000146.pub4 216. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database of Systematic Reviews 2013, Issue 5. Art. No.:CD009329. DOI: 10.1002/14651858.CD009329.pub2 217. Benowitz NL, Pipe A, West R, et al. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial. JAMA Intern Med 2018;178:622_631 218. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2012;(4):CD006103. Published 2012 Apr 18. doi:10.1002/14651858.CD006103.pub6 219. Karnieg T, Wang X. Cytisine for smoking cessation. CMAJ 2018; 190:E596 220. Hajek P, McRobbie H, Myers K. Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis. Thorax 2013; 68:1037 275 221. Hajek P, Phillips-Waller A, Przulj D, et al. A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy. N Engl J Med 2019;380:629_637 222. Hartmann-Boyce J, McRobbie H, Lindson N, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev 2020;10:CD010216 223. Kavousi M, Pisinger C, Barthelemy JC, et al. Electronic cigarettes and health with special focus on cardiovascular effects:, position paper of the European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol 2020:2047487320941993 224. Willsa T. A., Paganoa I., Williamsb R.J., Tamc E.K. E-cigarette use and respiratory disorder in an adult sample. Drug and Alcohol Dependence Volume 194, 1 January 2019, Pages 363-370 https://doi.org/10.1016/j.drugalcdep.2018.10.004 225. European Heart Network. Electronic cigarettes and cardiovascular disease _ an update from the European Heart Network http://www.ehnheart.org/component/attachments/attachments.html?task=att achment&id=3093 (21 July 2020) 226. Гамбарян М.Г., Калинина А.М., Попович М.В., соавт. Вся правда об электронных сигаретах: Российская реальность. Часть II. Потребление электронных сигарет в России: связь с демографическими факторами, рекламой и продвижением, курением табака и попытками бросить курить. // Профилактическая медицина.— 2019.— 22, 6.- 14-27, DOI 10.17116/profmed20192206214 227. Федеральный закон "Об охране здоровья граждан от воздействия окружающего табачного дыма, последствий потребления табака или потребления никотинсодержащей продукции" от 23.02.2013 б.м.: Специализированный правовой сайт Консультант Плюс, http://www.consultant.ru/document/cons_doc_LAW_142515/ 228. Федеральный закон от 31.07.2020г № 303-ФЗ «О внесении изменений в отдельные законодательные акты Российской Федерации по вопросу охраны здоровья граждан от последствий потребления никотинсодержащей продукции. http://www.consultant.ru/document/cons_doc_LAW_358791/ 229. Распоряжение Правительства РФ от 30.04.2021 N 1151-р Специализированный правовой сайт Консультант Плюс http://www.consultant.ru/document/cons_doc_LAW_383623/ 230. Barone-Adesi F, Gasparrini A, Vizzini L, Merletti F, Richiardi L (2011) Effects of Italian Smoking Regulation on Rates of Hospital Admission for Acute Coronary Events: A Country-Wide Study. PLOS ONE 6(3): e17419 231. Meyers DG, Neuberger JS, He J (2009) Cardiovascular effect of bans on smoking in public places: a systematic review and meta-analysis. J Am Coll Cardiol 54: 1249–1255 232. Cox B, Vangronsveld J, Nawrot TS. Impact of stepwise introduction of smoke-free legislation on population rates of acute myocardial infarction deaths in Flanders, Belgium. Heart. 2014 Sep 15;100(18):1430-5. doi: 10.1136/heartjnl-2014-305613 276 233. Гамбарян М.Г., Драпкина О.М. Эффективность реализации антитабачных законодательных мер в отношении распространенности курения в 10 субъектах Российской Федерации с 2013 по 2018 г // Профилактическая медицина.— 2021.— 24, 2.- 44-51 234. Гамбарян М.Г., Концевая А.В., Агишина Т.А., Драпкина О.М. Оценка эффективности законодательных мер по борьбе с табаком в отношении снижения госпитальной заболеваемости стенокардией и инфарктом миокарда в Российской Федерации и ее 10 субъектах //, Кардиоваскулярная терапия и профилактика.— 2021.— 20, 6.- 14-23 235. Gambaryan M., Reeves A., Deev A., et al. Effects of tobacco control police on cardiovascular morbidity and mortality in Russia //, European Journal of Public Health.— 2018.— 28, S2.- 14-16 236. Федеральный закон от 01.03.2020 № 47-ФЗ "О внесении изменений в Федеральный закон "О качестве и безопасности пищевых продуктов" 237. Статья 37 Федерального закона "Об образовании в Российской Федерации" РФ 238. Методические рекомендации МР 2.3.1.0253-21 утверждены руководителем Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека - Главным государственным санитарным врачом РФ 22.07.2021. «Нормы физиологических потребностей в энергии и пищевых веществах для различных групп населения Российской Федерации» 239. Eilat-Adar S, Sinai T, Yosefy C, Henkin Y. Nutritional recommendations for cardiovascular disease prevention. Nutrients 2013;5:3646 3683 240. European Heart Network. Transforming European food and drink policies for cardiovascular health. http://www.ehnheart.org/publications-andpapers/publications/ 1093:transforming-european-food-and-drinks-policies-forcardiovascular-health.html (21 July 2020) 241. Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and metaanalysis. Am J Clin Nutr 2010;92:1189 1196 242. Estruch R, Ros E, Salas-Salvadó J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018;378(25):e34. doi:10.1056/NEJMoa1800389 243. Mensink RP. Effects of saturated fatty acids on serum lipids and lipoproteins: a systematic review and regression analysis https://apps.who.int/iris/bitstream/handle/ 10665/246104/9789241565349- eng.pdf?sequence=1 (21 July 2020) 244. Guasch-Ferre M, Satija A, Blondin SA, et al. Meta-Analysis of Randomized Controlled Trials of Red Meat Consumption in Comparison With Various Comparison Diets on Cardiovascular Risk Factors. Circulation 2019;139:1828 1845 245. Chen M, Li Y, Sun Q, et al. Dairy fat and risk of cardiovascular disease in 3 cohorts of US adults. Am J Clin Nutr 2016;104:1209 1217 246. Li Y, Hruby A, Bernstein AM, et al. Saturated Fats Compared With Unsaturated Fats and Sources of Carbohydrates in Relation to Risk of Coronary Heart Disease: A Prospective Cohort Study. J Am Coll Cardiol 2015;66:1538 1548 247. Sacks FM, Lichtenstein AH, Wu JHY, et al. Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association [published 277 correction appears in Circulation. 2017 Sep 5;136(10):e195]. Circulation. 2017;136(3):e1-e23. doi:10.1161/CIR.0000000000000510 248. He FJ, Tan M, Ma Y, MacGregor GA. Salt Reduction to Prevent Hypertension and Cardiovascular Disease: JACC State-of-the-Art Review. J Am Coll Cardiol 2020;75:632 647 249. Willett W, Rockstrom J, Loken B, et al. Food in the Anthropocene: the EAT-Lancet Commission on healthy diets from sustainable food systems. Lancet 2019;393:447 492 250. World Health Organization. A healthy diet sustainably produced. https://apps. who.int/iris/bitstream/handle/10665/278948/WHO-NMH-NHD-18.12-eng.pdf? ua=1 (21 July 2020) 251. Zeraatkar D, Johnston BC, Bartoszko J, et al. Effect of Lower Versus Higher Red Meat Intake on Cardiometabolic and Cancer Outcomes: A Systematic Review of Randomized Trials. Ann Intern Med 2019;171:721 731 252. Zhong VW, Van Horn L, Greenland P, et al. Associations of Processed Meat, Unprocessed Red Meat, Poultry, or Fish Intake With Incident Cardiovascular Disease and All- Cause Mortality. JAMA Intern Med 2020;180:503 512 253. Zheng J, Huang T, Yu Y, Hu X, Yang B, Li D. Fish consumption and CHD mortality: an updated meta-analysis of seventeen cohort studies. Public Health Nutr 2012;15:725 737 254. Mullee A, Romaguera D, Pearson-Stuttard J, et al. Association Between Soft Drink Consumption and Mortality in 10 European Countries. JAMA Intern Med 2019;179:1479 1490 255. World Health Organization. Guideline: sugars intake for adults and children. https://www.who.int/publications/i/item/9789241549028 (21 July 2020) 256. Wood AM, Kaptoge S, Butterworth AS, et al, Emerging Risk Factors Collaboration/EPIC-CVD/UK Biobank Alcohol Study Group. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet 2018;391:1513 1523 257. Millwood IY, Walters RG, Mei XW, et al, China Kadoorie Biobank Collaborative Group. Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China. Lancet 2019;393:1831 1842 258. Holmes MV, Dale CE, Zuccolo L, et al., InterAct Consortium. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ 2014;349:g4164 259. Sundfor TM, Svendsen M, Heggen E, et al. BMI modifies the effect of dietary fat on atherogenic lipids: a randomized clinical trial. Am J Clin Nutr 2019;110:832 841 260. Downs Shauna M, Thowa Anne Marie & Leedera Stephen R. The effectiveness of policies for reducing dietary trans fat: a systematic review of the evidence. Systematic reviews Bull World Health Organ 2013; 91: 262–269H doi:10.2471/BLT.12.111468. http://www.who.int/bulletin/volumes/91/4/12- 111468.pdf?ua=1 261. Mozaffarian D, Katan MB, Ascherio A, et al. Trans fatty acids and cardiovascular disease. N Engl J Med 2006;354:1601 1613 262. Livingstone KM Celis-Morales C, Navas-Carretero S et al. Effect of an Internetbased, personalized nutrition randomized trial on dietary changes associated 278 with the Mediterranean diet: the Food 4 Me Study Am J Clin Nutr August 1 2016; 104 288-297 263. Ros E, Martínez-González MA, Estruch R, et al. Mediterranean diet and cardiovascular health: Teachings of the PREDIMED study. Adv Nutr 2014;5(3):330S-6S. doi: 10.3945/an.113.005389. Print 2014 May 264. Sacks FM, Svetkey LP, Vollmer WM, et al. DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl JMed 2001;344:3 10 265. Mente A, O’Donnell M, Rangarajan S, et al., PURE, EPIDREAM and ONTARGET/TRANSCEND Investigators. Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies. Lancet 2016;388:465 475 266. Cappuccio FP, Campbell NR. Population Dietary Salt Reduction and the Risk of Cardiovascular Disease: A Commentary on Recent Evidence. J Clin Hypertens (Greenwich) 2017;19:4 5 267. He FJ, Ma Y, Campbell NRC, et al. Formulas to Estimate Dietary Sodium Intake From Spot Urine Alter Sodium-Mortality Relationship. Hypertension 2019;74:572 580 268. Huang L, Trieu K, Yoshimura S, et al. Effect of dose and duration of reduction in dietary sodium on blood pressure levels: systematic review and meta-analysis of randomised trials. BMJ 2020;368:m315-m315 269. Yin X, Liu H, Webster J, et al. Availability, formulation, labeling, and price of lowsodium salt worldwide: environmental scan. JMIR Public Health Surveill 2021;7(7):e27423-e27423 270. Neal B, Wu Y, Feng X, et al. Effect of Salt Substitution on Cardiovascular Events and Death. N Engl J Med. 2021 Sep 16;385(12):1067-1077. doi: 10.1056/NEJMoa2105675 271. Мартинчик А.Н., Батурин А.К., Кешабянц Э.Э., и соавт. Анализ фактического питания детей и подростков России в возрасте от 3 до 19 лет. Вопр. питания. 2017. Т. 86. № 4. С. 50-60. doi: 10.24411/0042-8833-2017-00059 272. Rippe J M, Angelopoulos T J. Added sugars and risk factors for obesity, diabetes and heart disease. International Journal of Obesity 2016;40:22-27 | doi:10.1038/ijo.2016.10 273. Oyebode O, Gordon-Dseagu V,Crowe FL, at al. Fruit and vegetable intake and mortality from ischemic heart disease: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Heart study. 1235-1243.First published online:18January2011. DOI: http://dx.doi.org/10.1093/eurheartj/ehq465 274. Wang X, Ouyang Y, Liu J, et al. Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and doseresponse meta-analysis of prospective cohort studies. BMJ 2014;349:g4490 275. He FJ, Nowson CA, MacGregor GA. Fruit and vegetable consumption and stroke: meta-analysis of cohort studies. Lancet 2006;367:320 326 276. Dauchet L, Amouyel P, Hercberg S, Dallongeville J. Fruit and vegetable consumption and risk of coronary heart disease: a meta-analysis of cohort studies. J Nutr 2006;136:2588 2593 279 277. Luo C, Zhang Y, Ding Y, et al. Nut consumption and risk of type 2 diabetes, cardiovascular disease, and all-cause mortality: a systematic review and metaanalysis. Am J Clin Nutr 2014;100:256 269 278. Afshin A, Micha R, Khatibzadeh S, Mozaffarian D. Consumption of nuts and legumes and risk of incident ischemic heart disease, stroke, and diabetes: a systematic review and meta-analysis. Am J Clin Nutr 2014;100:278 288 279. Тутельян ВА, Вялков АИ, Разумов АН и соавт. Научные основы здорового питания; 2010; М.; Издательский дом «Панорама»; 816 с. ISBN 978-5-86472- 224-4 280. Тутельян ВА, Самсонов МА, Каганов БС, Шарафетдинов ХЗ. Картотека блюд диетического (лечебного и профилактического) питания оптимизированного состава 2008; М.; 448с 281. AbuMweis SS, Jew S, Ames NP. β-glucan from barley and its lipid-lowering capacity: a meta-analysis of randomized, controlled trials. Eur J Clin Nutr. 2010;64(12):1472-1480. doi:10.1038/ejcn.2010.178 282. Wolever TM, Tosh SM, Gibbs AL, et al. Physicochemical properties of oat betaglucan influence its ability to reduce serum LDL cholesterol in humans: a randomized clinical trial. Am J Clin Nutr 2010; 92:723–732 283. Threapleton DE, Greenwood DC, Evans CE, et al. Dietary fibre intake and risk of cardiovascular disease: systematic review and meta-analysis. BMJ 2013;347:f6879. 284. Zhang Z, Xu G, Liu D, et al. Dietary fiber consumption and risk of stroke. Eur J Epidemiol 2013;28:119130 285. Giacco R, Costabile G, Della Pepa G, et al. A whole-grain cereal-based diet lowers postprandial plasma insulin and triglyceride levels in individuals with metabolic syndrome. Nutr Metab Cardiovasc Dis 2014;24:837-844 286. Aburto NJ, Hanson S, Gutierrez H, et al. Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. BMJ 2013;346:f1378 287. Manson JE, Cook NR, Lee IM, et al, VITAL Research Group. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med 2019;380:33 44 288. Huang T, Afzal S, Yu C, et al, China Kadoorie Biobank Collaborative Group. Vitamin D and causespecific vascular disease and mortality: a Mendelian randomisation study involving 99,012 Chinese and 106,911 European adults. BMC Med 2019;17:160 289. Chowdhury R, Kunutsor S, Vitezova A, et al. Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ 2014;348:g1903 290. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012;308:1024 1033 291. Aung T, Halsey J, Kromhout D, et al, Omega-3 Treatment Trialists’ Collaboration. Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77917 Individuals. JAMA Cardiol 2018;3:225 234 280 292. Hu Y, Hu FB, Manson JE. Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127 477 Participants. J Am Heart Assoc 2019;8:e013543 293. Nicholls SJ, Lincoff AM, Garcia M, et al. . Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA 2020;324:2268 2280 294. Newby DE, Mannucci PM, Tell GS, et al. Expert position paper on air pollution and cardiovascular disease. Eur Heart J. 2015;36(2):83-93b. doi:10.1093/eurheartj/ehu458 295. Lelieveld J, Pozzer A, Poschl U, et al. Loss of life expectancy from air pollution compared to other risk factors: a worldwide perspective. Cardiovasc Res 2020;116:1910 1917 296. Liu C, Chen R, Sera F, et al. . Ambient Particulate Air Pollution and Daily Mortality in 652 Cities. N Engl J Med 2019;381:705 715 297. Tverdal A, Selmer R, Cohen JM, Thelle DS. Coffee consumption and mortality from cardiovascular diseases and total mortality: Does the brewing method matter? Eur J Prev Cardiol 2020;27:1986 1993 298. Poole R, Kennedy OJ, Roderick P, et al. Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes. BMJ 2017;359:j5024 299. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67(5):968-977) 300. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of All-Cause Mortality With Overweight and Obesity Using Standard Body Mass Index Categories: A Systematic Review and Meta-analysis. JAMA. 2013;309(1):71–82. doi:10.1001/jama.2012.113905 301. Xue R, Li Q, Geng Y, Wang H, et al. Abdominal obesity and risk of CVD: a doseresponse meta-analysis of thirty-one prospective studies. Br J Nutr. 2021;126(9):1420-1430. doi:10.1017/S0007114521000064 302. Dai H, Alsalhe TA, Chalghaf N, et al. The global burden of disease attributable to high body mass index in 195 countries and territories, 1990-2017: An analysis of the Global Burden of Disease Study. PLoS Med. 2020;17(7):e1003198 303. О состоянии здорового питания в Российской Федерации: Доклад.—М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2020.—118 с 304. Стародубова А.В., Стародубов В.И. Тенденции, возрастные и региональные особенности заболеваемости ожирением населения Российской Федерации в 1992—2012 гг.. Профилактическая медицина. 2017;20(6):32‑40. https://doi.org/10.17116/profmed201720632-40 305. Муромцева ГА, Концевая АВ, Константинов ВВ и соавт. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012-2013гг. Результаты исследования ЭССЕРФ. Кардиоваскулярная терапия и профилактика 2014; 13 (6): 4-11 306. Баланова ЮА, Концевая АВ, Шальнова СА. и соавт. от имени участников исследования ЭССЕ-РФ. Распространенность поведенческих факторов риска сердечно-сосудистых заболеваний в Российской популяции по результатам исследования ЭССЕ-РФ. Профилактическая медицина 2014; 17; 5: 42-53 281 307. Чазова ИЕ, Ощепкова ЕВ. Борьба с сердечно-сосудистыми заболеваниями: проблемы и пути их решения на современном этапе. Вестник Росздравнадзора 2015; 5: 7-10. 169 308. Драпкина О. М., Самородская И. В., Старинская М. А., и соавт. Ожирение: оценка и тактика ведения пациентов. Коллективная монография. М.: ФГБУ “НМИЦ ТПМ” Минздрава России; ООО “Силицея-Полиграф”. 2021. — с. 174 https://gnicpm.ru/wp-content/uploads/2020/01/e-monography_obesity.pdf 309. Погосова НВ, Оганов РГ, Бойцов СА, и соавт. Мониторинг вторичной профилактики ишемической болезни в России и Европе: результаты российской части международного многоцентрового исследования EUROASPIRE IV. Кардиология 2015; 55 (12): 99-107 310. Погосова Н.В., Оганов Р.Г., Бойцов С.А., и соавт. Эффективность первичной профилактики заболеваний, обусловленных атеросклерозом, у пациентов с высоким сердечно-сосудистым риском в России и других странах Европы (часть 1). Кардиология. 2017;57(1S):333-344. https://doi.org/10.18087/cardio.2411 311. Prospective Studies Collaboration, Whitlock G, Lewington S, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083-1096. doi:10.1016/S0140- 6736(09)60318-4 312. Шальнова СА, Деев АД, Капустина АВ и соавт. Масса тела и ее вклад в смертность от сердечно-сосудистых заболеваний и всех причин среди российского населения. Кардиоваскулярная терапия и профилактика, 2014; 13(1): 44-48 313. Niedziela J, Hudzik B, Niedziela N, et al. The obesity paradox in acute coronary syndrome: a meta-analysis. Eur J Epidemiol. 2014;29(11):801-812. doi:10.1007/s10654-014-9961-9 314. Romero-Corral A, Montori VM, Somers VK, et al. Association of body weight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 2006; 368: 666–678 315. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009;53:1925–1932 316. Bucholz EM, Rathore SS, Reid KJ, et al. Body mass index and mortality in acute myocardial infarction patients. Am J Med 2012; 125: 796–803 317. Angerås O, Albertsson P, Karason K, et al. Evidence for obesity paradox in patients with acute coronary syndromes: a report from the Swedish Coronary Angiography and Angioplasty Registry. Eur Heart J 2013; 34 318. Oreopoulos A, Padwal R, Kalantar-Zadeh K, et al. Body mass index and mortality in heart failure: a metaanalysis. Am Heart J 2008; 156: 13–22 319. Carnethon MR, De Chavez PJ, Biggs ML, et al. Association of weight status with mortality in adults with incident diabetes. JAMA 2012; 308: 581–590 320. Doehner W, Erdmann E, Cairns R, et al. Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. Int J Cardiol 2012; 162: 20–26 321. Jackson CL, Yeh HC, Szklo M, et al. Body-mass index and all-cause mortality in US adults with and without diabetes. J Gen Intern Med 2014; 29: 25–33 282 322. Миклишанская С.В., Мазур Н.А., Соломасова Л.В., Чигинева В.В. «Парадокс ожирения» и степень его доказанности. Терапевтический архив. 2020; 92 (4): 84–90. DOI: 10.26442/00403660.2020.04.000421 323. Шальнова СА, Деев АД, Карамнова НС. Гендерные особенности связи образовательного статуса и характеристик массы тела по данным обследования национальной представительной выборки. Кардиоваскулярная терапия и профилактика 2009; 8(7): 17-24 324. Malden D, Lacey B, Emberson J, et al. Body Fat Distribution and Systolic Blood Pressure in 10,000 Adults with Whole-Body Imaging: UK Biobank and Oxford BioBank. Obesity (Silver Spring). 2019;27(7):1200-1206. doi:10.1002/oby.22509 325. Hall JE, do Carmo JM, da Silva AA, et al. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res 2015;116:991–1006 326. Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003;42:878–884 327. Rotar O, Boyarinova M, Orlov A, et al. Metabolically healthy obese and metabolically unhealthy non-obese phenotypes in a Russian population. Eur J Epidemiol. 2017;32(3):251-254. doi:10.1007/s10654-016-0221-z 328. Puzianowska-Kuznicka M, Kuryłowicz A, Walkiewicz D, et al. Obesity Paradox in Caucasian Seniors: Results of the PolSenior Study. J Nutr Health Aging. 2019;23(9):796-804. doi:10.1007/s12603-019-1257-z Blüher M. Metabolically Healthy Obesity. Endocr Rev. 2020;41(3):bnaa004. doi:10.1210/endrev/bnaa004 329. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society [published correction appears in Circulation. 2014 Jun 24;129(25 Suppl 2):S139-40]. Circulation. 2014;129(25 Suppl 2):S102- S138. doi:10.1161/01.cir.0000437739.71477.ee 330. Дедов И.И., Мельниченко Г.А., Шестакова М.В., и соавт. Национальные клинические рекомендации по лечению морбидного ожирения у взрослых. 3-ий пересмотр (лечение морбидного ожирения у взрослых). Ожирение и метаболизм. 2018;15(1):53-70. https://doi.org/10.14341/omet2018153-70 331. Петухов АБ, Никитюк ДБ, Сергеев ВН. Медицинская антропология: анализ и перспективы развития в клинической практике. Медпрактика. М. Москва. 2015 332. Mechanick J.I., Youdim A., Jones D.B., et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient-2013 update: Cosponsored by american association of clinical endocrinologists, The obesity society, and american society for metabolic & bariatric surgery // Obesity.-2013.-N21(S1)/-P.S1-S27. https://doi.org/10.1002/oby.20461 333. Garvey W.T., Mechanick J.I., Brett E.M., et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity // Endocr. Pract.- 2016.-N22(S3).-P.1-203. https://doi.org/10.4158/ep161365.gl 334. Oreopoulos A, Padwal R, Norris CM, et al. Effect of obesity on short- and longterm mortality postcoronary revascularization: a meta-analysis. Obesity 2008; 16: 442–450 283 335. Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med 2010; 363: 2211– 2219 336. Kane JA, Mehmood T, Munir I, et al. Cardiovascular Risk Reduction Associated with Pharmacological Weight Loss: A Meta-Analysis. Int J Clin Res Trials. 2019;4(1):131. doi: 10.15344/2456-8007/2019/131. Epub 2019 Jan 21. PMID: 31058246; PMCID: PMC6497407 337. Franz MJ, Boucher JL, Rutten-Ramos S, VanWormer JJ. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. J Acad Nutr Diet. 2015 Sep;115(9):1447-63. doi: 10.1016/j.jand.2015.02.031. Epub 2015 Apr 29. PMID: 25935570 338. Laura Chiavaroli, Stephanie K. Nishi, Tauseef A., et al . Sievenpiper, Portfolio Dietary Pattern and Cardiovascular Disease: A Systematic Review and Metaanalysis of Controlled Trials, Progress in Cardiovascular Diseases, Volume 61, Issue 1, 2018, Pages 43-53, ISSN 0033-0620, https://doi.org/10.1016/j.pcad.2018.05.004 339. Barbaresko J, Rienks J, Nöthlings U. Lifestyle Indices and Cardiovascular Disease Risk: A Meta-analysis. Am J Prev Med. 2018 Oct;55(4):555-564. doi: 10.1016/j.amepre.2018.04.046. PMID: 30241617 340. Chang SH, Stoll CR, Song J, et al. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg. 2014;149(3):275-287. doi:10.1001/jamasurg.2013.3654 341. Park, C.H., Nam, SJ., Choi, H.S. et al. Comparative Efficacy of Bariatric Surgery in the Treatment of Morbid Obesity and Diabetes Mellitus: a Systematic Review and Network Meta-Analysis. OBES SURG 29, 2180–2190 (2019). https://doi.org/10.1007/s11695-019-03831-6 342. Neda Haghighat, Asma Kazemi, Omid Asbaghi, et al. Long-term effect of bariatric surgery on body composition in patients with morbid obesity: A systematic review and meta-analysis, Clinical Nutrition, Volume 40, Issue 4, 2021, Pages 1755-1766, ISSN 0261-5614, https://doi.org/10.1016/j.clnu.2020.10.001 343. World Health Organization. Obesity: preventing and managing the global epidemic. 1997, Geneva:WHO http://www.who.int/nutrition/publications/obesity/WHO_TRS_894/en 344. Cefalu W.T., Bray G.A., Home P.D., et al. Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors’ Expert Forum // Diabetes Care.-2015.-N38(8).-P.1567-1582. https://doi.org/10.2337/dc15-1081 345. Hasan B, Nayfeh T, Alzuabi M, et al. Weight Loss and Serum Lipids in Overweight and Obese Adults: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2020;105(12):dgaa673. doi:10.1210/clinem/dgaa673 346. Bacon SL, Sherwood A, Hinderliter A, Blumenthal JA. Effects of exercise, diet and weight loss on high blood pressure. Sports Med. 2004;34(5):307-16. doi: 10.2165/00007256-200434050-00003. PMID: 15107009 347. Schwingshackl L, Chaimani A, Hoffmann G, et al. A network meta-analysis on the comparative efficacy of different dietary approaches on glycaemic control in patients with type 2 diabetes mellitus. Eur J Epidemiol. 2018;33(2):157-170. doi:10.1007/s10654-017-0352-x 284 348. Kritchevsky SB, Beavers KM, Miller ME, et al. Intentional weight loss and all-cause mortality: a meta-analysis of randomized clinical trials. PLoS One. 2015;10(3):e0121993. Published 2015 Mar 20. doi:10.1371/journal.pone.0121993 349. Singh N, Stewart RAH, Benatar JR. Intensity and duration of lifestyle interventions for long-term weight loss and association with mortality: a meta-analysis of randomised trials. BMJ Open. 2019;9(8):e029966. Published 2019 Aug 18. doi:10.1136/bmjopen-2019-029966 350. Rose G. The strategy of preventive medicine/ Oxford: Oxford University Press 1992 351. Pate RR. Physical Activity and Public Health. JAMA. 1995;273(5):402. doi: 10.1001/jama.1995.03520290054029 352. Warburton DER. Health benefits of physical activity: the evidence. Can. Med. Assoc. J. 2006;174(6):801-809. doi: 10.1503/cmaj.051351 353. Beccuti G, Pannain S. Sleep and obesity. Curr Opin Clin Nutr Metab Care. 2011;14(4):402-412. doi:10.1097/MCO.0b013e3283479109 354. Bryan Williams, Giuseppe Mancia, Wilko Spiering, et al, ESC Scientific Document Group, 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH), European Heart Journal, Volume 39, Issue 33, 01 September 2018, Pages 3021– 3104, https://doi.org/10.1093/eurheartj/ehy339 355. Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335(7631):1194-1199 356. Avenell A, Broom J, Brown TJ, et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. 2004. In: NIHR Health Technology Assessment programme: Executive Summaries. Southampton (UK): NIHR Journals Library; 2003-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK62231 357. Клинические рекомендации по бариатрической и метаболической хирургии. Российское общество хирургов. Общество баритрических хирургов. Москва, 2014 358. Kofman MD, Lent MR, Swencionis C. Maladaptive Eating Patterns, Quality of Life, and Weight Outcomes Following Gastric Bypass: Results of an Internet Survey. Obesity. 2010;18(10):1938-1943. https://doi.org/10.1038/oby.2010.27 359. Odom J, Zalesin KC, Washington TL, et al. Behavioral Predictors of Weight Regain after Bariatric Surgery. Obes. Surg. 2009;20(3):349-356. https://doi.org/10.1007/s11695-009-9895-6 360. Colles SL, Dixon JB, O'Brien PE. Grazing and Loss of Control Related to Eating: Two High-risk Factors Following Bariatric Surgery. Obesity. 2008;16(3):615-622. https://doi.org/10.1038/oby.2007.101 361. Schwartz, A. and Doucet, É. (2010), Relative changes in resting energy expenditure during weight loss: a systematic review. Obesity Reviews, 11: 531- 547. https://doi.org/10.1111/j.1467-789X.2009.00654.x 362. Российская ассоциация эндокринологов. Клинические рекомендации. Дефицит витамина D: диагностика, лечение и профилактика. Москва, 2015 285 363. Kraus WE, Powell KE, Haskell WL, et al, 2018 Physical Activity Guidelines Advisory Committee. «Physical Activity, All-Cause and Cardiovascular Mortality, and Cardiovascular Disease». // Med Sci Sports Exerc 2019;51:1270_1281 364. Powell KE, King AC, Buchner DM, et al. «The Scientific Foundation for the Physical Activity Guidelines for Americans, 2nd Edition». // J Phys Act Health 2018:1_11 365. Sattelmair J, Pertman J, Ding EL, Kohl HW 3rd, Haskell W, Lee IM. Dose response between physical activity and risk of coronary heart disease: a meta-analysis. Circulation. 2011;124(7):789-795. doi:10.1161/CIRCULATIONAHA.110.010710 366. Hupin D, Roche F, Gremeaux V, Chatard JC, Oriol M, Gaspoz JM, Barthelemy JC, Edouard P. «Even a low-dose of moderate-to-vigorous physical activity reduces mortality by 22% in adults aged ≥ 60 years: a systematic review and metaanalysis». // Br J Sports Med 2015;49:1262_1267 367. Ekelund U, Tarp J, Steene-Johannessen J, et al. «Dose-response associations between accelerometry measured physical activity and sedentary time and all cause mortality: systematic review and harmonised meta-analysis». // BMJ 2019;366:l4570 368. Patterson R, McNamara E, Tainio M, et al. «Sedentary behaviour and risk of allcause, cardiovascular and cancer mortality, and incident type 2 diabetes: a systematic review and dose response meta-analysis». // Eur J Epidemiol 2018;33:811_829 369. Biswas A, Oh PI, Faulkner GE, et al. «Sedentary time and its association with risk for disease incidence, mortality, and hospitalization in adults: a systematic review and meta-analysis». // Ann Intern Med 2015;162:123_132 370. Liu Y, Lee DC, Li Y, et al. «Associations of Resistance Exercise with Cardiovascular Disease Morbidity and Mortality». // Med Sci Sports Exerc 2019;51:499_508 371. Saeidifard F, Medina-Inojosa JR, West CP, et al. «The association of resistance training with mortality: A systematic review and meta-analysis». // Eur J Prev Cardiol 2019;26:1647_1665 372. Cradock KA, OL G, Finucane FM, Gainforth HL, Quinlan LR, Ginis KA. «Behaviour change techniques targeting both diet and physical activity in type 2 diabetes: A systematic review and meta-analysis». // Int J Behav Nutr Phys Act 2017;14:18 373. Howlett N, Trivedi D, Troop NA, Chater AM. «Are physical activity interventions for healthy inactive adults effective in promoting behavior change and maintenance, and which behavior change techniques are effective? A systematic review and meta-analysis». // Transl Behav Med 2019;9:147_157 374. Brickwood KJ, Watson G, O’Brien J, Williams AD. Consumer-Based Wearable Activity Trackers Increase Physical Activity Participation: Systematic Review and Meta-Analysis. // JMIR Mhealth Uhealth 2019;7:e11819 375. Kyu HH, Bachman VF, Alexander LT, et al. «Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013». // BMJ 2016;354:i3857 376. Moore SC, Patel AV, Matthews CE, et al. «Leisure time physical activity of moderate to vigorous intensity and mortality: a large pooled cohort analysis». // PLoS Med 2012;9:e1001335 377. Moore SC, Lee IM, Weiderpass E, et al. «Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults». // JAMA Intern Med 2016;176:816_825 286 378. Arem H, Moore SC, Patel A, et al. «Leisure time physical activity and mortality: a detailed pooled analysis of the dose-response relationship». // JAMA Intern Med 2015;175:959_967 379. Michael Pratt, Jeffrey Norris, Felipe Lobelo, et al. «The cost of physical inactivity: moving into the 21st century». // British Journal of Sports Medicine Feb 2014, 48 (3) 171-173; DOI: 10.1136/bjsports-2012-091810 380. Davis JC, Verhagen E, Bryan S, et al. 2014 consensus statement from the first Economics of Physical Inactivity Consensus (EPIC) conference (Vancouver). Br J Sports Med. 2014;48(12):947-951. doi:10.1136/bjsports-2014-093575 381. I-Min Lee, Eric J Shiroma, Felipe Lobelo, et al. «Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy». // Lancet. 2012 Jul 21;380(9838):219-29. doi: 10.1016/S0140-6736(12)61031-9 382. Lee SW, Lee J, Moon SY, et al. Physical activity and the risk of SARS-CoV-2 infection, severe COVID-19 illness and COVID-19 related mortality in South Korea: a nationwide cohort study. Br J Sports Med. 2022;56(16):901-912. doi:10.1136/bjsports-2021-104203 383. Robert Sallis, Deborah Rohm Young, Sara Y Tartof, et al. «Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients». // Br J Sports Med 2021;55:1099–1105. doi:10.1136/bjsports2021-104080 384. Talbot LA, Morrell CH, Fleg JL, Metter EJ. «Changes in leisure time physical activity and risk of all-cause mortality in men and women: the Baltimore Longitudinal Study of Aging». // Prev Med 2007; 45: 169–176 385. Schnohr P., O’Keefe J.H., Marott J.L. et al. «Dose of jogging and long-term mortality». // The Copenhagen City Heart Study. J Am Coll Cardiol 2015;65:411– 419 386. Garrett S, Elley CR, Rose SB, et al. «Are physical activity interventions in primary care and the community cost-effective? A systematic review of the evidence». // Br J Gen Pract 2011; 61: e125–e133 387. Marijon E, Tafflet M, Celermajer DS, et al. «Sportsrelated sudden death in the general population. // Circulation 2011;124:672–681 388. Garber CE, Blissmer B, Deschenes MR, et al, American College of Sports Medicine. «American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise». // Med Sci Sports Exerc 2011;43:1334_1359 389. Ainsworth BE, Haskell WL, Herrmann SD, et al. 2011 «Compendium of Physical Activities: a second update of codes and MET values». // Med Sci SportsExerc 2011;43:1575_1581 390. Howley ET. «Type of activity: resistance, aerobic and leisure versus occupational physical activity». // Med Sci Sports Exerc 2001;33:S364_369; discussion S419- 320 391. Jakicic JM, Kraus WE, Powell KE, et al, 2018 Physical Activity Guidelines Advisory Committee. «Association between Bout Duration of Physical Activity and Health: Systematic Review». // Med Sci Sports Exerc 2019;51:1213_1219 287 392. Ortega FB, Silventoinen K, Tynelius P, Rasmussen F. «Muscular strength in male adolescents and premature death: cohort study of one million participants». // BMJ 2012;345:e7279 393. Ruiz JR, Sui X, Lobelo F, et al. «Association between muscular strength and mortality in men: prospective cohort study». // BMJ 2008;337:a439 394. Volaklis KA, Halle M, Meisinger C. «Muscular strength as a strong predictor of mortality: A narrative review». // Eur J Intern Med 2015;26:303_310 395. Schwingshackl L, Missbach B, Dias S, et al. «Impact of different training modalities on glycaemic control and blood lipids in patients with type 2 diabetes: a systematic review and network meta-analysis». // Diabetologia 2014; 57: 1789– 1797 396. Physical Activity Guidelines Advisory Committee report, 2008. To the Secretary of Health and Human Services. Part A: executive summary. Nutr Rev. 2009;67(2):114-120. doi:10.1111/j.1753-4887.2008.00136.x 397. Chastin SFM, De Craemer M, De Cocker K, et al. «How does light-intensity physical activity associate with adult cardiometabolic health and mortality? Systematic review with metaanalysis of experimental and observational studies». // Br J Sports Med 2019;53:370_376 398. Lee IM, Shiroma EJ, Lobelo F, et al, Lancet Physical Activity Series Working Group. «Effect of physical inactivity on major noncommunicable diseases worldwide: an analysis of burden of disease and life expectancy». // Lancet 2012;380:219_229 399. Katzmarzyk PT, Powell KE, Jakicic JM, et al, 2018 «Physical Activity Guidelines Advisory Committee. Sedentary Behavior and Health: Update from the 2018 Physical Activity Guidelines Advisory Committee». // Med Sci Sports Exerc 2019;51:1227_1241 400. Young DR, Hivert MF, Alhassan S, et al, Physical Activity Committee of the Council on Lifestyle and Cardiometabolic Health, Council on Clinical Cardiology, Council on Epidemiology and Prevention, Council on Functional Genomics and Translational Biology, and Stroke Council. «Sedentary Behavior and Cardiovascular Morbidity and Mortality: A Science Advisory From the American Heart Association». // Circulation 2016;134:e262-279 401. Lollgen H, Bockenhoff A, Knapp G. «Physical activity and all-cause mortality: an updated meta-analysis with different intensity categories». // Int J Sports Med 2009; 30: 213–224 402. Pelliccia A, Sharma S, Gati S, et al, ESC Scientific Document Group. 2020 ESC «Guidelines on sports cardiology and exercise in patients with cardiovascular disease». // Eur Heart J 2021;42:17_96 403. Fletcher GF, Ades PA, Kligfield P, et al. «Exercise standards for testing and training: a scientific statement from the American Heart Association». // Circulation 2013;128:873–934 404. Donnelly JE, Blair SN, Jakicic JM, et al. American College of Sports Medicine position stand. «Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults». // Med Sci Sports Exerc 2009; 41: 459–471 405. Constantino MI, Molyneaux L, Limacher-Gisler F, et al. Long-term complications and mortality in young onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care 2013; 36: 3863–3869 288 406. Оганов РГ. Значение эпидемиологических исследований и доказательной медицины для клинической практики. Кардиоваскулярная терапия и профилактика 2015; 14(4) : 4-7 407. Lim SS, Vos T, Flaxman AD, Danaei G, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2224–2260 408. Шальнова СА, Деев АД, Баланова ЮА, и соавт. Двадцатилетние тренды ожирения и артериальной гипертонии и их ассоциации в России. Кардиоваскулярная терапия и профилактика 2017; 16(4): 4-10. DOI:10.15829/1728-8800-2017-4-4-10 409. Бойцов СА, Баланова ЮА, Шальнова СА, и соавт. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика 2014; 13(4): 4-14 410. Шальнова СА, Деев АД, Баланова ЮА, Жернакова ЮВ, Конради АО, Бойцов СА от имени участников исследования «ЭССЕ-РФ». Лечение гипертонии у пациентов высокого риска. Монотерапия или комбинация? Лечащий врач 2016; 7: 17 –23 411. Lawes CM, Van der Hoom C, Rodgers A. International Society of Hypertension: Global burden of blood-pressure-related disease. Lancet 2008; 371: 1513 412. Ji H, Niiranen TJ, Rader F, et al. Sex Differences in Blood Pressure Associations With Cardiovascular Outcomes. Circulation 2021;143:761-763 413. Ji H, Kim A, Ebinger JE, et al. Sex Differences in Blood Pressure Trajectories Over the Life Course. JAMA Cardiol 2020;5:19-26 414. Кобалава Ж.Д., Конради А.О., Недогода С.В., и соавт. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. https://doi.org/10.15829/1560- 4071-2020-3-3786 415. Stergiou GS, Palatini P, Parati G, et al.; on behalf of the European Society of Hypertension Council and the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens. 2021 Jul 1;39(7):1293-1302.doi: 10.1097/HJH.0000000000002843 416. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 2006;47:846 –853 417. Huang CJ, Chiang CE, Williams B, et al. Effect Modification by Age on the Benefit or Harm of Antihypertensive Treatment for Elderly Hypertensives: A Systematic Review and Meta-analysis. Am J Hypertens 2019;32:163-174 418. SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control [published correction appears in N Engl J Med. 2017 Dec 21;377(25):2506]. N Engl J Med. 2015;373(22):2103- 2116. doi:10.1056/NEJMoa1511939 419. Сheung AK, Rahman M, Reboussin DM, et al. Effects of intensive BP control in CKD. J Am Soc Nephrol. 2017;28:2812-2823 420. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3S):S1-S87. doi:10.1016/j.kint.2020.11.003 421. Rea F, Corrao G, Merlino L, Mancia G. Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. Eur Heart J 2018;39:3654-3661 422. Salam A, Kanukula R, Atkins E, et al. Efficacy and safety of dual combination therapy of blood pressure-lowering drugs as initial treatment for hypertension: a systematic review and meta-analysis of randomized controlled trials. J Hypertens 2019;37:1768-1774 423. Verma AA, Khuu W, Tadrous M, Gomes T, Mamdani MM. Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A populationbased retrospective cohort study. PLoS Med 2018;15:e1002584 424. Izzo J.L., Zappe D.H., Jia Y. et al. Efficacy and Safety of Crystalline Valsartan/Sacubitril (LCZ696) Compared With Placebo and Combinations of Free Valsartan and Sacubitril in Patients With Systolic Hypertension: The RATIO Study/ Cardiovasc Pharmacol. 2017;69:374–381 425. Jackson A.M., Jhund S.P., Anand A.S. et al. Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction/ Euro Heart J. 2021;42:3741-3752 426. McMurray J.J., Packer M., Desai A.S., et al., PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004 427. Velazquez EJ, Morrow DA, DeVore AD, et al.; PIONEER-HF Investigators. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11. Erratum in: N Engl J Med. 2019 Mar 14;380(11):1090 428. McDonagh, Theresa A., et al. "2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology, (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC." European heart journal 42.36 (2021): 3599-3726 429. Aronow, Wilbert S. "Approaches for the management of resistant hypertension in 2020." Current hypertension reports 22.1 (2020): 1-9 430. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/, American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13–e115. DOI: 10.1161/308. HYP.0000000000000065 431. Carey RM, Calhoun DA, Bakris GL. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018 Nov;72(5):e53-e90 432. Williams B, MacDonald TM, Morant S, et al. British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension 290 (PATHWAY-2):, a randomised, double-blind, crossover trial. Lancet 2015;386:2059–2068 433. Wang C, Xiong B, Huang J. Efficacy and safety of spironolactone in patients with resistant hypertension: a meta-analysis of randomised controlled trials.Heart Lung Circ 2016;25:1021–1030 434. Agarwal R, Rossignol P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2019;394:1540-1550 435. Chapman, Neil, et al. "Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the AngloScandinavian Cardiac Outcomes Trial." Circulation 118.1 (2008): 42-48 436. Бойцов С.А., Демкина А.Е. Совершенствование медпомощи пациентам с болезнями системы кровообращения в рамках федерального проекта "Борьба с сердечно-сосудистыми заболеваниями" \\ Управление качеством в здравоохранении. 2019. № 1. С. 26-33 437. Reino-Gonzalez S, Pita-Fernández S, Seoane-Pillado T, López-Calviño B, Pértega Díaz S. How in-office and ambulatory BP monitoring compare: A systematic review and meta-analysis. J Fam Pract. 2017;66(1):E5-E12 438. Sega R, Facchetti R, Bombelli M, et al.Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study., Circulation 2005;111:1777–1783 439. Albasri A. et al. A comparison of blood pressure in community pharmacies with ambulatory, home and general practitioner office readings: systematic review and meta-analysis //Journal of hypertension. – 2017. – Т. 35. – №. 10. – С. 1919 440. Clark CE, Taylor RS, Shore AC, et al. Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis. Lancet 2012;379:905–914 441. Tucker KL, Sheppard JP, Stevens R, et al. Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis. PLoS Med. 2017;14(9):e1002389. Published 2017 Sep 19. doi:10.1371/journal.pmed.1002389 442. Okin PM, Devereux RB, Jern S, et al, LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004;292:2343 2349 443. Sehestedt T, Jeppesen J, Hansen TW, et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J 2010;31:883 891 444. Perrone-Filardi P, Coca A, Galderisi M, et al. Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: A consensus paper from the European Association of Cardiovascular Imaging (EACVI), the European Society of Cardiology Council on Hypertension, and the European Society of Hypertension (ESH). Eur Heart J Cardiovasc Imaging 2017;18:945 960 291 445. Ninomiya T, Perkovic V, de Galan BE, et al, ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009;20:1813 1821 446. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957-967 447. Sundstrom J, Arima H, Jackson R, et al, Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med 2015;162:184191 448. Thomopoulos, Costas et al. “Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials.” Journal of hypertension vol. 32,12 (2014): 2285- 95. doi:10.1097/HJH.0000000000000378 449. Patel A, ADVANCE Collaborative Group, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829840 450. Williamson JD, Supiano MA, Applegate WB, et al, SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged >/=75 Years: A Randomized Clinical Trial. JAMA 2016;315:2673-2682 451. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials. J Hypertens 2016;34:613622 452. ACCORD Study Group, Cushman WC, Evans GW, et al. Effects of intensive bloodpressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-1585 453. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290300 454. Egan BM, Bandyopadhyay D, Shaftman SR, et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012;59:11241131 455. Gupta P, Patel P, Strauch B, et al. Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence. Hypertension 2017;70:1042-1048 456. MacDonald TM, Williams B, Webb DJ, et al, British Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithm-based Therapy (PATHWAY). Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial. J Am Heart Assoc 2017;6:e006986 457. Matsuzaki M, Ogihara T, Umemoto S et al. Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension:, a randomized controlled trial. J Hypertens 2011;29:1649– 1659 292 458. Volpe M, Christian Rump L, Ammentorp B, Laeis P. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin Drug Investig 2012;32:649–664 459. Weir, Matthew R et al. “A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide.” Journal of clinical hypertension (Greenwich, Conn.) vol. 13,6 (2011): 404-12. doi:10.1111/j.1751- 7176.2011.00437.x 460. Williams B, MacDonald TM, Morant SV, et al, British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol 2018;6:464475 461. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547 1559 462. Parving HH, Brenner BM, McMurray JJ, et al, ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204 2213 463. Pencina KM, Thanassoulis G, Wilkins JT, Vasan RS, Navar AM, Peterson ED, Pencina MJ, Sniderman AD. Trajectories of Non-HDL Cholesterol Across Midlife: Implications for Cardiovascular Prevention. J Am Coll Cardiol. 2019 Jul 9;74(1):70- 79. doi: 10.1016/j.jacc.2019.04.047. PMID: 31272554; PMCID: PMC7346311 464. Marston NA, Giugliano RP, Melloni GEM, et al. Association of Apolipoprotein BContaining Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. JAMA Cardiol. 2022 Mar 1;7(3):250-256. doi: 10.1001/jamacardio.2021.5083. PMID: 34773460; PMCID: PMC8590731 465. Holmes MV, Asselbergs FW, Palmer TM, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J 2015;36:539550 466. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012;380:572580 467. Frikke-Schmidt R, Nordestgaard BG, Stene MC, et al. Association of loss-offunction mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 2008;299:25242532 468. HPS3/TIMI55REVEAL Collaborative Group, Bowman L, Hopewell JC, et al. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med 2017;377:12171227 469. Sampson M, Ling C, Sun Q, et al. A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia. JAMA Cardiol 2020;5:540548 470. Penson P, Martin SS, Henney NC, Banach M. Comparison of LDL-C calculation by friedewald and martin/hopkins methods in 12,243 adults from the United States of America [abstract]. Eur Heart J 2020;41(Suppl 2):2932 471. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, nonHDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012;307:1302-1309 293 472. Welsh C, Celis-Morales CA, Brown R, et al. Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease. Circulation 2019;140:542-552 473. Cannon CP, Blazing MA, Giugliano RP, et al. IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015;372:23872397 474. Sabatine MS, Giugliano RP, Keech AC, et al, FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017;376:17131722 475. Schwartz GG, Steg PG, Szarek M, et al. ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med 2018;379:20972107 476. Ridker PM, Rose LM, Kastelein JJP, et al. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. J Clin Lipidol. 2018;12(4):958-965. doi:10.1016/j.jacl.2018.03.088 477. Mozaffarian D. Natural trans fat, dairy fat, partially hydrogenated oils, and cardiometabolic health: the Ludwigshafen Risk and Cardiovascular Health Study. Eur Heart J 2016;37:10791081 478. Mach F, Baigent C, Catapano AL, et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111188 479. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: metaanalysis of randomised controlled trials. BMJ 2009;338:b2376 480. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network metaanalysis involving more than 65,000 patients. J Am Coll Cardiol 2008;52:1769-1781 481. Cholesterol Treatment Trialists’ (CTT) Collaboration, Fulcher J, O’Connell R, et al. Efficacy and safety of LDL-lowering therapy among men and women: metaanalysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015;385:1397-1405 482. Amarenco P, Kim JS, Labreuche J, et al, Treat Stroke to Target Investigators. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. N Engl J Med 2020;382:9 483. Moriarty PM, Thompson PD, Cannon CP, et al, ODYSSEY ALTERNATIVE Investigators. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol 2015;9:758769 484. Nissen SE, Stroes E, Dent-Acosta RE, et al, GAUSS-3 Investigators. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA 2016;315:15801590 485. Baigent C, Landray MJ, Reith C, et al. , SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebocontrolled trial. Lancet 2011;377:21812192 294 486. Schreml J, Gouni-Berthold I. Role of Anti-PCSK9 Antibodies in the Treatment of Patients with Statin Intolerance. Curr Med Chem 2018;25:15381548 487. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016;388:25322561 488. Myocardial Infarction Genetics Consortium Investigators, Stitziel NO, Won HH, et al. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med. 2014;371(22):2072-2082. doi:10.1056/NEJMoa1405386 489. Cho L, Rocco M, Colquhoun D, et al. Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study. Cardiovasc Drugs Ther 2016;30:297304 490. Ray KK, Wright RS, Kallend D, et al, ORION-10 and ORION-11 Investigators. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med 2020;382:15071519 491. Triglyceride Coronary Disease Genetics Consortium, Emerging Risk Factors Collaboration, Sarwar N, Sandhu MS, Ricketts SL, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010;375:1634-1639 492. Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, et al. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. Circulation 2018;138:770-781 493. Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther 2010;126:314-345 494. ACCORD Study Group, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:15631574 495. Keech A, Simes RJ, Barter P, et al, FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:18491861 496. Mortensen MB, Nordestgaard BG. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort. Lancet 2020;396:1644-1652 497. Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 2019;393:407-415 498. Gencer B, Marston NA, Im K, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet 2020;396:16371643 499. Cholesterol Treatment Trialists’ (CTT) Collaborators, Kearney PM, Blackwell L, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117125 500. Emerging Risk Factors Collaboration, Di Angelantonio E, Kaptoge S, et al. Association of Cardiometabolic Multimorbidity With Mortality [published correction appears in JAMA. 2015 Sep 15;314(11):1179. Leening, Maarten [corrected to Leening, Maarten J G]]. JAMA. 2015;314(1):52-60. doi:10.1001/jama.2015.7008 501. Cholesterol Treatment Trialists’ (CTT) Collaboration, Herrington WG, Emberson J, et al. Impact of renal function on the effects of LDLcholesterol lowering with 295 statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol 2016;4:829839 502. Barylski M, Nikfar S, Mikhailidis DP, et al, Lipid and Blood Pressure Meta-Analysis Collaboration Group. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy–a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res 2013;72:35-44 503. Wanner C, Krane V, Marz W, et al, German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-248 504. Fellstrom BC, Jardine AG, Schmieder RE, et al, AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:13951407 505. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова 10- й выпуск (дополненный). Доступно на: https://www.endocrincentr.ru/sites/default/files/specialists/science/clinicrecomendations/algoritmy_sd_kniga_10-y_vypusk_dopolnennyy.pdf 506. Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016. 19 (2); 104-112. doi: 10.14341/DM2004116-17 507. Ôunpuu S, Negassa A, Yusuf S. INTER-HEART: A global study of risk factors for acute myocardial infarction. Am Heart J 2001; 141: 711-21 508. Dai, Xuming et al. “Genetics of coronary artery disease and myocardial infarction.” World journal of cardiology vol. 8,1 (2016): 1-23. doi:10.4330/wjc.v8.i1.1 509. Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group. Diabetes Care. 1990;13(4):427-433. doi:10.2337/diacare.13.4.427 510. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837–53 511. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129_139 512. U.S. Food and Drug Administration. Guidance for industry. Diabetes mellitus— evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring, MD, 2008. Accessed 21 October 2021. Available from https://www.federalregister.gov/documents/2008/12/19/E8-30086/guidancefor-industry-ondiabetes-mellitus-evaluating-cardiovascular-risk-innewantidiabetic 513. Patel A, MacMahon S, Chalmers J, et al. The ADVANCE Collaborative Group, Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–2572 514. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373(9681): 2125-35 515. Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015;373:232_242 296 516. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317_1326 517. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327_1335 518. Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321:69-79 519. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128 520. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR. CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-657 521. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-357 522. Cannon, C.P.; Pratley, R.; Dagogo-Jack, S.; et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N. Engl. J. Med. 2020, 383, 1425–1435 523. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019 Jan 5;393(10166):31-39 524. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380: 2295–2306 525. Heerspink HJL, Stefánsson B V., Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020; 383: 1436–1446 526. The EMPA-KIDNEY Collaborative Group. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrol Dial Transplant. 2022 Jun 23;37(7):1317-1329. doi: 10.1093/ndt/gfac040 527. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995_2008 528. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:1413-1424 529. Packer M, Butler J, Zannad F, et al. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. Circulation. 2021 Oct 19;144(16):1284-1294 530. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–57 531. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322 532. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844 533. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebocontrolled trial. Lancet 2019; pii: S0140-6736(19)31149-3 534. Kristensen SL, Rorth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a 297 systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019;7:776-785 535. James MT, Grams ME, Woodward M, et al. A meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with AKI. AM J Kidney 2015; 66(4): 602-612 536. Emdin CA, Rahimi K, Neal B, Callender T, et al. Blood Pressure Lowering in Type 2 Diabetes. A Systematic Review and Meta-analysis. JAMA 2015; 313(6): 603-615 537. Cholesterol Treatment Trialists Collaboration, Kearney PM, Blackwell L, et al. Efficacy of cholesterollowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117_125 538. Anand SS, Bosch J, Eikelboom JW, et al, COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018;391:219-229 539. Marmot M. Social determinants of health inequalities. Lancet 2005; 365: 1099– 1104 540. Donahoe, J.T., McGuire, T.G. The vexing relationship between socioeconomic status and health. Isr J Health Policy Res 9, 68 (2020). https://doi.org/10.1186/s13584-020-00430-0 541. Gerber Y, Goldbourt U, Drory Y. Interaction between income and education in predicting long-term survival acute myocardial infarction. Eur J Cardiovasc Prev Rehabil 2008; 15: 526–532 542. Albert MA, Glynn RJ, Buring J, Ridker PM. Impact of traditional and novel risk factors on the relationship between socioeconomic status and incident cardiovascular events. Circulation 2006;114: 2619–2626 543. Alter DA, Franklin B, Ko DT, Austin PC, Lee DS, Oh PI, Stukel TA, Tu JV. Socioeconomic status, functional recovery, and long-term mortality among patients surviving acute myocardial infarction. PLoS One 2014;8:e65130 544. Barth J, Schneider S, von KaЁnel R. Lack of social support in the etiology and the prognosis of coronary heart disease: A systematic review and meta-analysis. Psychosom Med 2010; 72: 229–238 545. Valtorta NK, Kanaan M, Gilbody S, Ronzi S, Hanratty B. Loneliness and social isolation as risk factors for coronary heart disease and stroke: systematic review and meta-analysis of longitudinal observational studies. Heart. 2016;102(13):1009–16 546. Frasure-Smith N, Lespeґrance F, Gravel G, et al. Social support, depression, and mortality during the first year after myocardial infarction. Circulation 2000; 101: 1919–1924 547. Chida Y, Steptoe A. The association of anger and hostility with future coronary heart disease: a meta-analytic review of prospective evidence. J Am Coll Cardiol 2009; 53: 936–946 548. Sogaro E, Schinina F, Burgisser C, et al. Type D personality impairs quality of life, coping and short-term psychological outcome in patients attending an outpatient intensive program of cardiac rehabilitation. Monaldi Arch Chest Dis 2010; 74: 181–191 549. Denollet J. DS14: Standard assessment of negative affectivity, social inhibition, and Type D personality. Psychosom Med 2005; 67: 89–97 298 550. Grande G, Romppel M, Barth J. Association between type D personality and prognosisin patients with cardiovascular diseases: a systematic review andmetaanalysis. Ann Behav Med 2012; 43: 299–310 551. Denollet J, Schiffer AA and Spek V. A general propensity to psychological distress affects cardiovascular outcomes. Circ Cardiovasc Qual Outcomes 2010; 3: 546– 557 552. O’Dell KR, Masters KS, Spielmans GI, et al. Does type-D personality predict outcomes among patients with cardiovascular disease? A meta-analytic review. J Psychosom Res 2011; 71: 199–206 553. Jung S-A. A Review on the Validity of Type-D Personality: From the Aspect of Construct and Predictability. Asia-pacific Journal of Convergent Research Interchange 2020; 6(1):51-61 http://dx.doi.org/10.21742/apjcri.2020.01.05 554. Lodder P. A re-evaluation of the Type D personality effect. Personality and Individual Differences. 2020; 167, [110254]. https://doi.org/10.1016/j.paid.2020.110254 555. Wei D, Janszky I, Fang F, et al. Death of an offspring and parental risk of ischemic heart diseases: A population-based cohort study. PLoS Med. 2021;18(9):e1003790. Published 2021 Sep 29. doi:10.1371/journal.pmed.1003790 556. Bazoukis G, Tse G, Naka KK, et al. Impact of major earthquakes on the incidence of acute coronary syndromes - A systematic review of the literature. Hellenic J Cardiol. Sep-Oct 2018;59(5):262-267. doi: 10.1016/j.hjc.2018.05.005. Epub 2018 May 25 557. Boos CJ, De Villiers N, Dyball D, et al. The Relationship between Military Combat and Cardiovascular Risk: A Systematic Review and Meta-Analysis. Int J Vasc Med. 2019;2019:9849465. Published 2019 Dec 22. doi:10.1155/2019/9849465 558. Lin LL, Gu HY, Yao YY, et al. The association between watching football matches and the risk of cardiovascular events: A meta-analysis. J Sports Sci. 2019 Dec;37(24):2826-2834. doi: 10.1080/02640414.2019.1665246. Epub 2019 Sep 9 559. Оганов РГ, Погосова ГВ, Колтунов И.Е. и соавт. Депрессивная симптоматика ухудшает прогноз сердечно-сосудистых заболеваний и снижает продолжительность жизни больных артериальной гипертонией и ишемической болезнью сердца. Кардиология 2011; 2: 59 – 66 560. Kivimaki M, Jokela M, Nyberg ST, et al. Long working hours and risk of coronary heart disease and stroke: a systematic review and meta-analysis of published and unpublished data for 603 838 individuals. Lancet 2015;386:1739–1746 561. Погосова Н.В., Колтунов И.Е., Юферева Ю.М. Тревожные расстройства в кардиологической практике: состояние проблемы. Российский кардиологический журнал. 2010;(5):98-102 562. Roest AM, Martens EJ, Denollet J, et al. Prognostic association of anxiety post myocardial infarction with mortality and new cardiac events: A meta-analysis. Psychosom Med 2010; 72: 563–569 563. Tully PJ, Turnbull DA, Beltrame J, et al. Panic disorder and incident coronary heart disease: A systematic review and meta-regression in 1 131 612 persons and 58 111 cardiac events. Psychological Medicine. 2015 Oct;45(14):2909-20 564. Farooqi A, Khunti K, Abner S., et al. Comorbid depression and risk of cardiac events and cardiac mortality in people with diabetes: A systematic review and 299 meta-analysis. Diabetes Res Clin Pract. 2019 Oct;156:107816. doi: 10.1016/j.diabres.2019.107816. Epub 2019 Aug 14 565. Lichtman JH, Froelicher ES, Blumenthal JA, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation 2014;129: 1350–1369 doi: 10.1161/CIR.0000000000000019. Epub 2014 Feb 24 566. Zhang WY, Nan N, Song XT, et al. Impact of depression on clinical outcomes following percutaneous coronary intervention: a systematic review and metaanalysis. BMJ Open 2019;9:e026445. doi: 10.1136/bmjopen-2018-026445 567. Meijer A, Conradi HJ, Bos EH, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: A meta-analysis of 25 years of research. Gen Hosp Psychiatry 2011; 33:203–216 568. Чазов Е.И., Оганов Р.Г., Погосова Н.В., и соавт. Клинико-эпидемиологическая программа изучения депрессии в кардиологической практике: у больных артериальной гипертонией и ишемической болезнью сердца (КООРДИНАТА): первые результаты многоцентрового исследования. Кардиология 2005; 11: 4 – 11 569. Погосова  Н.В., Оганов  Р.Г., Бойцов С.А., и соавт. Психосоциальные факторы и качество жизни у пациентов с ишемической болезнью сердца: результаты российской части международного многоцентрового исследования EUROASPIRE IV. Кардиоваскулярная терапия и профилактика. 2017;16(5):20- 26. https://doi.org/10.15829/1728-8800-2017-5-20-26 570. Krupchanka D, Mladá K, Winkler P, et al. Mortality in people with mental disorders in the Czech Republic: a nationwide, register-based cohort study. Lancet Public Health. 2018 Jun;3(6):e289-e295.doi: 10.1016/S2468- 2667(18)30077-X 571. Momen NC, Plana-Ripoll O, Agerbo E, et al. Mortality Associated With Mental Disorders and Comorbid General Medical Conditions. JAMA Psychiatry. Published online March 30, 2022. doi:10.1001/jamapsychiatry.2022.0347 572. John U, Rumpf HJ, Hanke M, et al. Mental disorders and total mortality after 20 years in an adult general population sample. Eur Psychiatry. 2020 Mar 2;63(1):e30. doi: 10.1192/j.eurpsy.2020.27 573. Starace F, Mungai F, Baccari F, et al. Excess mortality in people with mental illness: findings from a Northern Italy psychiatric case register. Soc Psychiatry Psychiatr Epidemiol. 2018 Mar;53(3):249-257. doi: 10.1007/s00127-017-1468-8. Epub 2017 Dec 22 574. Scott KM, de Jonge P, Alonso J, et al. Associations between DSM-IV mental disorders and subsequent heart disease onset: beyond depression. Int J Cardiol. 2013 Oct 15;168(6):5293-9. doi: 10.1016/j.ijcard.2013.08.012. Epub 2013 Aug 15 575. Härter M, Baumeister H, Reuter K, et al. Increased 12-month prevalence rates of mental disorders in patients with chronic somatic diseases. Psychother Psychosom 2007;76(6):354-60. doi: 10.1159/000107563 576. Dar T, Radfar A, Abohashem S, et al. Psychosocial Stress and Cardiovascular Disease. Curr Treat Options Cardiovasc Med. 2019;21(5):23. Published 2019 Apr 26. doi:10.1007/s11936-019-0724-5 300 577. Petersen BD, Stenager E, Mogensen CB, et al. The association between heart diseases and suicide: a nationwide cohort study. J Intern Med. 2020 May;287(5):558-568. doi: 10.1111/joim.13025. Epub 2020 Feb 7 578. Wang J, Geng L. Effects of Socioeconomic Status on Physical and Psychological Health: Lifestyle as a Mediator. Int J Environ Res Public Health. 2019;16(2):281. Published 2019 Jan 20. doi:10.3390/ijerph16020281 579. Lin Y, Zhang S, Wang S, et al. Behavioral Factors Mediating the Impact of Educational Attainment on Incident Heart Failure - A Mediation Analysis. Circ J. 2021 Aug 25;85(9):1545-1552. doi: 10.1253/circj.CJ-21-0109. Epub 2021 Jun 15 580. Doyle F, Rohde D, Rutkowska A, et al. Systematic review and meta-analysis of the impact of depression on subsequent smoking cessation in patients with coronary heart disease: 1990–2013. Psychosom Med 2014; 76: 44–57 581. DiMatteo MR, Lepper HS and Croghan TW. Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160: 2101–2107 582. de Looff PC, Cornet LJM, Embregts PJCM, et al. Associations of sympathetic and parasympathetic activity in job stress and burnout: A systematic review. PLoS One. 2018;13(10):e0205741. Published 2018 Oct 18. doi:10.1371/journal.pone.0205741 583. Lê-Scherban F, Brenner AB, Hicken MT, et al. Child and adult socioeconomic status and the cortisol response to acute stress: evidence from the Multi-Ethnic Study of Atherosclerosis. Psychosom Med 2018; 80(2):184-192. doi: 10.1097/PSY.0000000000000543 584. Koch C, Wilhelm M, Salzmann S, Rief W, et al. A meta-analysis of heart rate variability in major depression. Psychological Medicine. 2019;49(12):1948-1957. doi:10.1017/S0033291719001351 585. Williams MS. Platelets and depression in cardiovascular disease: A brief review of the current literature. World J Psychiatry. 2012;2(6):114-123. doi:10.5498/wjp.v2.i6.114 586. Koudouovoh-Tripp, P., Hüfner, K., Egeter, J. et al. Stress Enhances Proinflammatory Platelet Activity: the Impact of Acute and Chronic Mental Stress. J Neuroimmune Pharmacol. 2021 Jun;16(2):500-512. doi: 10.1007/s11481-020- 09945-4. Epub 2020 Aug 5 587. Yin H, Cheng X, Liang Y, et al. High perceived stress may shorten activated partial thromboplastin time and lead to worse clinical outcomes in patients with coronary heart disease. Front Cardiovasc Med 2021.Nov 29;8:769857. doi: 10.3389/fcvm.2021.769857. eCollection 2021 588. Waclawovsky AJ, de Brito E, Smith L, et al. Endothelial dysfunction in people with depressive disorders: A systematic review and meta-analysis. J Psychiatr Res. 2021 Sep;141:152-159. doi: 10.1016/j.jpsychires.2021.06.045. Epub 2021 Jun 26 589. Boyle SH, Samad Z, Becker RC, et al. Depressive symptoms and mental stressinduced myocardial ischemia in patients with coronary heart disease. Psychosom Med 2013; 75: 822–831 590. Osimo EF, Pillinger T, Rodriguez IM, et al. Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. Brain Behav Immun. 2020;87:901-909. doi:10.1016/j.bbi.2020.02.010 301 591. Knaak S, Mantler E, Szeto A. Mental illness-related stigma in healthcare: Barriers to access and care and evidence-based solutions. Healthc Manage Forum. 2017;30(2):111-116. doi:10.1177/0840470416679413 592. Solmi M, Fiedorowicz J, Poddighe L, et al. Disparities in Screening and Treatment of Cardiovascular Diseases in Patients With Mental Disorders Across the World: Systematic Review and Meta-Analysis of 47 Observational Studies. Am J Psychiatry. 2021 Sep 1;178(9):793-803. doi: 10.1176/appi.ajp.2021.21010031. Epub 2021 Jul 14 593. Hoebel J, Maske UE, Zeeb H, Lampert T. Social Inequalities and Depressive Symptoms in Adults: The Role of Objective and Subjective Socioeconomic Status. PLoS One. 2017;12(1):e0169764. Published 2017 Jan 20. doi:10.1371/journal.pone.0169764 594. Mwinyi J, Pisanu C, Castelao E, et al. Anxiety Disorders are Associated with Low Socioeconomic Status in Women but Not in Men. Womens Health Issues. MayJun 2017;27(3):302-307. doi: 10.1016/j.whi.2017.01.001. Epub 2017 Feb 15 595. Wang H, Yang XY, Yang T, et al. Socioeconomic inequalities and mental stress in individual and regional level: a twenty one cities study in China. International Journal for Equity in Health 14, 25 (2015). DOI 10.1186/s12939-015-0152-4 596. Matthews KA, Gallo LC. Psychological perspectives on pathways linking socioeconomic status and physical health. Annu Rev Psychol. 2011; 62():501- 30.doi: 10.1146/annurev.psych.031809.130711 597. Rosengren A, Hawken S, Ounpuu S, et al, for the INTERHEART investigators. Association of psychosocial risk factors with risk of acute myocardial infarction in 11 119 cases and 13 648 controls from 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:953-962 598. Santosa A, Rosengren A, Ramasundarahettige C, et al. Psychosocial Risk Factors and Cardiovascular Disease and Death in a Population-Based Cohort From 21 Low-, Middle-, and High-Income Countries. JAMA Netw Open. 2021;4(12):e2138920. doi:10.1001/jamanetworkopen.2021.38920 599. Barber S, Thornicroft G. Reducing the Mortality Gap in People With Severe Mental Disorders: The Role of Lifestyle Psychosocial Interventions. Front Psychiatry. 2018 Sep 28;9:463. doi: 10.3389/fpsyt.2018.00463. eCollection 2018 600. Mensah GA, Collins PY. Understanding mental health for the prevention and control of cardiovascular diseases. Glob Heart. 2015;10(3):221-224. doi:10.1016/j.gheart.2015.08.003 601. Richards SH, Anderson L, Jenkinson CE, et al. Psychological interventions for coronary heart disease: Cochrane systematic review and meta-analysis. Eur J Prev Cardiol. 2018 Feb;25(3):247-259. doi: 10.1177/2047487317739978. Epub 2017 Dec 7 602. Gulliksson M, Burell G, Vessby B, et al. Randomized controlled trial of cognitive behavioral therapy vs standard treatment to prevent recurrent cardiovascular events in patients with coronary heart disease: Secondary Prevention in Uppsala Primary Health Care project (SUPRIM). Arch Intern Med. 2011 Jan 24;171(2):134- 40. doi: 10.1001/archinternmed.2010.510 603. Schneider RH, Grim CE, Rainforth MV, et al. Stress reduction in the secondary prevention of cardiovascular disease: randomized, controlled trial of transcendental meditation and health education in Blacks. Circ Cardiovasc Qual Outcomes. 2012;5(6):750-758. doi:10.1161/CIRCOUTCOMES.112.967406 302 604. Blumenthal JA, Sherwood A, Smith PJ, et al. Enhancing Cardiac Rehabilitation With Stress Management Training: A Randomized, Clinical Efficacy Trial. Circulation. 2016;133(14):1341-1350. doi:10.1161/CIRCULATIONAHA.115.018926 605. Pizzi C, Rutjes AWS, Costa GM, et al. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol. 2011 Apr 1;107(7):972-9. doi: 10.1016/j.amjcard.2010.11.017. Epub 2011 Jan 20 606. Kim JM, Stewart R, Lee YS, et al. Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial. JAMA. 2018 Jul 24;320(4):350-358.doi: 10.1001/jama.2018.9422 607. Ostuzzi G, Turrini G, Gastaldon C, et al. Efficacy and acceptability of antidepressants in patients with ischemic heart disease: systematic review and meta-analysis. Int Clin Psychopharmacol. 2019 Mar;34(2):65-75. doi: 10.1097/YIC.0000000000000248 608. Angermann CE, Gelbrich G, Störk S, et al. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. JAMA. 2016 Jun 28;315(24):2683-93. doi: 10.1001/jama.2016.7635 609. He W, Zhou Y, Ma J, et al. Effect of antidepressants on death in patients with heart failure: a systematic review and meta-analysis. Heart Fail Rev. 2020 Nov;25(6):919-926. doi: 10.1007/s10741-019-09850-w 610. Zigmond A.S., Snaith R.P. Hospital Anxiety and Depression Scale. ActaPsychiatScand 1983; 67: 361– 370 611. Погосова Н.В., Довженко Т.В., Бабин А.Г., Курсаков А.А., Выгодин В.А. Русскоязычная версия опросников PHQ-2 И 9: чувствительность и специфичность при выявлении депрессии у пациентов общемедицинской амбулаторной практики. Кардиоваскулярная терапия и профилактика. 2014;13(3):18-24 612. Taylor G, McNeill A, Girling A, et al. Change in mental health after smoking cessation: systematic review and meta-analysis. BMJ. 2014 Feb 13;348:g1151.doi: 10.1136/bmj.g1151 613. Cooney GM, Dwan K, Greig CA, et al. Exercise for depression. Cochrane Database Syst Rev. 2013 Sep 12;(9):CD004366. doi: 10.1002/14651858.CD004366.pub6 614. Wang L, Sun Y, Zhan J, et al. Effects of Exercise Therapy on Anxiety and Depression in Patients With Coronary Heart Disease: A Meta-Analysis of a Randomized Controlled Study. Front Cardiovasc Med. 2021 Oct 11;8:730155. doi: 10.3389/fcvm.2021.730155. eCollection 2021 615. Firth J, Marx W, Dash S, et al. The Effects of Dietary Improvement on Symptoms of Depression and Anxiety: A Meta-Analysis of Randomized Controlled Trials [published correction appears in Psychosom Med. 2020 Jun;82(5):536] [published correction appears in Psychosom Med. 2021 Feb-Mar 01;83(2):196]. Psychosom Med. 2019;81(3):265-280. doi:10.1097/PSY.0000000000000673 616. Palmer VJ, Lewis M, Stylianopolous V, et al. Primary care prevention of the cardiovascular health crisis for people with severe mental illnesses: The elephant in the room. Aust J Gen Pract. 2018 Dec;47(12):846-850. doi: 10.31128/AJGP-09- 18-4692 303 617. Rutledge T, Redwine LS, Linke SE, Mills PJ. A meta-analysis of mental health treatments and cardiac rehabilitation for improving clinical outcomes and depression among patients with coronary heart disease. Psychosom Med 2013;75:335–349 618. Погосова Г.В., Калинина А.М., Спивак Е.Ю., Назаркина В.А. Эффективность образовательной профилактической технологии у больных стабильной стенокардией в амбулаторных условиях. Кардиология 2008; 7:4-9 619. Glozier N, Christensen H, Naismith S, Cockayne N, Donkin L, Neal B, Mackinnon A, Hickie I. Internet-delivered cognitive behavioural therapy for adults with mild to moderate depression and high cardiovascular disease risks: a randomized attention-controlled trial. PLoS One 2013;8:e59139 620. Albus C, Ladwig KH, Herrmann-Lingen C. [Psychocardiology: clinically relevant recommendations regarding selected cardiovascular diseases]. Dtsch Med Wochenschr 2014; 139: 596–601 621. Tully PJ, Baumeister H. Collaborative care for comorbid depression and coronary heart disease: a systematic review and meta-analysis of randomised controlled trials. BMJ Open 2015;5:e009128. doi: 10.1136/bmjopen-2015-009128 622. Patil SJ, Ruppar T, Koopman RJ, et al. Effect of peer support interventions on cardiovascular disease risk factors in adults with diabetes: a systematic review and meta-analysis. BMC Public Health. 2018;18(1):398. Published 2018 Mar 23. doi:10.1186/s12889-018-5326-8 623. McEvoy CT, McAuley E, Moore SE, et al. A systematic review and meta-analysis of the effectiveness of peer support to reduce cardiovascular risk. Proceedings of the Nutrition Society. 2017;76(OCE3):E117. doi:10.1017/S0029665117001902 624. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018 Apr 7;391(10128):1357-1366. doi: 10.1016/S0140-6736(17)32802-7. Epub 2018 Feb 21 625. Blumenthal JA, Smith PJ, Jiang W, et al. Effect of Exercise, Escitalopram, or Placebo on Anxiety in Patients With Coronary Heart Disease: The Understanding the Benefits of Exercise and Escitalopram in Anxious Patients With Coronary Heart Disease (UNWIND) Randomized Clinical Trial. JAMA Psychiatry. 2021;78(11):1270–1278. doi:10.1001/jamapsychiatry.2021.2236 626. Honkola J, Hookana E, Malinen S, et al. Psychotropic medications and the risk of sudden cardiac death during an acute coronary event. Eur Heart J. 2012 Mar;33(6):745-51. doi: 10.1093/eurheartj/ehr368. Epub 2011 Sep 14 627. O'Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol. . 2010 Aug 24;56(9):692-9. doi: 10.1016/j.jacc.2010.03.068 628. Ladwig KH, Baghai TC, Doyle F, et al. Mental Health-Related Risk Factors and Interventions in Patients with Heart Failure. A Position Paper endorsed by the European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol. 2022 Feb 1;zwac006. doi: 10.1093/eurjpc/zwac006. Online ahead of print 629. Biomarkers Definitions Working Group. Biomarkers and surrogate end points: preferred definitions and conceptual frame work. Clin Pharmacol Ther. 2001;69:89-95. doi:10.1067/mcp.2001.113989 304 630. Ioannidis JP, Tzoulaki I. Minimal and null predictive effects for the most popular blood biomarkers of cardiovascular disease. Circ Res. 2012;110:658-662. doi: 10.1161/RES.0b013e31824da8ad 631. Tzoulaki I, Siontis KC, Evangelou E, Ioannidis JP. Bias in associations of emerging biomarkers with cardiovascular disease. JAMA Intern Med. 2013;173:664-671. doi:10.1001/jamainternmed.2013.3018 632. Гуманова Н. Г. Аналитический комплекс биохимических маркеров для доклинической диагностики и профилактики сердечно-сосудистых заболеваний. Кардиоваскулярная терапия и профилактика. 2019;18(5):117- 27. doi:10.15829/1728-8800-2019-5-117-127 633. Метельская В. А., Гуманова Н. Г. Валидные кардиоспецифические биохимические маркеры. Часть I. Кардиоваскулярная терапия и профилактика. 2020;19(4):2573. doi:10.15829/1728-8800-2020-2573 634. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;28;107(3):499- 511. doi:10.1161/01.cir.0000052939.59093.45 635. Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol. 2013;61:1146- 1156. doi: 10.1016/j.jacc.2012.12.023 636. Willeit P, Welsh P, Evans JDW, et al. High-Sensitivity Cardiac Troponin Concentration and Risk of First-Ever Cardiovascular Outcomes in 154,052 Participants. J Am Coll Cardiol. 2017;70:558-568. doi: 10.1016/j.jacc.2017.05.062 637. Willeit P, Kaptoge S, Welsh P, et al. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant data metaanalysis. Lancet Diabetes Endocrinol. 2016;4:840-849. doi: 10.1016/S2213- 8587(16)30196-6 638. Sivapalaratnam S, Boekholdt SM, Trip MD, et al. Family history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study. Heart 2010;96:1985–1989 639. Gray, B. Genetic testing for inherited cardiovascular disease: implications of the AHA scientific statement for cardiologists. / B. Gray , C. Semsarian. // Heart Lung Circ. — 2020. — Vol. 29. — № 11. P. 1581-1584 640. Roberts, R. A less than provocative approach for the primary prevention of CAD. / R. Roberts, J. Fair. // J Cardiovasc Transl Res. — 2021. — Jun 14 641. Roberts, R. Genetic risk stratification: a paradigm shift in prevention of coronary artery disease. / R. Roberts, C.C. Chang, T. Hadley. // JACC Basic Transl Sci. — 2021. — Vol. 6. — № 3. — P. 287-304 642. Мешков А.Н. Молекулярно-генетическая диагностика предрасположенности к развитию ишемической болезни сердца: современное состояние проблемы. / А.Н. Мешков, Н.В. Щербакова. // Consilium Medicum. — 2016. — Т. 18. — № 12. — С. 22-26 643. Polygenic Risk Score: Clinically Useful Tool for Prediction of Cardiovascular Disease and Benefit from Lipid-Lowering Therapy? / N. Arnold, W. Koenig // Cardiovasc Drugs Ther.–2021. – Vol. 35. – № 3. – P. 627–635 305 644. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations / A. V. Khera, M. Chaffin, K. G. Aragam et al] // Nature Genetics.– 2018.– Vol. 50 – № 9 –P.1219–1224 645. Whole-Genome Sequencing to Characterize Monogenic and Polygenic Contributions in Patients Hospitalized With Early-Onset Myocardial Infarction / A. V. Khera, M. Chaffin, S. M. Zekavat et al. // Circulation. – 2019. – Vol. 139. – № 13. – P. 1593–1602 646. Trinder, M. Association of monogenic vs polygenic hypercholesterolemia with risk of atherosclerotic cardiovascular disease. / M. Trinder, G.A. Francis, L.R. Brunham. // JAMA Cardiol. — 2020. — Vol. 5. — № 4. — P. 390-399 647. Genetic risk, adherence to a healthy lifestyle, and coronary disease / A. V. Khera, C. A. Emdin, I. Drake , et al // N Engl J Med – 2016. – Vol. 375. – № 24. – P. 2349– 2358 648. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: An analysis of primary and secondary prevention trials / J. L. Mega, N. O. Stitziel, J. G. Smith , et al // Lancet. – 2015. – Vol. 385. – № 9984. – P. 2264– 2271 649. Incorporating a Genetic Risk Score Into Coronary Heart Disease Risk Estimates: Effect on Low-Density Lipoprotein Cholesterol Levels (the MI-GENES Clinical Trial) / I. J. Kullo, H. Jouni, E. E. Austin , et al // Circulation. – 2016. – Vol. 22. – № 12. – P. 1181–1188 650. Kavousi M, Desai CS, Ayers C, et al. Prevalence and prognostic implications of coronary artery calcification in low-risk women: a meta-analysis. JAMA2016; 316: 2126-2134 651. Lorenz MW, Polak JF, Kavousi M, PROG-IMT Study Group et al. Carotid intimamedia thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. Lancet 2012; 379: 2053-2062 652. Kavousi M, Elias-Smale S, Rutten JH, et al. Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med 2012; 156: 438-444 653. Vlachopoulos C, Xaplanteris P, Aboyans V, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis 2015; 241: 507-532 654. Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 2012; 308: 788-795 655. Garg PK ,Jorgensen NW, McClelland RL, et al.Use of coronary artery calcium testing to improve coronary heart disease risk assessment in a lung cancer screening population: the Multi-Ethnic Study of Atherosclerosis (MESA). J Cardiovasc Comput Tomogr 2018; 12: 493-499 656. Bear M., Butcher M. and Shaughnessy S.G. : "Oxidized low-density lipoprotein acts synergistically with β-glycerophosphate to induce osteoblast differentiation in primary cultures of vascular smooth muscle cells". J Cell Biochem 2008; 105: 185 306 657. Rumberger J.A., Simons D.B., Fitzpatrick L.A., Sheedy P.F. and Schwartz R.S. : "Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study". Circulation 1995; 92: 2157 658. Sangiorgi G., Rumberger J.A., Severson A.et al. : "Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology". J Am Coll Cardiol 1998; 31: 126 659. Agatston A.S., Janowitz W.R., Hildner F.J., Zusmer N.R., Viamonte M. and Detrano R. "Quantification of coronary artery calcium using ultrafast computed tomography". J Am Coll Cardiol 1990; 15: 827 660. Schmermund A., Möhlenkamp S., Stang A., et al. and for the Heinz Nixdorf RECALL Study Investigative Group : "Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL Study". Am Heart J 2002; 144: 212 661. Lehmann N., Erbel R., Mahabadi A.A., et al. and for the Heinz Nixdorf Recall Study Investigators : "Value of progression of coronary artery calcification for risk prediction of coronary and cardiovascular events: result of the HNR study (Heinz Nixdorf Recall)". Circulation 2018; 137: 665 662. McClelland R.L., Jorgensen N.W., Budoff M.et al. "10-Year coronary heart disease risk prediction using coronary artery calcium and traditional risk factors: derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) with validation in the HNR (Heinz Nixdorf Recall) study and the DHS (Dallas Heart Study)". J Am Coll Cardiol 2015; 66: 1643 663. Miedema M.D., Duprez D.A., Misialek J.R.et al. "Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the Multi-Ethnic Study of Atherosclerosis". Circ Cardiovasc Qual Outcomes 2014; 7: 453 664. Mortensen M.B., Falk E., Li D.et al. "Statin trials, cardiovascular events, and coronary artery calcification: implications for a trial-based approach to statin therapy in MESA". J Am Coll Cardiol Img 2018; 11: 221 665. Knuuti J, Wijns W, Saraste A et al. 2019 ESC guidelines on the diagnosis and management of chronic coronary syndromes: the task force for diagnosis and management of chronic coronary syndromes of the European society of cardiology (ESC). Eur Heart J. 2020; 41:407–477. https://doi.org/10. 1093/eurheartj/ehz425 666. Leipsic J, Abbara S, Achenbach S et al. SCCT guidelines for the interpretation and reporting of coronary CT angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee. J Cardiovasc Comput Tomogr.2014; 8:342–358. https://doi.org/10.1016/j.jcct. 2014.07.003 667. Hadamitzky M, Freissmuth B, Meyer T, et al. Prognostic value of coronary computed tomographic angiography for prediction of cardiac events in patients with suspected coronary artery disease. JACC Cardiovasc Imaging. 2009;2(4):404-411. doi:10.1016/j.jcmg.2008.11.015 668. Min JK, Dunning A, Lin FY et al. Age- and sexrelated differences in all-causemortality risk based on coronary computed tomography angiography findings resultsfrom the International Multicenter CONFIRM (CoronaryCTAngiographyEvaluationfor Clinical Outcomes: An International Multicenter Registry) of 23,854 patients without known 307 coronary artery disease. J Am Coll Cardiol. 2011; 58:849–860. https://doi.org/10.1016/j.jacc.2011. 02.074 669. Douglas PS, Hoffmann U, Patel MR et al. Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med. 2015; 372:1291–1300. https://doi.org/10.1056/ NEJMoa1415516 670. SCOT-HEART Investigators. CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open-label, parallel-group, multicentre trial. Lancet. 2015; 385:2383–2391. https://doi.org/10.1016/ S0140-6736(15)60291-4 671. Веселова Т.Н., Терновой С.К., Чеповский А.М., и соавт. Оценка фракционного резерва кровотока по данным компьютерной томографии: сравнение расчетных показателей с результатами инвазивных измерений. Кардиология. 2021; 61(7): 28- 35. doi: 10.18087/cardio.2021.7.n1540 672. Веселова Т.Н., Омаров Ю.А., Шахнович Р.М., и соавт. Диагностическая эффективность перфузионной компьютерной томографии миокарда и неинвазивного измерения фракционного резерва кровотока по данным компьютерной томографической ангиографии Российский электронный журнал лучевой диагностики. 2020: 10 (3);150-156. doi: 10.21569/2222-7415-2020-10-2-71- 77 673. Celeng C, Leiner T, Maurovich-Horvat P. Anatomical and functional computed tomography for diagnosing hemodynamically significant coronary artery disease: a meta-analysis. JACC Cardiovasc Imaging. 2019; 12:1316–1325. https://doi. org/10.1016/j.jcmg.2018.07.022 674. Nørgaard BL, Terkelsen CJ, Mathiassen ON et al. Coronary CT angiographic and flow reserve-guided management of patients with stable ischemic heart disease. J Am Coll Cardiol. 2018; 72:2123–2134. https://doi.org/10.1016/j.jacc. 2018.07.043 675. Lu MT, Ferencik M, Roberts RS et al. Noninvasive FFR derived from coronary CT angiography: management and outcomes in the PROMISE trial. JACC Cardiovasc Imaging. 2017; 10:1350–1358. https://doi.org/10.1016/j.jcmg. 2016.11.024 Herz 5 · 2020 419 676. Douglas PS, De Bruyne B, Pontone G et al. 1-year outcomes of FFR CT-guided care in patients with suspected coronary disease. J Am Coll Cardiol. 2016; 68:435–445. https://doi.org/10.1016/j.jacc.2016. 05.057 677. Ершова А.И., Балахонова Т.В., Мешков А.Н., и соавт. Распространенность атеросклероза сонных и бедренных артерий среди населения Ивановской области: исследование АТЕРОГЕН-Иваново. Кардиоваскулярная терапия и профилактика. 2021;20(5):2994. https://doi.org/10.15829/1728-8800-2021- 2994 678. Генкель В.В., Кузнецова А.С., Лебедев Е.В., Шапошник И.И. Прогностическая значимость атеросклеротического поражения одного или двух сосудистых бассейнов у пациентов высокого и очень высокого сердечно-сосудистого риска. Кардиоваскулярная терапия и профилактика. 2021;20(2):2669. https://doi.org/10.15829/1728-8800-2021-2669 679. Ершова А.И., Мешков А.Н., Деев А.Д. и соавт. Атеросклеротическая бляшка в сонных артериях как маркер риска развития сердечно-сосудистых событий в популяции среднего возраста. Кардиоваскулярная терапия и профилактика. 2018;17(4):34-39. https://doi.org/10.15829/1728-8800-2018-4- 34-39 680. Inaba, Y. Carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events: A meta-analysis / Y. Inaba, J. A. Chen, S. R. Bergmann // Atherosclerosis. – 2012. – Vol. 220. – № 1. – P. 128– 133 308 681. Бойцов С.А., Кухарчук В.В., Карпов Ю.А и соавт. Субклинический атеросклероз как фактор риска сердечно-сосудистых осложнений. Кардиоваскулярная терапия и профилактика. 2012;11(3):82-86. https://doi.org/10.15829/1728-8800-2012-3-82-86 682. Johri AM, Nambi V, Naqvi TZ, et al. Recommendations for the Assessment of Carotid Arterial Plaque by Ultrasound for the Characterization of Atherosclerosis and Evaluation of Cardiovascular Risk: From the American Society of Echocardiography. J Am Soc Echocardiogr. 2020 Aug;33(8):917-933. doi: 10.1016/j.echo.2020.04.021 683. Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis. 2012;34(4):290-296. doi:10.1159/000343145 684. А. И. Ершова, Т. В. Балахонова, А. А. Иванова и соавт. Проблема стратификации сердечно-сосудистого риска в зависимости от выраженности атеросклероза сонных и бедренных артерий/ // Кардиоваскулярная терапия и профилактика. – 2020. – Т. 19. – № 2. – С. 75–81 685. M. Plichart, D. S. Celermajer, M. Zureik, et al. Carotid intima-media thickness in plaque-free site, carotid plaques and coronary heart disease risk prediction in older adults. The Three-City Study / Atherosclerosis. – 2011. – Vol. 219. – № 2. – P. 917–924 686. E. Bérard, V. Bongard, J. B. Ruidavets, et al. Pulse wave velocity , pulse pressure and number of carotid or femoral plaques improve prediction of cardiovascular death in a population at low risk / J Hum Hypertens. – 2013. – Vol. 27. – № 9. – P. 529–534 687. J. F. Polak, M. Szklo, R. A. Kronmal, et al. The value of carotid artery plaque and intima-media thickness for incident cardiovascular disease: the multi-ethnic study of atherosclerosis / J Am Heart Assoc. – 2013. – Vol. 2. – № 2. – P. 1–11 688. Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763-816. doi:10.1093/eurheartj/ehx095 689. L. Davidsson, B. Fagerberg, G. Bergström et al. Ultrasound-assessed plaque occurrence in the carotid and femoral arteries are independent predictors of cardiovascular events in middle-aged men during 10 years of follow-up / Atherosclerosis. Atherosclerosis, – 2010. – Vol. 209. – № 2. – P. 469–473 690. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and metaanalysis. J Am Coll Cardiol 2010;55:13181327 691. Van Bortel LM, Laurent S, Boutouyrie P, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse 309 wave velocity. J Hypertens. 2012;30(3):445-448. doi:10.1097/HJH.0b013e32834fa8b0 692. Ben-Shlomo Y, Spears M, Boustred C, et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol. 2014;63(7):636-646. doi:10.1016/j.jacc.2013.09.063 693. McDermott MM, Greenland P, Liu K, et al. The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study. Ann Intern Med 2002;136:873883 694. Feringa HH, Bax JJ, van Waning VH, et al. The long-term prognostic value of the resting and postexercise ankle-brachial index. Arch Intern Med 2006;166:529– 535 695. Ankle Brachial Index Collaboration, Fowkes FG, Murray GD, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a metaanalysis. JAMA 2008;300:197208 696. Owens DK, Davidson KW, Krist AH, et al. Screening for Abdominal Aortic Aneurysm: US Preventive Services Task Force Recommendation Statement. JAMA. 2019 Dec 10;322(22):2211-2218. doi: 10.1001/jama.2019.18928 697. Glauser F, Mazzolai L, Darioli R, Depairon M. Interaction between widening of diameter of abdominal aorta and cardiovascular risk factors and atherosclerosis burden. Intern Emerg Med. 2014 Jun;9(4):411-7. doi: 10.1007/s11739-013-0941- y 698. Altobelli E, Rapacchietta L, Profeta VF, Fagnano R. Risk Factors for Abdominal Aortic Aneurysm in Population-Based Studies: A Systematic Review and MetaAnalysis. Int J Environ Res Public Health. 2018 Dec 10;15(12):2805. doi: 10.3390/ijerph15122805 699. Genkel V, Kuznetcova A, Shaposhnik I. Relationship between the abdominal aortic diameter and carotid atherosclerosis in middle-aged patients without established atherosclerotic cardiovascular diseases. Int Angiol. 2021 Apr;40(2):131-137. doi: 10.23736/S0392-9590.21.04493-X 700. Vallabhaneni SR. Final follow-up of the Multicentre Aneurysm Screening Study (MASS) randomized trial of abdominal aortic aneurysm screening. Br J Surg. 2012 Dec;99(12):1656. doi: 10.1002/bjs.8941 701. Ying AJ, Affan ET. Abdominal Aortic Aneurysm Screening: A Systematic Review and Meta-analysis of Efficacy and Cost. Ann Vasc Surg. 2019 Jan;54:298-303.e3. doi: 10.1016/j.avsg.2018.05.044 702. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic InterSociety Consensus; and Vascular Disease Foundation. J Am Coll Cardiol. 2006 Mar 21;47(6):1239-312. doi: 10.1016/j.jacc.2005.10.009. PMID: 16545667 703. Erbel R, Aboyans V, Boileau C, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2014 Nov 1;35(41):2873-926. doi: 10.1093/eurheartj/ehu281. 704. Балахонова Т.В., Ершова А.И., Ежов М.В. и соавт. Фокусированное ультразвуковое исследование сосудов. Консенсус российских экспертов. Кардиоваскулярная терапия и профилактика. 2022;21(7):3333. doi:10.15829/1728-8800-2022-3333. EDN WLJEHZ 705. Chaikof EL, Brewster DC, Dalman RL, et al. Society for Vascular Surgery. The care of patients with an abdominal aortic aneurysm: the Society for Vascular Surgery practice guidelines. J Vasc Surg. 2009;50(4)(suppl):S2-S49. doi:10.1016/j.jvs.2009.07.002 706. Lane DA, Skjoth F, Lip GYH, Larsen TB, Kotecha D. Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care. J AmHeart Assoc 2017;6:e005155 707. Emdin CA, Wong CX, Hsiao AJ, et al. Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis ofcohort studies. BMJ 2016;532:h7013 708. Ko D, Rahman F, Schnabel RB, Yin X, Benjamin EJ, Christophersen IE. Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis.Nat Rev Cardiol 2016;13:321-332 709. Mou L, Norby FL, Chen LY, et al. Lifetime Risk of Atrial Fibrillation by Race and Socioeconomic Status: ARIC Study (Atherosclerosis Risk in Communities). Circ Arrhythm Electrophysiol 2018;11:e006350 710. Аракелян М.Г., Бокерия Л.А., Васильева Е.Ю., и соавт. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Одобрено на заседании Научно-практического совета Минздрава Российской Федерации. Российский кардиологический журнал. 2021;26(7):4594. doi:10.15829/1560- 4071-2021-4594 711. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D’Agostino RB. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996;27:1760- 1764 712. Hindricks G, Potpara T, Dagres N, et al, ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42:373-498 713. Kalantarian S, Stern TA, Mansour M, Ruskin JN. Cognitive impairment associated with atrial fibrillation: a meta-analysis. Ann Intern Med 2013;158:338-346 714. Andersson T, Magnuson A, Bryngelsson IL, et al. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study. Eur Heart J 2013;34:1061-1067 715. Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GYH. Improved Outcomes by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the 311 Simple ABC (Atrial Fibrillation Better Care) Pathway. Am J Med 2018;131:1359- 1366 e1356 716. Yoon M, Yang PS, Jang E, et al. Improved Population-Based Clinical Outcomes of Patients with Atrial Fibrillation by Compliance with the Simple ABC (Atrial Fibrillation Better Care) Pathway for Integrated Care Management: A Nationwide Cohort Study. Thromb Haemost 2019;19:1695-1703 717. Pastori D, Pignatelli P, Menichelli D, Violi F, Lip GYH. Integrated Care Management of Patients With Atrial Fibrillation and Risk of Cardiovascular Events: The ABC (Atrial fibrillation Better Care) Pathway in the ATHERO-AF Study Cohort. Mayo Clin Proc 2019;94:1261-1267 718. Pastori D, Farcomeni A, Pignatelli P, Violi F, Lip GY. ABC (Atrial fibrillation Better Care) Pathway and Healthcare Costs in Atrial Fibrillation: The ATHERO-AF Study. Am J Med 2019;132:856-861 719. Stewart S, Ball J, Horowitz JD et al. Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial. Lancet. 2015;385:775–84 720. An J, Niu F, Zheng C et al. Warfarin Management and Outcomes in Patients with Nonvalvular Atrial Fibrillation Within an Integrated Health Care System. J Manag Care Spec Pharm. 2017;23:700–712 721. Voskoboinik A, Kalman JM, De Silva A, et al. Alcohol Abstinence in Drinkers with Atrial Fibrillation. N Engl J Med 2020;382:20-28 722. Conen D, Albert CM. Alcohol consumption and risk of atrial fibrillation: how much is too much? J Am Coll Cardiol 2014;64:290-292 723. Larsson SC, Drca N, Wolk A. Alcohol consumption and risk of atrial fibrillation: a prospective study and dose-response meta-analysis. J Am Coll Cardiol 2014;64:281-289 724. Lavie CJ, Thomas RJ, Squires RW, Allison TG, Milani RV. Exercise training and cardiac rehabilitation in primary and secondary prevention of coronary heart disease. Mayo Clin Proc 2009;84:373-383 725. Mont L. Arrhythmias and sport practice. Heart 2010;96:398-405 726. Menezes AR, Lavie CJ, De Schutter A, et al. Lifestyle modification in the prevention and treatment of atrial fibrillation. Prog Cardiovasc Dis 2015;58:117- 125 727. Karjalainen J, Kujala UM, Kaprio J, Sarna S, Viitasalo M. Lone atrial fibrillation in vigorously exercising middle aged men: case-control study. BMJ 1998;316:1784- 1785 728. Baldesberger S, Bauersfeld U, Candinas R, et al. Sinus node disease and arrhythmias in the long-term follow-up of former professional cyclists. Eur Heart J 2008;29:71-78 729. Molina L, Mont L, Marrugat J, et al. Long-term endurance sport practice increases the incidence of lone atrial fibrillation in men: a follow-up study. Europace 2008;10:618-623 730. Nielsen JR, Wachtell K, Abdulla J. The Relationship Between Physical Activity and Risk of Atrial Fibrillation-A Systematic Review and Meta-Analysis. J Atr Fibrillation 2013;5:789 731. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in 312 patients with atrial fibrillation: a randomized clinical trial. JAMA 2013;310:2050- 2060 732. Pathak RK, Middeldorp ME, Lau DH, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol 2014;64:2222-2231 733. Pathak RK, Middeldorp ME, Meredith M, et al. Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY). J Am Coll Cardiol 2015;65:2159-2169 734. Pathak RK, Elliott A, Middeldorp ME, et al. Impact of CARDIOrespiratory FITness on Arrhythmia Recurrence in Obese Individuals With Atrial Fibrillation: The CARDIO-FIT Study. J Am Coll Cardiol 2015;66:985-996 735. Lip GYH, Coca A, Kahan T, et al. Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), AsiaPacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Europace 2017;19:891-911 736. Dzeshka MS, Shantsila A, Shantsila E, Lip GYH. Atrial Fibrillation and Hypertension. Hypertension 2017;70:854-861 737. Huxley RR, Misialek JR, Agarwal SK, et al. Physical activity, obesity, weight change, and risk of atrial fibrillation: the Atherosclerosis Risk in Communities study. Circ Arrhythm Electrophysiol 2014;7:620-625 738. Linz D, McEvoy RD, Cowie MR, et al. Associations of Obstructive Sleep Apnea With Atrial Fibrillation and Continuous Positive Airway Pressure Treatment: A Review. JAMA Cardiol 2018;3:532-540 739. Holmqvist F, Guan N, Zhu Z, et al, ORBIT-AF Investigators. Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation-Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J 2015;169:647- 654 e642 740. Qureshi WT, Nasir UB, Alqalyoobi S, et al. Meta-Analysis of Continuous Positive Airway Pressure as a Therapy of Atrial Fibrillation in Obstructive Sleep Apnea. Am J Cardiol 2015;116:1767-1773 741. Shukla A, Aizer A, Holmes D, et al. Effect of Obstructive Sleep Apnea Treatment on Atrial Fibrillation Recurrence: A Meta-Analysis. JACC Clin Electrophysiol 2015;1:41-51 742. Fatemi O, Yuriditsky E, Tsioufis C, et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). Am J Cardiol 2014;114:1217-1222 743. Donnellan E, Aagaard P, Kanj M, et al. Association Between Pre-Ablation Glycemic Control and Outcomes Among Patients With Diabetes Undergoing Atrial Fibrillation Ablation. JACC Clin Electrophysiol 2019;5:897-903 744. Ponikowski P, Voors AA, Anker SD, et al, Authors/Task Force Members, Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891-975 313 745. Терещенко С. Н., Галявич А. С., Ускач Т. М. и соавт. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. doi:10.15829/1560-4071-2020- 4083 746. Rienstra M, Hobbelt AH, Alings M, et al, RACE 3 Investigators. Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial. Eur Heart J 2018;39:2987- 2996 747. Long L, Mordi IR, Bridges C, et al. Exercise-based cardiac rehabilitation for adults with heart failure. Cochrane Database Syst Rev 2019;1:CD003331 748. Khan H, Kella D, Rauramaa R, et al. Cardiorespiratory fitness and atrial fibrillation: A population-based follow-up study. Heart Rhythm 2015;12:1424-1430 749. Kernan WN, Ovbiagele B, Black HR et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014;45:2160-2236 750. Steiner T, Al-Shahi Salman R, Beer R et al. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke 2014;9:840-855 751. Ornello R, Degan D, Tiseo C et al. Distribution and temporal trends from 1993 to 2015 of ischemic stroke subtypes: a systematic review and meta-Analysis. Stroke 2018;49:814-819 752. Rodrigues MA, Samarasekera N, Lerpiniere et al. The Edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage associated with cerebral amyloid angiopathy: model development and diagnostic test accuracy study. Lancet Neurol 2018;17:232-240 753. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-867 754. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457 755. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151 756. Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-2104 757. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992 758. Klijn CJ, Paciaroni M, Berge E et al. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline. Eur Stroke J 2019;4:198-223 759. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891 760. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials. Lancet 2009;373:1849-1860 314 761. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329- 1339 762. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86 763. ESPRIT Study Group, Halkes PH, van Gijn J et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006;367:1665-1673 764. Sacco RL, Diener HC, Yusuf S et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008;359:1238-1251 765. Johnston SC, Amarenco P, Albers GW et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med 2016;375:35-43 766. SPS3 Investigators, Benavente OR, Hart RG et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012;367:817-825 767. Bhatt DL, Fox KA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-1717 768. Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-337 769. Johnston SC, Easton JD, Farrant M et al. Neurological Emergencies Treatment Trials Network, the POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med 2018;379:215-225 770. Wang Y, Wang Y, Zhao X et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013;369:11-19 771. Liu M, Counsell C, Sandercock P. Anticoagulants for preventing recurrence following ischaemic stroke or transient ischaemic attack. Cochrane Database Syst Rev 2000:CD000248 772. Mohr JP, Thompson JL, Lazar RM et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444-1451 773. Amarenco P, Denison H, Evans SR et al. Ticagrelor added to aspirin in acute nonsevere ischemic stroke or transient ischemic attack of atherosclerotic origin. Stroke 2020;51:3504-3513 774. Johnston SC, Amarenco P, Denison H et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med 2020;383:207-217 775. Diener HC, Sacco RL, Easton JD et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med2019;380:1906-1917 776. Hart RG, Sharma M, Mundl H et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018;378:2191-2201 777. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J (Engl) 1995;108:710-717 778. Wang WT, You LK, Chiang CE et al. Comparative effectiveness of blood pressurelowering drugs in patients who have already suffered from stroke: traditional and bayesian network metaanalysis of randomized trials. Medicine (Baltimore) 2016;95:e3302 315 779. Odden MC, McClure LA, Sawaya BP et al. Achieved blood pressure and outcomes in the secondary prevention of small subcortical strokes trial.Hypertension 2016;67:63-69 780. PROGRESS Collaborative Group. Randomised trial of a perindopril-based bloodpressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41 781. Amarenco P, Bogousslavsky J, Callahan A et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-559 782. Vermeer SE, Hollander M, van Dijk EJ et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003;34:1126-1129 783. Bernick C, Kuller L, Dulberg C et al. Silent MRI infarcts and the risk of future stroke: the cardiovascular health study. Neurology 2001;57:1222-1229 784. Debette S, Beiser A, DeCarli C et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. Stroke 2010;41:600-606 785. Katsanos AH, Filippatou A, Manios E, et al. Blood Pressure Reduction and Secondary Stroke Prevention: A Systematic Review and Metaregression Analysis of Randomized Clinical Trials. Hypertension 2017;69:171179 786. Roger VL, Go AS, Lloyd-Jones DM et al. Heart Disease and Stroke Statistics 2012 Update: A Report From the American Heart Association. Circulation 2012; 125: 2- 220 787. Шальнова СА, Деев АД. Тенденции смертности в России в начале XXI века (по данным официальной статистики). Кардиоваскулярная терапия и профилактика 2011; 10(6): 5-10 788. Kerr M, Bray B, Medcalf J, et al. Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol Dial Transplant 2012; 27(3): 73-80 789. Coresh J, Stevens L, Levey A. Chronic kidney disease is common: What do we do next? Nephrol Dial Transplant 2008; 23(8): 1122-1125 790. Xu R, Zhang L, Zhang P, et al. Comparison of the prevalence of chronic kidney disease among different ethnicities: Beijing CKD survey and American NHANES. Nephrol Dial Transplant 2009;24(4): 1220-6 791. McClellan WM, Resnick B, Lei L, et al. Prevalence and Severity of Chronic Kidney Disease and Anemia in the Nursing Home Population. J Am Med Dir Assoc 2010; 11: 33-41 792. GBD 2016 CausesofDeathCollaborators. Global, regional, and national agesex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet2017;390:1151-1210 793. Amann K, Wanner C, Ritz E. Cross-Talk between the kidney and the cardiovascular system. J Am Soc Nephrol 2006; 17; 2112-2119 794. Zoccali C, Goldsmith D, Agarwal R et al. The complexity of the cardio–renal link: taxonomy, syndromes, and diseases. Kidney Intern Suppl 2011; 1: 2-5 795. Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in populationbased studies: systematic review. BMC Public Health 2008; 8: 117 796. Zoccali C, Kramer A, Jager KJ. Epidemiology of CKD in Europe: an uncertain scenario. Nephrol Dial Transplant 2010; 25: 1731-1733 797. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 85-97 316 798. Henry RM, Kostense PJ, Bos G, et al. Mild renal insuffi ciency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 2002; 62: 1402- 1407 799. Schillaci G, Reboldi G, Verdecchia P. Highnormal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. Arch Intern Med 2001; 161: 886-891 800. Culleton BF, Larson MG, Wilson PW, et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insuffi ciency. Kidney Int 1999; 56: 2214-2219 801. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305 802. Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol 2002;13(5): 1338-1349 803. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: 112-119 804. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-1295 805. Herzog C. Kidney disease in cardiology. Nephrol Dial Transplant 2008; 23(8): 42- 46 806. Segura J, Garcia-Donair J, Praga M, et al. Chronic kidney disease as a situation of high added risk in hypertensive patients. J Am Soc Nephrol 2006; 17(2): 136-140 807. Gansevoort RT, Matsushita K, van der Velde M, et al. Chronic Kidney Disease Prognosis Consortium. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes: a collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 2011; 80(1): 93-104 808. Latchamsetty R, Fang J, Kline-Rogers E, et al. Prognostic Value of Transient and Sustained Increase in In-Hospital Creatinine on Outcomes of Patients Admitted With Acute Coronary Syndrome. Am J Cardiol 2007; 99 (7): 939-942 809. Ronco C, Bellomo R, McCullough PA. Cardiorenal syndromes in critical care. Contrib Nephrol 2010; 165: 366 810. Singbartl K, Kellum JA. AKI in the ICU: definition, epidemiology, risk stratification, and outcomes. Kidney Int 2012; 81: 819-825 811. Piccinni P, Cruz DN, Gramaticopolo S, et al. Prospective multicenter study on epidemiology of acute kidney injury in the ICU: a critical care nephrology Italian collaborative effort (NEFROINT)/NEFROINT investigators. Minerva Anestesiol 2011; 77: 1072–1083 812. Kolhe NV, Muirhead AW, Wilkes SR, et al. National trends in acute kidney injury requiring dialysis in England between 1998 and 2013. Kidney Int 2015; 29. doi: 10.1038/ki.2015.234 813. van der Velde M, Matsushita K, Coresh J, et al. Chronic Kidney Disease Prognosis Consortium. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta analysis of high-risk population cohorts. Kidney Int 2011; 79(12): 1341-1352 814. Dzaye O, Dudum R, Reiter-Brennan C, Kianoush S, Tota-Maharaj R, Cainzos Achirica M, Blaha MJ. Coronary artery calcium scoring for individualized cardiovascularrisk estimation in important patient subpopulations after the 317 2019AHA/ACC primary prevention guidelines. ProgCardiovasc Dis 2019;62:423- 430 815. Chen J, Budoff MJ, Reilly MP, et al, CRIC Investigators. Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease. JAMA Cardiol2017;2:635-643 816. Matsushita K, Sang Y, Ballew SH, et al. Subclinical atherosclerosis measures for cardiovascular prediction in CKD. J Am SocNephrol2015;26:439-447 817. Смирнов А.В., Ватазин А.В., Добронравов В.А. и соавт. Клинические рекомендации. Хроническая болезнь почек (ХБП). Нефрология; 2021; 25(5); 10-84 doi: 10.36485/1561-6274-2021-25-5-10-84 818. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int (Suppl) 2013; 3: 1-150 819. KuE, SarnakMJ, TotoR., et al. Effect of Blood Pressure Control on Long-Term Risk of End-Stage Renal Disease and Death Among Subgroups of Patients With Chronic Kidney Disease. J Am Heart Assoc 2019;8(16):e012749. doi: 10.1161/J AH A. 119.012749 0003 820. Huang Q, Li K, Li M, Xu G. Comparisons of Three Main Treatments on Renoprotective Effects in Diabetes Mellitus. Iran J Kidney Dis. 2019 Jan;13(1):36- 47. PMID: 30851718 821. Xie X, Liu Y, Perkovic V, et al. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Metaanalysis of Randomized Clinical Trials. Am J Kidney Dis. 2016 May;67(5):728-741. doi: 10.1053/j.ajkd.2015.10.011. Epub 2015 Nov 18. PMID: 26597926 822. GiuglianoD, BellastellaG, LongoM, et al. Relationship between improvement of glycaemic control and reduction of major cardiovascular events in 15 cardiovascular outcome trials: A meta-analysis with meta-regression. Diabetes ObesMetab. 2020;22:1397-405 823. Perkovic V, Jardine MJ, Neal B, CREDENCE Trial Investigators, et al. Canaglifozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295-2306 824. Heerspink HJL, Stefánsson BV, Correa-Rotter R, for the DAPA-CKD Trial Committees and Investigators, et al. Dapaglifozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436-1446 825. Wanner C, Tonelli M, Kidney Disease: Improving Global Outcomes LipidGuideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. KidneyInt2014;85:1303_1309 826. Cholesterol Treatment Trialists’ (CTT) Collaboration, Herrington WG, Emberson J, et al. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol2016;4:829-839 827. Charytan DM, Sabatine MS, Pedersen TR, et al. Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial [published correction appears in J Am Coll Cardiol. 2019 Aug 27;74(8):1162-1166]. J Am Coll Cardiol. 2019;73(23):2961-2970. doi:10.1016/j.jacc.2019.03.513 318 828. de Weerd M, Greving JP, de Jong AW, Buskens E, Bots ML. Prevalence of asymptomatic carotid artery stenosis according to age and sex: systematic review and metaregression analysis. Stroke 2009;40:1105-1113 829. Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013;382:1329–1340 830. Shadman R, Criqui MH, Bundens WP, et al. Subclavian artery stenosis: prevalence, risk factors, and association with cardiovascular diseases. J Am Coll Cardiol 2004;44:618–623 831. Giannopoulos A, Kakkos S, Abbott A, et al. Long-term mortality in patients with asymptomatic carotid stenosis: implications for statin therapy. Eur J Vasc Endovasc Surg 2015;50:573–582 832. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res 2015;116:1509–1526 833. American Diabetes Association. Standards of medical care in diabetes-2015 abridged for primary care providers. Clin Diabetes 2015 ; 33 (2):97-111 834. Приказ Министерства здравоохранения и социального развития Российской Федерации № 597н от 19 августа 2009 года «Об организации деятельности центров здоровья по формированию здорового образа жизни у граждан Российской Федерации, включая сокращение потребления алкоголя и табака». http://www.minzdravsoc.ru/docs/mzsr/orders/930 835. Lijmer JG, Hunink MG, van den Dungen JJ, Loonstra J, Smit AJ. ROC analysis of noninvasive tests for peripheral arterial disease. Ultrasound Med Biol 1996;22:391–398 836. Stoffers HE, Kester AD, Kaiser V, et al. The diagnostic value of the measurement of the ankle-brachial systolic pressure index in primary health care. J Clin Epidemiol 1996;49:1401–1405 837. Bullen C. Impact of tobacco smoking and smoking cessation on cardiovascular risk and disease. Expert Rev Cardiovasc Ther 2008;6:883-895 838. Mazari FA, Khan JA, Samuel N, et al. Long-term outcomes of a randomized clinical trial of supervised exercise, percutaneous transluminal angioplasty or combined treatment for patients with intermittent claudication due to femoropopliteal disease. Br J Surg 2017;104:7683 839. Fakhry F, Spronk S, van der Laan L, et al. Endovascular Revascularization and Supervised Exercise for Peripheral Artery Disease and Intermittent Claudication: A Randomized Clinical Trial. JAMA 2015;314:1936-1944 840. Jansen SCP, Hoorweg BBN, Hoeks SE, et al. A systematic review and meta-analysis of the effects of supervised exercise therapy on modifiable cardiovascular risk factors in intermittent claudication. J Vasc Surg 2019;69:12931308 e1292 841. Bavry AA, Anderson RD, Gong Y, et al. Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the International VErapamil-SR/Trandolapril STudy. Hypertension 2010;55:4853 842. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ2009;338:b1665 843. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of 319 arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-1357 844. Singh S, Armstrong EJ, Sherif W, et al. Association of elevated fasting glucose with lower patency and increased major adverse limb events among patients with diabetes undergoing infrapopliteal balloon angioplasty. Vasc Med 2014;19:307- 314 845. Ostergren J, Sleight P, Dagenais G, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004;25:1724 846. Fowkes FG, Housley E, Riemersma RA, et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol 1992;135:331–340 847. Malgor RD, Alahdab F, Elraiyah TA, et al. A systematic review of treatment of intermittent claudication in the lower extremities. J Vasc Surg 2015;61(3):54–73 848. Schmit K, Dolor RJ, Jones WS, et al. Comparative effectiveness review of antiplatelet agents in peripheral artery disease. J Am Heart Assoc 2014;3:e001330 849. Momsen AH, Jensen MB, Norager CB, et al. Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. Eur J Vasc Endovasc Surg 2009;38:463-474 850. Kumbhani DJ, Steg PG, Cannon CP, et al, REACH Registry Investigators. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J 2014;35:2864-2872. 851. Murphy SA, Cannon CP, Blazing MA, et al. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. J Am Coll Cardiol 2016;67:353-361 852. Bonaca MP, Nault P, Giugliano RP, et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation 2018;137:338-350 853. Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients [published correction appears in 2000 May 4;342(18):1376] [published correction appears in N Engl J Med 2000 Mar 9;342(10):748]. N Engl J Med. 2000;342(3):145-153. doi:10.1056/NEJM200001203420301 854. Shahin Y, Barnes R, Barakat H, Chetter IC. Meta-analysis of angiotensin converting enzyme inhibitors effect on walking ability and ankle brachial pressure index in patients with intermittent claudication. Atherosclerosis 2013;231:283-290 855. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991;151:1769-1776 856. Mueller C., McDonald K., de Boer R.A., et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019 Jun;21(6):715-731 857. Bozkurt B, Coats A, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association.Eur J Heart Fail 2021;23:352-380 858. Phillips CO, Wright SM, Kern DE, et al. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a metaanalysis. JAMA 2004;291:1358-1367 859. Stewart S, Vandenbroek AJ, Pearson S, et al. Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure. Arch Intern Med 1999;159:257-261 860. McAlister FA, Stewart S, Ferrua S, et al. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol 2004;44:810-819 861. Feltner C, Jones CD, Cene CW, et al. Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and metaanalysis. Ann Intern Med 2014;160:774-784 862. Horwich TB, Hamilton MA, Maclellan WR, et al. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002;8:216-224 863. Greene SJ, Vaduganathan M, Lupi L, et al. EVEREST Trial Investigators. Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). Am J Cardiol 2013;111:574-581 864. Sharma A, Lavie CJ, Borer JS, et al. Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. Am J Cardiol 2015;115:1428-1434; Gupta PP, Fonarow GC, Horwich TB. Obesity and the obesity paradox in heart failure. Can J Cardiol 2015;31:195-202 865. Pandey A, Parashar A, Kumbhani D, et al. Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. Circ Heart Fail 2015;8:33-40 866. O’Connor CM, Whellan DJ, Lee KL, et al. HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009;301:1439-145 867. Taylor RS, Sagar VA, Davies EJ, et al. Exercise-based rehabilitation for heart failure. Cochrane Database Syst Rev 2014:CD003331 868. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435 869. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450-1456 870. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on 321 morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100:2312-2318 871. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302 872. DeVore AD, Braunwald E, Morrow DA, et al. PIONEER-HF Investigators. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. JAMA Cardiol 2020;5:202-207 873. Wachter R, Senni M, Belohlavek J, et al. TRANSITION Investigators. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail 2019;21:998-1007 874. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000;283:1295-1302 875. Packer M, Coats AJ, Fowler MB, et al. Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-1658 876. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-1355 877. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007 878. Packer M, Fowler MB, Roecker EB, et al. Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194-2199 879. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13 880. Flather MD, Shibata MC, Coats AJ, et al. SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-225 881. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717 882. Zannad F, McMurray JJ, Krum H, et al. EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21 883. McMurray JJV, Jackson AM, Lam CSP, et al. Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. Circulation 2020;141:338-351 322 884. Santema BT, Ouwerkerk W, Tromp J, et al. ASIAN-HF investigators. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Lancet 2019;394:1254-1263 885. Granger CB, McMurray JJ, Yusuf S, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-776 886. Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2020;382:1883-1893 887. Faris RF, Flather M, Purcell H, et al. Diuretics for heart failure. Cochrane Database Syst Rev 2012:CD003838 888. Faris R, Flather M, Purcell H, et al. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol 2002;82:149-158 889. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-885 890. Swedberg K, Komajda M, Bohm M, et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol 2012;59:1938-1945 891. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-1552 892. Anker SD, Comin-Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-2448 893. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of longterm intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015;36:657-668 894. van Veldhuisen DJ, Ponikowski P, van der Meer P, et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation 2017;136:1374-1383 895. Jankowska EA, Tkaczyszyn M, Suchocki T, et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail 2016;18:786-795 896. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-533 897. Ponikowski P, Kirwan BA, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 2020;396:1895-1904 898. Badran M, Yassin BA, Fox N, Laher I, Ayas N. Epidemiology of Sleep Disturbances and Cardiovascular Consequences. Can J Cardiol 2015;31:873-879 899. Sofi F, Cesari F, Casini A, Macchi C, Abbate R, Gensini GF. Insomnia and risk of cardiovascular disease: a meta-analysis. Eur J Prev Cardiol 2014;21:57-64 900. Ge L, Guyatt G, Tian J, et al. Insomnia and risk of mortality from all-cause, cardiovascular disease, and cancer: Systematic review and meta-analysis of 323 prospective cohort studies. Sleep Med Rev. 2019;48:101215. doi:10.1016/j.smrv.2019.101215 901. Yin J, Jin X, Shan Z, et al. Relationship of Sleep Duration With All-Cause Mortality and Cardiovascular Events: A Systematic Review and Dose-Response MetaAnalysis of Prospective Cohort Studies. J Am Heart Assoc. 2017;6(9):e005947. Published 2017 Sep 9. doi:10.1161/JAHA.117.005947 902. Kerkhof GA. Epidemiology of sleep and sleep disorders in The Netherlands. Sleep Med. 2017 Feb;30:229-239. doi: 10.1016/j.sleep.2016.09.015. Epub 2016 Nov 5. PMID: 28215254 903. Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. Chest. 2014 Nov;146(5):1387-1394. doi: 10.1378/chest.14- 0970. PMID: 25367475 904. Lichstein KL, Taylor DJ, McCrae CS, Petrov ME. Insomnia: epidemiology and risk factors. In: Kryger MH, Roth T, Dement WC (eds.) Principles and Practice of Sleep Medi- cine. 6th ed. Philadelphia: Elsevier, 2016; p. 761–768 905. Bankier B, Januzzi JL, Littman AB. The high prevalence of multiple psychiatric disorders in stable outpatients with coronary heart disease. Psychosom Med 2004;66:645-50 906. Taylor DJ, Mallory LJ, Lichstein KL, Durrence HH, Riedel BW, Bush AJ. Comorbidity of chronic insomnia with medical problems. Sleep 2007;30:213-218 907. Fernandez-Mendoza J., Vgontzas A.N., Liao D. Insomnia with objective short sleep duration and incident hypertension: the Penn State cohort. Hypertension. 2012;60(4):929–935 908. Gangwisch J.E., Malaspina D., Posner K. Insomnia and sleep duration as mediators of the relationship between depression and hypertension incidence. Am J Hypertens. 2010;23(1):62–69 909. Laugsand L.E., Vatten L.J., Platou C., Janszky I. Insomnia and the risk of acute myocardial infarction: a population study. Circulation. 2011;124(19):2073–2081 910. Coryell V.T., Ziegelstein R.C., Hirt K., Quain A., Marine J.E., Smith M.T. Clinical correlates of insomnia in patients with acute coronary syndrome. Int Heart J. 2013;54(5):258–265 911. Cappuccio F.P., Cooper D., D'Elia L., Strazzullo P., Miller M.A. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Eur Heart J. 2011;32(12):1484–1492 912. Mallon L., Broman J.E., Hetta J. Sleep complaints predict coronary artery disease mortality in males: a 12-year follow-up study of a middle-aged Swedish population. J Intern Med. 2002;251(3):207–216 913. Laugsand L.E., Strand L.B., Platou C., Vatten L.J., Janszky I. Insomnia and the risk of incident heart failure: a population study. Eur Heart J. 2014;35(21):1382–1393 914. Javaheri S., Blackwell T., Ancoli-Israel S., Ensrud K.E., Stone K.L., Redline S. Sleepdisordered breathing and incident heart failure in older men. Am J Respir Crit Care Med. 2016;193(5):561–568 915. Bathgate C.J., Edinger J.D., Wyatt J.K., Krystal A.D. Objective but not subjective short sleep duration associated with increased risk for hypertension in individuals with insomnia. Sleep. 2016;39(5):1037–1045 916. Morin C.M., Belleville G., Belanger L., Ivers H. The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011;34(5):601–608 324 917. Javaheri S, Redline S, Insomnia and risk of cardiovascular disease, CHEST (2017), doi: 10.1016/j.chest.2017.01.026 918. Полуэктов М.Г., Бузунов Р.В., Авербух В.М. и др. Проект клинических рекомендаций по диагностике и лечению хронической инсомнии у взрослых. Consilium Medicum. Неврология и Ревматология (Прил.). 2016; 2: 41–51 919. Benjafield AV, Ayas NT, Eastwood PR, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019;7(8):687-698. doi:10.1016/S2213-2600(19)30198-5 920. Бочкарев М.В., Коростовцева Л.С., Фильченко И.А., и соавт. Жалобы на нарушения дыхания во сне и факторы риска сердечно-сосудистых заболеваний в регионах России: данные исследования ЭССЕРФ. Российский кардиологический журнал. 2018;(6):152- 158. https://doi.org/10.15829/1560-4071-2018-6-152-158 921. Peppard PE, Young T, Palta M, Skatrud Prospective study of the association between sleep-disordered breathing and hypertension. J N Engl J Med. 2000;342(19):1378 922. Punjabi NM, Caffo BS, Goodwin JL, et al. Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med. 2009;6(8):e1000132. Epub 2009 Aug 18 923. Cadby G, McArdle N, Briffa T, et al. Severity of OSA is an independent predictor of incident atrial fibrillation hospitalization in a large sleep-clinic cohort. Chest. 2015;148(4):945 924. Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation. 2010;122(4):352. Epub 2010 Jul 12 925. Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(3):479–504 926. Patil SP, Ayappa IA, Caples SM, et al. Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2019 Feb 15;15(2):335-343. doi: 10.5664/jcsm.7640. PMID: 30736887; PMCID: PMC6374094 927. Tietjens JR, Claman D, Kezirian EJ, et al. Obstructive Sleep Apnea in Cardiovascular Disease: A Review of the Literature and Proposed. Multidisciplinary Clinical Management Strategy. J Am Heart Assoc . 2019;8:e010440 928. McEvoy RD, Antic NA, Heeley E, et al. CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. N Engl J Med. 2016;375(10):919-931. doi:10.1056/NEJMoa1606599 929. Collen J, Lettieri C, Wickwire E, Holley A. Obstructive sleep apnea and cardiovascular disease, a story of confounders! Sleep Breath 2020;24:1299-1313 930. Drager LF, McEvoy RD, Barbe F, Lorenzi-Filho G, Redline S; INCOSACT Initiative (International Collaboration of Sleep Apnea Cardiovascular Trialists). Sleep Apnea and Cardiovascular Disease: Lessons From Recent Trials and Need for Team Science. Circulation. 2017 Nov 7;136(19):1840-1850 doi: 10.1161/CIRCULATIONAHA.117.029400. PMID: 29109195; PMCID: PMC5689452 325 931. Kasiakogias A, Tsioufis C, Thomopoulos C, Tousoulis D. Effects of continuous . positive airway pressure on blood pressure in hypertensive patients with obstructive sleep apnoea. J Hypertens 2014;32:2279-2280 932. А. В. Аксенова, О. А. Сивакова, Н. В. Блинова и соавт. Консенсус экспертов Российского медицинского общества по артериальной гипертонии по диагностике и лечению резистентной артериальной гипертонии / Терапевтический архив. – 2021. – Т. 93. – № 9. – С. 1018-1029. – DOI 10.26442/00403660.2021.09.201007 933. Ревишвили А.Ш., Артюхина Е.А., Глезер М.Г., и соавт. Брадиаритмии и нарушения проводимости. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(4):4448. https://doi.org/10.15829/1560- 4071-2021-4448 934. Хроническая обструктивная болезнь легких. Клинические рекомендации. РРО. 2021 https://spulmo.ru/upload/kr/HOBL_2021.pdf 935. Eisner M.D., Anthonisen N., Coultas D., et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;182:693–718. DOI: 10.1164/rccm.200811-1757ST 936. Cohen A.J., Brauer M., Burnett R., et al. Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015. The Lancet, 2017;389(10082),1907- 1918. DOI: 10.1016/S0140-6736(17)30505-6 937. Global strategy for the diagnosis, management and prevention of COPD (2022 report). https://goldcopd.org/2022-gold-reports 938. Chuchalin A.G., Khaltaev N., Antonov N.S., et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9 (1): 963–974. DOI: 10.2147/COPD.S67283 939. Григорьева Н Ю., Майоров, М В., Королёв, М.Е., Самолюк М.О. Особенности формирования и развития сердечно-сосудистых заболеваний у больных хронической обструктивной болезнью легких. Терапевтический архив, 2019;91(1),43-47. DOI: 10.26442/00403660.2019.01.000027 940. Чазова И.Е., Лазарева Н.В., Ощепкова Е.В. Артериальная гипертония и хроническая обструктивная болезнь легких: клиническая характеристика и эффективность лечения (по данным Национального регистра артериальной гипертонии). Терапевтический архив. 2019;91(3), 4-10. DOI: 10.26442/00403660.2019.03.000110 941. Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015 Aug;3(8):631-639. doi:10.1016/S2213-2600(15)00241-6. Epub 2015 Jul 22 942. ВОЗ 10 ведущих причин смерти в мире https://www.who.int/ru/newsroom/fact-sheets/detail/the-top-10-causes-of-death 943. Спирометрия. Методическое руководство, 2021. https://spulmo.ru/upload/spirometriya_16_12_2021_extEd.pdf?t=1 944. Bednarek M., Maciejewski J., Wozniak M., Kuca P., Zielinski J. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax. 2008 May;63(5):402-407. doi: 10.1136/thx.2007.085456 326 945. Wang LY, Zhu YN, Cui JJ, Yin KQ, Liu SX, Gao YH. Subclinical atherosclerosis risk markers in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. Respir Med 2017;123:18-27. DOI: 10.1016/j.rmed.2016.12.004 946. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008;32:962-969. DOI: 10.1183/09031936.00012408 947. Болотова Е.В., Являнская В.В., Дудникова А.В. Предикторы развития больших кардиоваскулярных событий у больных хронической обструктивной болезнью легких в сочетании с ранними стадиями хронической болезни почек. Кардиология. 2019;59(3S):52-60. doi.org/10.18087/cardio.2539 948. Curkendall S.M., DeLuise C., Jones J.K., et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006;16:63-70. DOI: 10.1016/j.annepidem.2005.04.008 949. Clarenbach C.F., Kohler M. Is COPD a Cardiovascular Risk Factor? Praxic (Bern 1994): 2011 Jan 19; 100 (2): 85-90. DOI: 10.1024/1661-8157/a000411 950. Don D. Sin, S.F. Paul Man. Pharmacotherapy for Mortality Reduction in Chronic Obstructive Pulmonary Disease. ProcAm Thorac Soc: 2006;3:624-629. DOI: 10.1513/pats.200603-096SS 951. Huiart L., Ernst P., Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005;128:2640-2646. DOI: 10.1378/chest.128.4.2640 952. Anthonisen N.R., Connett J.E., Enright P.L., Manfreda J. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002;166(3):333–339. DOI: 10.1164/rccm.2110093 953. Feary J.R., Rodrigues L.C., Smith C.J., Hubbard R.B., Gibson J.E. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010;65:956-962. doi: 10.1136/thx.2009.128082 954. Barnes P.J. Chronic Obstructive Pulmonary Disease: Effects beyond the Lungs. PLoS Med 2010 Mar 16;7(3):e1000220. doi: 10.1371/journal.pmed.1000220 955. Thomsen M., Dahl M., Lange P., Vestbo J., Nordestgaard B.G. Inflammatory Biomarkers and Comorbidities in Chronic Obstructive Pulmonary Disease. AJRCCM 2012; 186(10):982–988. https://doi.org/10.1164/rccm.201206-1113OC 956. Soumagne T., Roche N., Guillien A., et al. Cardiovascular Risk in COPD. Deciphering the Contribution of Tobacco Smoking. CHEST 2020;157(4):834-845. doi: 10.1016/j.chest.2019.11.002 957. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2016;138(1):16-27. doi: 10.1016/j.jaci.2016.05.011 958. Domej W., Oettl K., Renner W. Oxidative stress and free radicals in COPD – implications and relevance for treatment. Int J Chron Obstruct Pulmon Dis 2014;9:1207-1224. DOI: 10.2147/COPD.S51226 959. Maclay J.D., McAllister D.A., Johnston S., et al. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax 2011;66:769-774. DOI: 10.1136/thx.2010.157529 960. Miller B.E., Tal-Singer R., Rennard S.I., et al. Plasma Fibrinogen Qualification as a Drug Development Tool in Chronic Obstructive Pulmonary Disease. Perspective 327 of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium. Am J Respir Crit Care Med. 2016;193(6):607-613. doi:10.1164/rccm.201509-1722PP 961. Поликутина О.М., Слепынина Ю.С., Каретникова В.Н., и соавт. Анализ выживаемости и исходы госпитального этапа у пациентов с инфарктом миокарда с подъемом сегмента ST и сопутствующей хронической обструктивной болезнью легких. Пульмонология. 2014;(2):73-77. https://doi.org/10.18093/0869-0189-2014-0-2-73-77 962. Krahnke J.S., Abraham W.T., Adamson P.B., et al. Heart failure and respiratory hospitalizations are reduced in patients with heart failure and chronic obstructive pulmonary disease with the use of an implantable pulmonary artery pressure monitoring device. Journal of cardiac failure. 2015;21(3):240-249. DOI: 10.1016/j.cardfail.2014.12.008 963. Leavitt B.J., Ross C.S., Spence B., et al. Long-term survival of patients with chronic obstructive pulmonary disease undergoing coronary artery bypass surgery. Circulation. 2006;114(1_supplement), I-430-434. DOI: 10.1161/CIRCULATIONAHA.105.000943 964. Mascarenhas J., Lourenço P., Lopes R., Azevedo A., Bettencourt P. Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. American heart journal. 2008 Mar;155(3):521-525. doi: 10.1016/j.ahj.2007.10.040 965. Kunisaki K.M., Dransfield M.T., Anderson J.A., et al. Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial. Am J Respir Crit Care Med 2018;198(1):51-57. DOI: 10.1164/rccm.201711-2239OC 966. Rothnie K.J., Connell O., Mullerova H., et al. Myocardial Infarction and Ischemic Stroke after Exacerbations of Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc 2018;15(8):935-946. DOI: 10.1513/AnnalsATS.201710-815OC 967. MacDonald M.I., Shafuddin E., King P.T., Chang C.L., Bardin P.G., Hancox R.J. Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease. Lancet Respir Med 2016;4(2):138-148. DOI: 10.1016/S2213- 2600(15)00509-3 968. Wang M., Lin E.P.Y., Huang L.C., Li C.Y., Shyr Y., Lai C.H. Mortality of cardiovascular events in patients with COPD and preceding hospitalization for acute exacerbation. Chest. 2020;158(3):973-985. DOI: 10.1016/j.chest.2020.02.046 969. Adamson P.D., Anderson J.A., Brook R.D., et al. Cardiac troponin I and cardiovascular risk in patients with chronic obstructive pulmonary disease. Journal of the American College of Cardiology. 2018;72(10):1126-1137. DOI: 10.1016/j.jacc.2018.06.051 970. Lahousse L, Tiemeier H, Ikram MA, Brusselle GG. Chronic obstructive pulmonary disease and cerebrovascular disease: A comprehensive review. Respir Med. 2015;109(11):1371-1380. doi:10.1016/j.rmed.2015.07.014 971. Morgan A.D., Sharma C., Rothnie K.J., Potts J., Smeeth L., Quint J.K. Chronic Obstructive Pulmonary Disease and the Risk of Stroke. Ann Am Thorac Soc. 2017;14(5):754-765. doi:10.1513/AnnalsATS.201611-932SR 972. Goudis C.A., Konstantinidis A.K., Ntalas I.V., Korantzopoulos P. Electrocardiographic abnormalities and cardiac arrhythmias in chronic 328 obstructive pulmonary disease. Int J Cardiol. 2015;199:264-273. DOI: 10.1016/j.ijcard.2015.06.096 973. Buch P., Friberg J., Scharling H., Lange P., Prescott E. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J 2003;21(6):1012-1016. DOI: 10.1183/09031936.03.00051502 974. Goudis C.A. Chronic obstructive pulmonary disease and atrial fibrillation: An unknown relationship. J Cardiol 2017;69(5):699-705. DOI: 10.1016/j.jjcc.2016.12.013 975. Konecny T., Somers K.R., Park J.Y., et al. Chronic obstructive pulmonary disease as a risk factor for ventricular arrhythmias independent of left ventricular function. Heart Rhythm 2018;15(6):832-838. DOI: 10.1016/j.hrthm.2017.09.042 976. van den Berg M.E., Stricker B.H., Brusselle G.G., Lahousse L. Chronic obstructive pulmonary disease and sudden cardiac death: A systematic review. Trends Cardiovasc Med 2016;26(7):606-613. DOI: 10.1016/j.tcm.2016.04.001 977. Li J., Agarwal S.K., Alonso A., et al. Airflow obstruction, lung function, and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2014;129(9):971–980. DOI: 10.1161/CIRCULATIONAHA.113.004050 978. Johnson L.S., Juhlin T., Engstrom G., Nilsson P.M. Reduced forced expiratory volume is associated with increased incidence of atrial fibrillation: the Malmo Preventive Project. Europace. 2014;16(2):182–188. DOI: 10.1093/europace/eut255 979. Chahal H., Heckbert S.R., Barr R.G., et al. Ability of reduced lung function to predict development of atrial fibrillation in persons aged 45 to 84 years (from the Multi-Ethnic Study of Atherosclerosis-Lung Study). Am J Cardiol 2015;115(12):1700–1704. DOI: 10.1016/j.amjcard.2015.03.018 980. Konecny T., Park J.Y., Somers K.R., et al. Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias. Am J Cardiol 2014;114(2):272–277. DOI: 10.1016/j.amjcard.2014.04.030 981. Mita N., Kuroda M., Miyoshi S., Saito S. Association of preoperative right and left ventricular diastolic dysfunction with postoperative atrial fibrillation in patients undergoing lung surgery: a prospective observational study. J Cardiothorac Vasc Anesth 2017 Apr;31(2):464-473. doi: 10.1053/j.jvca.2016.09.003 982. Terzano C., Romani S., Conti V., Paone G., Oriolo F., Vitarelli A. Atrial fibrillation in the acute, hypercapnic exacerbations of COPD. Eur Rev Med Pharmacol Sci 2014;18(19):2908–2917 983. Singh S., Loke Y.K., Enright P., Furberg C.D. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax. 2013;68(1):114-116. DOI: 10.1136/thoraxjnl-2011-201275 984. Wilchesky M., Ernst P., Brophy J.M., Platt R.W., Suissa S. Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest. 2012; 142(2):305-311. DOI: 10.1378/chest.11-1597/ 985. Wise R.A., Anzueto A., Cotton D., et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369(16): 1491-1501 986. Tashkin D.P., Fabbri L.M. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respiratory research. 2010; 11(1):149. DOI: 10.1186/1465-9921-11-149 329 987. Calverley P.M., Anderson J.A., Celli B., et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax. 2010;65(8):719-725. DOI: 10.1136/thx.2010.136077 988. Vestbo J., Anderson J.A., Brook R.D., et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. The Lancet. 2016;387(10030): 1817-1826. DOI: 10.1016/S0140-6736(16)30069-1 989. Wilchesky M., Ernst P., Brophy J.M., Platt R.W., Suissa S. Bronchodilator use and the risk of arrhythmia in COPD: part 1: Saskatchewan cohort study. Chest. 2012;142(2):298-304. DOI: 10.1378/chest.10-2499 990. Ohta K., Fukuchi Y., Grouse L., et al. A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD. Respiratory medicine. 2004;98(10):1016-1024. DOI: 10.1016/j.rmed.2004.02.020 991. COPD Working Group. Pulmonary rehabilitation for patients with chronic pulmonary disease (COPD): an evidence-based analysis. Ont Health Technol Assess Ser. 2012;12(6):1-75. Epub 2012 Mar 1. PMID: 23074434; PMCID: PMC3384375 992. Dransfield M.T., McAllister D.A., Anderson J.A., et al. Beta-blocker therapy and clinical outcomes in patients with moderate COPD and heightened cardiovascular risk: an observational sub-study of SUMMIT. Annals of the American Thoracic Society. 2018 May;15(5):608-614. DOI: 10.1513/AnnalsATS.201708-626OC 993. Celli B., Decramer M., Kesten S., et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine. 2009;180(10):948-955. DOI: 10.1164/rccm.200906-0876OC 994. Tashkin D.P., Leimer I., Metzdorf N., Decramer M. Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial. Respiratory research. 2015 Jun 2;16(1):65. DOI: 10.1186/s12931-015-0216-4 995. Martinez F., Rabe K., Ferguson G., et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease. A randomized, doubleblind, multicenter, parallel-group study. Am J Respir Crit Care Med. 2021;203(5):553–564. DOI: 10.1164/rccm.202006-2618OC 996. Lipson D.A., Crim C., Criner G.J., et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2020; 201:1508–1516. DOI: 10.1164/rccm.201911-2207OC 997. Li C., Cheng W., Guo J., Guan W. Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials. Int J Chron Obstruct Pulmon Dis. 2019;14:799-808. DOI: 10.2147/COPD.S198288 998. Horita N, Miyazawa N, Morita S, et al. Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease. Resp Res. 2014, 15: 37 . DOI: 10.1186/1465-9921-15-37.doi: 10.1186/1465-9921-15-37 999. Walters JAE, Tan DJ, White CJ, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2014, Issue 9. Art. No.: CD001288. DOI: 10.1002/14651858.CD001288.pub4.206 330 1000. Barnes PJ. Glucocorticosteroids. Handb Exp Pharmacol. 2017;237:93-115. doi: 10.1007/164_2016_62. PMID: 27796513 1001. Lofdahl C-G., Postma D.S., Pride N.B., Thorén A. Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD. 2007 Jun;29(6):1115- 1119. doi: 10.1183/09031936.00128806 1002. Krammer F., Smith G.J.D., Fouchier R.A.M., et al. Influenza (Primer). Nature Reviews: Disease Primers. 2018;4:3. DOI: 10.1038/s41572-018-0002-y 1003. Williamson E., Walker A.J., Bhaskaran K.J., et al. OpenSAFELY: Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020 Aug;584(7821):430-436. doi: 10.1038/s41586-020-2521-4. Epub 2020 Jul 8. PMID: 32640463; PMCID: PMC7611074 1004. Tal-Singer R, Crapo JD. COPD at the Time of COVID-19: A COPD Foundation Perspective. Chronic obstructive pulmonary diseases (Miami, Fla.). 2020;7(2):73- 75. DOI: 10.15326/jcopdf.7.2.2020.0149 1005. Mehra M.R., Desai S.S., Kuy S., Henry T.D., Patel A.N. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. 2020;382(25):e102. DOI: 10.1056/NEJMoa2007621 1006. Clayton T.C., Thompson M., Meade T.W. Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. Eur. Heart J. 2008;29:96–103. DOI: 10.1093/eurheartj/ehm516 1007. Shea K.M., Edelsberg J., Weycker D., et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014 May 27;1(1):ofu024. DOI: 10.1093/ofid/ofu024 1008. Soto-Gomez N., Anzueto A., Waterer G.W., Restrepo M.I., Mortensen E.M. Pneumonia: an arrhythmogenic disease? Am J Med. 2013 Jan;126(1):43-48. doi: 10.1016/j.amjmed.2012.08.005 1009. Corrales-Medina V.F., Alvarez K.N, Weissfeld L.A., et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA 2015;313: 264–274. DOI: 10.1001/jama.2014.18229 1010. Corrales-Medina V.F., Taljaard M., et al. Intermediate and long-term risk of newonset heart failure after hospitalization for pneumonia in elderly adults. Am. Heart J. 2015;170: 306–312 1011. Приказ Министерства здравоохранения Российской Федерации от 06.12.2021 № 1122н "Об утверждении национального календаря профилактических прививок, календаря профилактических прививок по эпидемическим показаниям и порядка проведения профилактических прививок" (Зарегистрирован 20.12.2021 № 66435 1012. Havers F.P., Moro P.L., Hunter P., Hariri S., Bernstein H. Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2019. 2020 Jan 24;69(3):77-83. DOI: 10.15585/mmwr.mm6903a5 1013. Eschenhagen T, Forse T, Ewer MS et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2011;13(1):1-10. doi 10.1093/eurjhf/hfq213 1014. Zamorano JL, Lancellotti P, Munioz DR, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC 331 Committee for Practice Guidelines. European Heart Journal. 2016;37:2768–2801 doi:10.1093/eurheartj/ehw211 1015. Lyon A R, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. European Journal of Heart Failure. 2020; 22:1945–1960. doi:10.1002/ejhf.1920 1016. Taunk NK, Haffty BG, Kostis JB, Goyal S. Radiation-induced heart disease: pathologic abnormalities and putative mechanisms [serial online]. Front Oncol. 2015;5:39 1017. Eckel RH, Jakicic JMA, Jesus JM et al. 2013AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;129 (25Suppl2):S76–99. (doi:10.1161/01.cir.0000437740.48606.dl 1018. Васюк Ю. А., Гендлин Г. Е., Емелина Е. И., и соавт. Согласованное мнение российских экспертов по профилактике, диагностике и лечению сердечнососудистой токсичности противоопухолевой терапии. Российский кардиологический журнал. 2021;26(9):4703. doi:10.15829/1560-4071-2021- 4703; Larsen CM, Mulvagh SL. Cardio-oncology: what you need to know now for clinical practice and echocardiography. Echo Res Prat. 2017; 4:1:33-41. doi: 10.1530 / ERP-17-0013 1019. Ferdinandy P, Baczkó I, Bencsik P, et al. Definition of hidden drug cardiotoxicity: Paradigm change in cardiac safety testing and its clinical implications. Eur Heart J 2019;40:1771–1777 1020. Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol 2017;35:893–911 1021. Curigliano G, Lenihan D, Fradley M et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol 2020;31:171–190 1022. Celutkiene J, Pudil R, Lopez-Fernandez T et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail 2020;22:1504-1524 1023. Bosch X, Rovira M, Sitges M et al Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 2013;61:2355-2362 1024. Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer 2013;49:2900-2909 332 1025. Food and Drug Administration. Drug Safety and Availability. FDA statement and dexrazoxan. Jul 20, 2011. Available at: http:www.fda/Drugs/DrugSafety/ucm 263729.htm 1026. Чазова И.Е., Агеев Ф.Т., Аксенова А.В., и соавт. Евразийские клинические рекомендации по диагностике, профилактике и лечени сердечнососудистых осложнений при противоопухолевой терапии (2022). Евразийский кардиологический журнал. 2022; (1):6-79, https://doi.org/10.38109/2225-1685-2022-1-6-79 1027. Маевская М. В., Котовская Ю. В., Ивашкин В. Т., и соавт. (2022). Национальный Консенсус для врачей по ведению взрослых пациентов с неалкогольной жировой болезнью печени и ее основными коморбидными состояниями. Терапевтический архив, 94(2), 216-253 1028. Jichitu A, Bungau S, Stanescu AMA, et al. Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management. Diagnostics (Basel).2021;11(4):689. DOI:10.3390/diagnostics11040689 1029. Ивашкин В.Т., Маевская М.В., Павлов Ч.С., и соавт. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(2):24-42 1030. Younossi Z, et al. Global epidemiology of nonalcoholic fatty liver desease – Metaanalytic assessment of prevalence, incidence and outcomes. Hepatology. 2016;64:73-84 1031. Luo J, Xu L, Li J, et al. Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease. Eur J Gastroenterol Hepatol. 2015;27(3):193-199 1032. Targher G, Byrne, CD, Lonardo A, et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016,65,589-600 1033. Polyzos SA, Kang ES, Boutari C, et al. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism. 2020;111S:154203. DOI:10.1016/j.metabol.2020.154203 1034. Athyros VG, Boutari C, Stavropoulos K, et al. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. Curr. Vasc. Pharmacol. 2018;16:246-253 1035. Ratziu V, de Ledinghen V, Oberti F, et al. FRESGUN. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol. 2011;54(5):1011-9.DOI:10.1016/j.jhep.2010.08.030 1036. Марцевич С.Ю., Кутишенко Н.П., Дроздова Л.Ю., и соавт. Исследование РАКУРС: повышение эффективности и безопасности терапии статинами у больных с заболеваниями печени, желчного пузыря и/или желчевыводящих путей с помощью урсодеоксихолевой кислоты. Терапевтический архив. 2014;86(12):48-52. 1037. Nadinskaia M, Maevskaya M, Ivashkin V, et al. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2021;14;27(10):959-975. DOI:10.3748/wjg.v27.i10.959 1038. Sánchez-García A, Sahebkar A, Simental-Mendía M, Simental-Mendía LE. Effect of ursodeoxycholic acid on glycemic markers: A systematic review and meta- 333 analysis of clinical trials. Pharmacol Res. 2018;135:144-149. DOI:10.1016/j.phrs.2018.08.008 1039. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957–2963 1040. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England andWales: prospective derivation and validation of QRISK2. BMJ 2008;336:1475–1482 1041. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017 Jan;76(1):17-28. doi: 10.1136/annrheumdis-2016-209775. Epub 2016 Oct 3. PMID: 27697765 1042. Singh S, Singh H, Loftus EV, Jr., Pardi DS. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014;12:382-393 e381: quiz e322 1043. Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 2015;74:326-332 1044. Ahlehoff O, Gislason GH, Jorgensen CH. Psoriasis and risk of atrial fibrillation and ischemic stroke: Danish Nationalwide Cohort Study. EurHeart J 2011; 33(16): 2054-2064 1045. Hung YM, Chang WP, Wei JC, Chou P, Wang PY. Midlife Ankylosing Spondylitis Increases the Risk of Cardiovascular Diseases in Males 5 Years Later: A National Population-Based Study. Medicine (Baltimore) 2016;95:e3596 1046. Semb AG, Kvien TK, DeMicco DA, et al. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum 2012;64:2836–2846 1047. Edwards CJ, Rheumatism 2009;58 (9): 420 1048. De Vera MA, Choi H, Abrahamowicz M, et al. Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a populationbased cohort study. Ann Rheum Dis 2011;70(6):1020 1049. Sheng X, Murphy MJ, Macdonald TM, Wei L. The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population. BMC Public Health 2012;12(1):712 1050. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325–331 1051. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004; 351: 2611–2618 1052. Siriwardena AN, Gwini SM, Coupland CA. Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case-control study. CMAJ 2010; 182: 1617–1623 1053. Gwini SM, Coupland CA, Siriwardena AN. The effect of influenza vaccination on risk of аcute myocardial infarction: self-controlled case-series study. Vaccine 2011; 29:1145–1149 1054. Udell JA, Zawi R, Bhatt DL, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA 2013;310:1711–1720 1055. Meschia JF, Bushnell B, Boden-Albala B et al. Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/ American Stroke Association. Stroke 2014; 45(12):3754–3832 1056. Warren-Gash C, Hayward AC, Hemingway H, et al. Influenza infection and risk of acute myocardial infarction in England and Wales: a CALIBER self-controlled case series study. J Infect Dis 2012; 206: 1652–1659 1057. de Diego C, Vila-Corcoles A, Ochoa O et al. Effects of annual influenza vaccination on winter mortality in elderly people with chronic heart disease. Eur Heart J 2008; 30: 209 – 216 1058. Бойцов СА, Лукьянов ММ, Платонова ЕВ и соавт. Исследование эффективности и безопасности вакцинопрофилактики гриппа у пациентов с болезнями системы кровообращения. Профилактическая медицина 2014; 6: 13 – 20 1059. Бойцов СА, Лукьянов ММ, Платонова ЕВ и c соавт. Оценка эффективности вакцинопрофилактики гриппа у лиц, находящихся под диспансерным наблюдением по поводу болезней системы кровообращения. Рациональная фармакотерапия в кардиологии 2016; 6: 703-710 1060. Clar C, Oseni Z, Flowers N, Keshtkar-Jahromi M, Rees K. Influenza vaccines for preventing cardiovascular disease. Cochrane Database of Systematic Reviews 2015, 5. No.: CD005050. DOI: 10.1002/14651858.CD005050.pub3 1061. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. DOI:10.1016/S0140- 6736(20)30183-5 1062. Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242. DOI:10.1001/jama.2020.2648 1063. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531e. DOI:10.1007/s00392-020-01626-9 1064. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA.2020;323(20):2052-2059. DOI:10.1001/jama.2020.6775 1065. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ.2020;369:m1966. DOI:10.1136/bmj.m1966 1066. Бойцов С.А., Погосова Н.В., Палеев Ф.Н., и соавт. Клиническая картина и факторы, ассоциированные с неблагоприятными исходами у госпитализированных пациентов с новой коронавирусной инфекцией COVID-19. Кардиология. 2021;61(2):4-14. DOI:10.18087/cardio.2021.2.n1532 335 1067. Ren S, Newby D, Li SC, et al. Effect of the adult pneumococcal polysaccharide vaccine on cardiovascular disease: a systematic review and meta-analysis. Open Heart 2015; 2(1): e000247. Published online 2015 Jun 26. doi: 10.1136/openhrt2015-000247 1068. Vlachopoulos CV, Terentes-Printzios DG, Aznaouridis KA, Pietri PG, Stefanadis CI. Association between pneumococcal vaccination and cardiovascular outcomes: a systematic review and meta-analysis of cohort studies. Eur J Prev Cardiol 2015; 22(9):1185-1199 1069. Marques Antunes M, Duarte GS, Brito D, et al. Pneumococcal vaccination in adults at very high risk or with established cardiovascular disease: systematic review and meta-analysis. Eur Heart J Qual Care Clin Outcomes. 2021 Jan 25;7(1):97-106. doi: 10.1093/ehjqcco/qcaa030. PMID: 32259237 1070. Hsue PY, Waters DD. HIV infection and coronary heart disease: mechanisms and management. Nat Rev Cardiol 2019;16:745-759 1071. Sinha A, Feinstein MJ. Coronary Artery Disease Manifestations in HIV: What, How, and Why. Can J Cardiol 2019;35:270-279 1072. Beckman JA, Duncan MS, Alcorn CW, et al. Association of Human Immunodeficiency Virus Infection and Risk of Peripheral Artery Disease. Circulation 2018;138:255-265 1073. Dietrich T, Jimenez M, Krall Kaye EA, Vokonas PS, Garcia RI. Age-dependent associations between chronic periodontitis/edentulism and risk of coronary heart disease. Circulation 2008;117:16681674 1074. Carrizales-Sepulveda EF, Ordaz-Farias A, Vera-Pineda R, Flores-Ramirez R. Periodontal Disease, Systemic Inflammation and the Risk of Cardiovascular Disease. Heart Lung Circ 2018;27:1327-1334 1075. Ryden L, Buhlin K, Ekstrand E, et al. Periodontitis Increases the Risk of a First Myocardial Infarction: A Report From the PAROKRANK Study. Circulation 2016;133:576-583 1076. Qi J, Zihang Z, Zhang J, Park YM, Shrestha D, Jianling B, Merchant AT. Periodontal Antibodies and All-Cause and Cardiovascular Disease Mortality. J Dent Res 2020;99:51-59 1077. Beck JD, Eke P, Lin D, et al. Associations between IgG antibody to oral organisms and carotid intima-medial thickness in community-dwelling adults. Atherosclerosis 2005;183: 342–348 1078. Lee YL, Hu HY, Chou P, Chu D. Dental prophylaxis decreases the risk of acute myocardial infarction: a nationwide population-based study in Taiwan. Clin Interv Aging 2015;10:175-182 1079. Park SY, Kim SH, Kang SH, et al. Improved oral hygiene care attenuates the cardiovascular risk of oral health disease: a population-based study from Korea. Eur Heart J 2019;40:1138-1145 1080. Ayzenberg I., Katsarava Z., Sborowski A. et al. The prevalence of primary headache disorders in Russia: A countrywide survey. Cephalalgia. 2012; 32(5): 373–381 1081. Лебедева Е.Р., Кобзева Н.Р., Гилев Д.В., Олесен Ес. Анализ качества диагностики и лечения первичных головных болей в различных социальных группах Уральского региона. Неврология, нейропсихиатрия, психосоматика. 2015; 1: 19-26 336 1082. GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:954–976. doi: 10.1016/S1474-4422(18)30322-3 1083. Adelborg K, Szepligeti SK, Holland-Bill L, et al. Migraine and risk of cardiovascular diseases: Danish population based matched cohort study. BMJ 2018;360:k96 1084. Sacco S, Ornello R, Ripa P, Tiseo C, Degan D, Pistoia F, Carolei A. Migraine and risk of ischaemic heart disease: a systematic review and meta-analysis of observational studies. Eur J Neurol 2015;22:10011011 1085. Kurth T, Winter AC, Eliassen AH, et al. Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ 2016;353:i2610 1086. Schurks M, Rist PM, Bigal ME, et al. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 2009;339:b3914 1087. Mahmoud AN, Mentias A, Elgendy AY, et al. Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects. BMJ Open 2018;8:e020498 1088. Chang CL, Donaghy M, Poulter N. Migraine and stroke in young women: casecontrol study. The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. BMJ 1999;318:1318 1089. Champaloux SW, Tepper NK, Monsour M, et al. Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke. Am J Obstet Gynecol 2017;216:489 e481489 e487 1090. Sacco S, Kurth T. Migraine and the risk for stroke and cardiovascular disease. Curr Cardiol Rep 2014;16:524 1091. Sacco S, Merki-Feld GS, Ægidius KL, et al. Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC) [published correction appears in J Headache Pain. 2018 Sep 10;19(1):81]. J Headache Pain. 2017;18(1):108. Published 2017 Oct 30. doi:10.1186/s10194-017-0815-1 1092. Ornello R, Canonico M, Merki-Feld GS, et al. Migraine, low-dose combined hormonal contraceptives, and ischemic stroke in young women: a systematic review and suggestions for future research. Expert Rev Neurother 2020;20:313- 317 1093. Карпов Ю.А., Сорокин Е.В. Стабильная ишемическая болезнь сердца: стратегия и тактика лечения. 2-е изд., перераб. и доп. М.: Медицинское информационное агентство, 2012. 271 с 1094. Карпов Ю.А., Кухарчук В.В., Лякишев А. и др. Диагностика и лечение хронической ишемической болезни сердца. Практические рекомендации. Кардиологический вестник 2015; 3: 3–33. 1095. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Российское кардиологическое общество (РКО) https://doi.org/10.15829/29/1560-4071-2020-4076 1096. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502 337 1097. Wiviott SD, Braunwald E, McCabe CH, et al., TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015 1098. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057 1099. Schupke S, Neumann FJ, Menichelli M, et al, ISAR-REACT 5 Trial Investigators. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med 2019;381:1524-1534 1100. Navarese EP, Khan SU, Kolodziejczak M, et al. Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials. Circulation 2020;142:150-160 1101. Hahn JY, Song YB, Oh JH, et al, SMARTDATE investigators. 6-month versus 12- month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet 2018;391:1274-1284 1102. Mauri L, Kereiakes DJ, Yeh RW, et al, DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155-2166 1103. Bonaca M.P., Bhatt D.L., Cohen M., et al., for the PEGASUS-TIMI 54 Steering Committee and Investigators. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. N Engl J Med 2015; 372:1791-1800. DOI:10.1056/NEJMoa1500857 1104. Steg PG, Bhatt DL, Simon T, et al, THEMIS Steering Committee and Investigators. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. N Engl J Med 2019;381:1309-1320 1105. Оганов Р.Г., Симаненков В.И., Бакулин И.Г. с соавт. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика, 2019; 18 (1): 5-66. doi.org/10.15829/1728-8800-2019-1-5-66 1106. Multimorbidity: clinical assessment and management. National Guideline Centre. London (UK): National Institute for Health and Care Excellence (NICE); 2016. 23 p. (NICE guideline; no. 56) 1107. Forman DE, Maurer MS, Boyd C, et al. Multimorbidity in Older Adults With Cardiovascular Disease. J Am Coll Cardiol 2018;71:2149-2161. DOI: 10.1016/j.jacc.2018.03.022 1108. Tran J, Norton R, Conrad N, et al. Patterns and temporal trends of comorbidity among adult patients with incident cardiovascular disease in the UK between 2000 and 2014: A population-based cohort study. PLoS Med 2018;15:e1002513. DOI: 10.1371/journal.pmed.1002513 1109. Buddeke J, Bots ML, van Dis I, Liem A, Visseren FLJ, Vaartjes I. Trends in comorbidity in patients hospitalised for cardiovascular disease. Int J Cardiol 2017;248:382-388. DOI: 10.1016/j.ijcard.2017.06.106 1110. Dunlay SM, Chamberlain AM. Multimorbidity in Older Patients with Cardiovascular Disease. Curr Cardiovasc Risk Rep 2016;10:3. doi: 10.1007/s12170-016-0491-8 1111. Jani BD, Nicholl BI, McQueenie R, et al. Multimorbidity and co-morbidity in atrial fibrillation and effects on survival: findings from UK Biobank cohort. Europace 2018;20:f329-f336. doi: 10.1093/europace/eux322 338 1112. Tisminetzky M, Goldberg R, Gurwitz JH. Magnitude and Impact of Multimorbidity on Clinical Outcomes in Older Adults with Cardiovascular Disease: A Literature Review. Clin Geriatr Med 2016;32:227-246. doi: 10.1016/j.cger.2016.01.014 1113. Bell SP, Saraf AA. Epidemiology of Multimorbidity in Older Adults with Cardiovascular Disease. Clin Geriatr Med 2016;32:215-226. DOI: 10.1016/j.cger.2016.01.013 1114. Andersson C., Vasan R.S. Epidemiology of cardiovascular disease in young individuals. Nature Reviews |Cardiology, 2018 (15):.230-240. doi:10.1038/nrcardio.2017.154 1115. Hussaina A., Leea M., Ranab J., Virania S/S. Epidemiology and risk factors for stroke in young individuals: implications for prevention Curr Opin Cardiol 2021, 35:000–000 DOI:10.1097/HCO.0000000000000894 1116. Андреенко Е.Ю., Лукьянов М.М., Якушин С.С. с соавт. Ранняя кардиоваскулярная мультиморбидность в амбулаторной и госпитальной практике: возрастные характеристики и медикаментозное лечение пациентов (данные регистров РЕКВАЗА и РЕКВАЗА-КЛИНИКА). Кардиоваскулярная терапия и профилактика. 2020; 19(5): 195-204. doi:10.15829/1728-8800-2020-2672 1117. Бойцов С.А., Лукьянов М.М., Якушин С.С. с соавт. Регистр кардиоваскулярных заболеваний (РЕКВАЗА): диагностика, сочетанная сердечно-сосудистая патология, сопутствующие заболевания и лечение в условиях реальной амбулаторно-поликлинической практики. Кардиоваскулярная терапия и профилактика. 2014;13(6):44-50. doi.org/10.15829/1728-8800-2014-6-3-8 1118. Hall M, Dondo TB, Yan AT, Mamas MA, Timmis AD, Deanfield JE, Jernberg T, Hemingway H, Fox KAA, Gale CP. Multimorbidity and survival for patients with acute myocardial infarction in England and Wales: Latent class analysis of a nationwide population-based cohort. PLoS Med 2018;15:e1002501. DOI: 10.1371/journal.pmed.1002501 1119. Kim DH, Rich MW. Patient-Centred Care of Older Adults With Cardiovascular Disease and Multiple Chronic Conditions. Can J Cardiol 2016;32:1097-1107. DOI: 10.1016/j.cjca.2016.04.003 1120. Forouzanfar M.M., Afskin A., Alexander L.T. et al. GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, 2016; 388(10053):1659-1724 1121. Du Vaure C.B., Ravaud P., Baron G., et al. Potential workload in applying clinical practice guidelines for patients with chronic conditions and multimorbidity: a systematic analysis. BMJ Open 2016;6:e010119. DOI: 10.1136/bmjopen-2015- 010119 1122. Arnett D.A., Goodman R.A., Halperin J.L. et al. AHA/ACC/HHS Strategies to Enhance Application of Clinical Practice Guidelines in Patients With Cardiovascular Disease and Comorbid Conditions. Circulation. 2014;130: 1662- 1667.DOI: 10.1161/CIR.0000000000000128 1123. Cohen-Stavi C.J., Giveon S., Key C., et al. Guideline deviation and its association with specific chronic diseases among patients with multimorbidity: a crosssectional cohort study in a care management setting. BMJ Open 2021;11:e040961. DOI 10.1136/bmjopen-2020-040961 339 1124. Rahimi K, Lam CSP, Steinhubl S. Cardiovascular disease and multimorbidity: A call for interdisciplinary research and personalized cardiovascular care. PLoS Med 2018;15:e1002545. doi.org/10.1371/journal.pmed.1002545 1125. Кучма ВР. Основы формирования здоровья детей. Учебное пособие. Феникс 2016 1126. Kavey REW, Allada V, Daniels SR, et al. Cardiovascular Risk Reduction in High-Risk Pediatric Patients. A Scientific Statement From the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research. Endorsed by the American Academy of Pediatrics. Circulation 2006;114: 2710-2738 1127. Погосова НВ, Вергазова ЭК, Аушева АК, и соавт. Актуальные результаты работы центров здоровья России. Профилактическая медицина 2016; 6: 50- 58. doi: 10.17116/profmed201619550-58 1128. Погосова НВ, Кучма ВР, Юферева ЮМ, и соавт. Оказание медицинской помощи детскому населению в центрах здоровья для детей. Методические рекомендации. Москва 2017 1129. Тутульян ВА и соавт. Распространенность ожирения и избыточной массы тела среди детского населения РФ: мультицентровое исследование. Педиатрия 2015; 93(5): 28 1130. Varvarigou AA. Intrauterine growth restriction as a potential risk factor for disease onset in adulthood. J Pediatr Endocrinol Metab 2010; 23(3): 215-224 1131. Журавлёва ИВ. Здоровье подростков: социологический анализ. Москва. Институт социологии РАН. 2002.240с 1132. GATS глобальный опрос взрослого населения о потреблении табака. Российская Федерация 2009, страновой отчет. http://www.who.int/tobacco/surveillance/ru_tfi_gatsrussian_countryreport.pd f 1133. ВОЗ Европейское Региональное бюро. Неравенства в период взросления: гендерные и социально-экономические различия в показателях здоровья и благополучия детей и подростков. Исследование "Поведение детей школьного возраста в отношении здоровья" (HBSC): международный отчет по результатам исследования 2013/2014 гг. Копенгаген, Дания 2016. http://www.euro.who.int/__data/assets/pdf_file/0016/331711/HSBC-No.7- Growing-up-unequal-Full-Report-ru.pdf?ua=1 1134. Национальные рекомендации по профилактике сердечно-сосудистых заболеваний в детском и подростковом возрасте. Российский кардиологический журнал 2012 6 (98), приложение 1 1135. Report of commission on ending childhood obesity. World Health Organization 2016 1136. Lurbe E, Agabiti-Rosei E, Cruickshank JKб et al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. Journal of Hypertension 2016, 34: 1887-1920 DOI:10.1097/HJH.0000000000001039 1137. Daniels SR, Greer FR and the Committee on Nutrition. Lipid Screening and Cardiovascular Health in Childhood. Pediatrics 2008; 122;198-208 340 1138. Boney CM, Verma A, Tucker R, Vohr BR. Metabolic syndrome in childhood: Association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics 2005; 115(3): 290-296 1139. Whitaker RC. Predicting preschooler obesity at birth: the role of maternal obesity in early pregnancy. Pediatrics 2004; 114(1): 29-36 1140. Глобальная стратегия по кормлению детей грудного и раннего возраста. ВОЗ ЮНИСЕФ. 2003. http://www.who.int/publications/list/9241562218/ru/ 1141. Barker DJ, Osmond C, Forsen TJ, Kajantie E, Eriksson JG.Trajectories of growth among children who have coronary events as adults. N Engl J Med 2005; 353:(17): 1802-1809 1142. Rich-Edwards JW, Kleinman K, Michels KB, et al. Longitudinal study of birth weight and adult body mass index in predicting risk of coronary heart disease and stroke in women. BMJ 2005; 330(7500): 1115 1143. Kavey R-E.W., Daniels S.R., Lauer R.M., et al. American Heart Association Guidelines for Primary Prevention of Atherosclerotic Cardiovascular Disease Beginning in Childhood. Circulation 2003; 107; 1562-1566 1144. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Full Report 2012 1145. World Health Organization WHO Guidelines on Physical Activity and Sedentary Behaviour World Health Organization, Geneva (2020) License: CC BY-NC-SA 3.0 IGO https://apps.who.int/iris/handle/10665/336656 1146. de Ferranti SD, Steinberger J, Ameduri R, et al. Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association. Circulation. 2019 Mar 26;139(13):e603-e634.doi: 10.1161/CIR.0000000000000618 1147. Global Health 50/50. Gender and global health. https://globalhealth5050.org/gender-and-global-health (4 June 2021) 1148. Шаповалова Э.Б., Максимов С.А., Артамонова Г.В. Половые и гендерные различия сердечно-сосудистого риска. Российский кардиологический журнал. 2019;(4):99-104. https://doi.org/10.15829/1560-4071-2019-4-99-104 1149. Оганов Р.Г., Масленникова Г.Я. Гендерные различия кардиоваскулярной патологии. Кардиоваскулярная терапия и профилактика. 2012;11(4):101-104. https://doi.org/10.15829/1728-8800-2012-4-101-104 1150. Peters SAE, Muntner P, Woodward M. Sex Differences in the Prevalence of, and Trends in, Cardiovascular Risk Factors, Treatment, and Control in the United States, 2001 to 2016. Circulation 2019;139:1025-1035 1151. Lee CMY, Mnatzaganian G, Woodward M, Chow CK, Sitas F, Robinson S, Huxley RR. Sex disparities in the management of coronary heart disease in general practices in Australia. Heart 2019;105:1898-1904 1152. Cushman M, Shay CM, Howard VJ, et al, American Heart Association. Ten-Year Differences in Women’s Awareness Related to Coronary Heart Disease: Results of the 2019 American Heart Association National Survey: A Special Report From the American Heart Association. Circulation 2021;143:e239-e248 1153. Pelletier R, Khan NA, Cox J, et al, GENESIS-PRAXY Investigators. Sex Versus Gender-Related Characteristics: Which Predicts Outcome After Acute Coronary Syndrome in the Young? J Am Coll Cardiol 2016;67:127-135 341 1154. Bots SH, Groepenhoff F, Eikendal ALM, et al. Adverse Drug Reactions to Guideline-Recommended Heart Failure Drugs in Women: A Systematic Review of the Literature. JACC Heart Fail 2019;7:258-266 1155. Regitz-Zagrosek V, Seeland U. Sex and gender differences in clinical medicine. Handb Exp Pharmacol 2012:3-22 1156. Wehner GJ, Jing L, Haggerty CM, et al. Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie? Eur Heart J 2020;41:1249-1257 1157. Chung AK, Das SR, Leonard D, et al. Women have higher left ventricular ejection fractions than men independent of differences in left ventricular volume: the Dallas Heart Study. Circulation 2006;113:1597-1604 1158. Mauvais-Jarvis F, Bairey Merz N, Barnes PJ, et al. Sex and gender: modifiers of health, disease, and medicine. Lancet 2020; 396:565-582 1159. Engeland A, Bjorge T, Daltveit AK, et al. Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230,000 women in Norway. Eur J Epidemiol 2011;26:157-163 1160. Lykke JA, Langhoff-Roos J, Sibai BM, et al. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension 2009;53:944-951 1161. Skjaerven R, Wilcox AJ, Klungsoyr K, et al. Cardiovascular mortality after preeclampsia in one child mothers: prospective, population based cohort study. BMJ 2012;345:e7677 1162. Wilson BJ, Watson MS, Prescott GJ, Sunderland S, Campbell DM, Hannaford P, Smith WC. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ 2003;326:845 1163. Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 2009;373:1773-1779 1164. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010;16:347-363 1165. Morgan CL, Jenkins-Jones S, Currie CJ, Rees DA. Evaluation of adverse outcome in young women with polycystic ovary syndrome versus matched, reference controls: a retrospective, observational study. J Clin Endocrinol Metab 2012;97:3251-3260 1166. Venkataraman H, Sattar N, Saravanan P. Postnatal testing following gestational diabetes: time to replace the oral glucose tolerance test? Lancet Diabetes Endocrinol 2015;3:754-756 1167. Bonamy AK, Parikh NI, Cnattingius S, Ludvigsson JF, Ingelsson E. Birth characteristics and subsequent risks of maternal cardiovascular disease: effects of gestational age and fetal growth. Circulation 2011;124:2839-2846 1168. Lykke JA, Paidas MJ, Damm P, Triche EW, Kuczynski E, Langhoff-Roos J. Preterm delivery and risk of subsequent cardiovascular morbidity and type-II diabetes in the mother. BJOG 2010;117:274-281 1169. DeLay KJ, Haney N, Hellstrom WJ. Modifying Risk Factors in the Management of Erectile Dysfunction: A Review. World J Mens Health 2016;34:89-100 1170. Kessler A, Sollie S, Challacombe B, Briggs K, Van Hemelrijck M. The global prevalence of erectile dysfunction: a review. BJU Int 2019:[Online ahead of print] 342 1171. Ibrahim A, Ali M, Kiernan TJ, Stack AG. Erectile Dysfunction and Ischaemic Heart Disease. Eur Cardiol 2018;13:98-103 1172. Miner M, Nehra A, Jackson G, et al. All men with vasculogenic erectile dysfunction require a cardiovascular workup. Am J Med 2014;127:174-182 1173. Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol 2011; 58: 1378– 1385. 1174. Vlachopoulos C, Jackson G, Stefanadis C, Montorsi P. Erectile dysfunction in the cardiovascular patient. Eur Heart J 2013; 34: 2034–2046 1175. Chrysant SG. Antihypertensive therapy causes erectile dysfunction. Curr Opin Cardiol 2015;30:383-390 1176. Fan Y, Hu B, Man C, Cui F. Erectile dysfunction and risk of cardiovascular and allcause mortality in the general population: a meta-analysis of cohort studies. World J Urol 2018;36:1681-1689 1177. Imprialos KP, Stavropoulos K, Doumas M, Tziomalos K, Karagiannis A, Athyros VG. Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy. Curr Vasc Pharmacol 2018;16:130-142 1178. Osondu CU, Vo B, Oni ET, Blaha MJ, Veledar E, Feldman T, Agatston AS, Nasir K, Aneni EC. The relationship of erectile dysfunction and subclinical cardiovascular disease: A systematic review and meta-analysis. Vasc Med 2018;23:9-20 1179. Raheem OA, Su JJ, Wilson JR, Hsieh TC. The Association of Erectile Dysfunction and Cardiovascular Disease: A Systematic Critical Review. Am J Mens Health 2017;11:552-563 1180. Zhao B, Zhang W. Does erectile dysfunction independently predict cardiovascular events? It’s time to act on the evidence. Eur J Prev Cardiol 2018;25:1307-1311 1181. Gowani Z, Uddin SMI, Mirbolouk M, et al. Vascular Erectile Dysfunction and Subclinical Cardiovascular Disease. Curr Sex Health Rep 2017;9:305-312 1182. Montorsi P, Ravagnani PM, Galli S, et al. Association between erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right patient. Eur Urol 2006;50:721-731 1183. Shah NP, Cainzos-Achirica M, Feldman DI, et al. Cardiovascular Disease Prevention in Men with Vascular Erectile Dysfunction: The View of the Preventive Cardiologist. Am J Med 2016;129:251-259 1184. Gerbild H, Larsen CM, Graugaard C, Areskoug Josefsson K. Physical Activity to Improve Erectile Function: A Systematic Review of Intervention Studies. Sex Med 2018;6:75-89 1185. Young L, Cho L. Unique cardiovascular risk factors in women. Heart 2019;105:1656-1660 1186. Dam V, Onland-Moret NC, Verschuren WMM, et al, CREW-consortium. Cardiovascular risk model performance in women with and without hypertensive disorders of pregnancy. Heart 2019;105:330-336 1187. Grandi SM, Filion KB, Yoon S, et al. Cardiovascular Disease-Related Morbidity and Mortality in Women With a History of Pregnancy Complications. Circulation 2019;139:1069-1079 1188. Riise HKR, Sulo G, Tell GS, et al. Association Between Gestational Hypertension and Risk of Cardiovascular Disease Among 617 589 Norwegian Women. J Am Heart Assoc 2018;7:e008337 343 1189. Grandi SM, Reynier P, Platt RW, Basso O, Filion KB. The timing of onset of hypertensive disorders in pregnancy and the risk of incident hypertension and cardiovascular disease. Int J Cardiol 2018;270:273-275 1190. Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis. Diabetologia 2019;62:905-914 1191. Claesson R, Ignell C, Shaat N, Berntorp K. HbA1c as a predictor of diabetes after gestational diabetes mellitus. Prim Care Diabetes 2017;11:46-51 1192. Timpka S, Markovitz A, Schyman T, et al. Midlife development of type 2 diabetes and hypertension in women by history of hypertensive disorders of pregnancy. Cardiovasc Diabetol 2018;17:124 1193. Ding T, Hardiman PJ, Petersen I, Wang FF, Qu F, Baio G. The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis. Oncotarget 2017;8:96351-96358 1194. Liu J, Wu Q, Hao Y, et al. Measuring the global disease burden of polycystic ovary syndrome in 194 countries: Global Burden of Disease Study 2017. Hum Reprod 2021;36:1108-1119 1195. Shaw LJ, Bairey Merz CN, Azziz R, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health–National Heart, Lung, and Blood Institute sponsored Women’s Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008;93:1276-1284 1196. Muka T, Oliver-Williams C, Kunutsor S, et al. Association of Age at Onset of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes, Intermediate Vascular Traits, and All-Cause Mortality: A Systematic Review and Meta-analysis. JAMA Cardiol 2016;1:767-776 1197. Ding DC, Tsai IJ, Wang JH, Lin SZ, Sung FC. Coronary artery disease risk in young women with polycystic ovary syndrome. Oncotarget 2018;9:8756-8764 1198. Hong JS, Yi SW, Kang HC, et al. Age at menopause and cause-specific mortality in South Korean women: Kangwha Cohort Study. Maturitas 2007;56:411-419 1199. Zhao L, Zhu Z, Lou H, et al. Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis. Oncotarget 2016;7:33715-33721 1200. Wellons M, Ouyang P, Schreiner PJ, Herrington DM, Vaidya D. Early menopause predicts future coronary heart disease and stroke: the Multi-Ethnic Study of Atherosclerosis. Menopause 2012;19:1081-1087 1201. Ткачева О.Н., Котовская Ю.В., Рунихина Н.К., и соавт. Комплексная гериатрическая оценка у пациентов пожилого и старческого возраста с сердечно-сосудистыми заболеваниями. Экспертное мнение Российской Ассоциации Геронтологов и Гериатров. Кардиология. 2021;61(5):71-78. https://doi.org/10.18087/cardio.2021.5.n1349 1202. Ткачева О.Н., Котовская Ю.В., Рунихина Н.К., и соавт. Клинические рекомендации «Старческая астения». Российский журнал гериатрической медицины. 2020;(1):11-46. https://doi.org/10.37586/2686-8636-1-2020-11-46 1203. Ткачева О.Н., Котовская Ю.В., Рунихина Н.К., и соавт. Артериальная гипертония и антигипертензивная терапия у пациентов старших возрастных групп. Согласованное мнение экспертов Российской ассоциации геронтологов и гериатров, Антигипертензивной Лиги, Национального общества профилактической кардиологии. Рациональная Фармакотерапия 344 в Кардиологии. 2021;17(4):642-661 https://doi.org/10.20996/1819-6446-2021- 07-01 1204. Дедов ИИ, Шестакова МВ, Майоров АЮ. Алгоритмы специализированной медицинской помощи больным сахарным диабетом (клинические рекомендации,8-й выпуск.) Сахарный диабет 2017;20(1):1-112. DOI: 10.14341/DM20171S8 1205. Котовская Ю.В., Ткачева О.Н., Сергиенко И.В. Липидснижающая терапия для первичной профилактики у пациентов 75 лет и старше. Консенсус экспертов Российской ассоциации геронтологов и гериатров, Национального общества по изучению атеросклероза, Российского кардиологического общества, Ассоциации клинических фармакологов. Кардиология. 2020;60(6):119–132. https://doi.org/10.18087/cardio.2020.6.n1037 1206. Flicker L, McCaul KA, Hankey GJ, et al. Body Mass Index and Survival in Men and Women Aged 70 to 75. Journal of the American Geriatrics Society 2010;58:234– 241. doi:10.1111/j.1532-5415.2009.02677.x. 1207. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295:306-313 1208. ASCEND Study Collaborative Group, Bowman L, Mafham M, et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med 2018;379:1529-1539 1209. McNeil JJ, Wolfe R, Woods RL, et al, ASPREE Investigator Group. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med 2018;379:1509-1518 1210. Gaziano JM, Brotons C, Coppolecchia R, et al, ARRIVE Executive Committee. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 2018;392:1036-1046 1211. Abdelaziz HK, Saad M, Pothineni NVK, et al. Aspirin for Primary Prevention of Cardiovascular Events. J Am Coll Cardiol 2019;73:2915-2929 1212. Zheng SL, Roddick AJ. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Metaanalysis. JAMA 2019;321:277-287 1213. Mahmoud AN, Gad MM, Elgendy AY, Elgendy IY, Bavry AA. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur Heart J 2019;40:607-617 1214. Halvorsen S, Andreotti F, ten Berg JM, et al. Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis. J Am Coll Cardiol 2014;64:319-327 1215. Yusuf S, Joseph P, Dans A, et al, International Polycap Study 3 Investigators. Polypill with or without Aspirin in Persons without Cardiovascular Disease. N Engl J Med 2021;384:216-228 1216. Seidu S, Kunutsor SK, Sesso HD, et al. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials. Cardiovasc Diabetol 2019;18:70 1217. Brott T.G., Halperin J.L., Abbara S., et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS 345 Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Developed in Collaboration With the American Academy of Neurology and Society of Cardiovascular Computed Tomography. Circulation 2011; 124: 489-532 1218. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin inpatients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329– 1339 1219. Bhatt D.L., Steg P.G., Mehta S.R., et al., on behalf of the THEMIS Steering Committee and Investigators. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet 2019; 394: 1169-1180. doi: 10.1016/S0140-6736(19)31887-2 1220. Pogosova N, Bosch J, Bhatt DL, et al. Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis. Circulation. 2022;145(25):1875-1877. doi:10.1161/CIRCULATIONAHA.122.059405 1221. Mega J.L., Braunwald E., Wiviott S.D., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19 1222. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315. doi:10.1093/eurheartj/ehv320 1223. Kim B.K., Hong M.K., Shin D.H., et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). JACC 2012; 60: 1340-1348 1224. Feres F., Costa R.A., Abizaid A., et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 2013; 310: 2510–2522 1225. Gwon H.C., Hahn J.Y., Park K.W., et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 2012; 125: 505-513 1226. Schulz-Schupke S., Byrne R.A., Ten Berg J.M., et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J 2015; 36: 1252–1263 1227. Hiatt W.R., Bonaca M.P., Patel M.R., et al. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant 346 Clopidogrel on Efficacy and Safety. Circulation 2020; 142: 2219-2230. doi:10.1161/CIRCULATIONAHA.120.050465 1228. Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a metaanalysis of randomised trials. Lancet Gastroenterol Hepatol 2018;3:231 -241 1229. Agewall S, Cattaneo M, Collet JP, et al, ESC Working Group on Cardiovascular Pharmacology and Drug Therapy and ESC Working Group on Thrombosis. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J 2013;34:17081713, 1713a- 1713b 1230. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022 Feb 12;43(7):561-632. doi: 10.1093/eurheartj/ehab395 1231. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994;89:635-641 1232. Mok CK, Boey J, Wang R, et al. Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial. Circulation 1985;72:1059-1063 1233. Heneghan C, Ward A, Perera R, et al. Self-monitoring of oral antico- agulation: systematic review and meta-analysis of individual patient data. Lancet 2012;379:322-334 1234. Guimaraes HP, Lopes RD, de Barros ESPGM, et al. Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. N Engl J Med. 2020;383(22):2117-2126. doi:10.1056/NEJMoa2029603 1235. Shim CY, Seo J, Kim YJ, et al. Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: A randomized clinical trial [published online ahead of print, 2021 Feb 9]. J Thorac Cardiovasc Surg. 2021;S0022-5223(21)00228-2. doi:10.1016/j.jtcvs.2021.01.127 1236. Carnicelli AP, De Caterina R, Halperin JL, et al, ENGAGE AF-TIMI 48 Investigators. Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves. Circulation 2017;135: 1273-1275 1237. Philippart R, Brunet-Bernard A, Clementy N, et al. Prognostic value of CHA2DS2- VASc score in patients with ‘non-valvular atrial fibrillation’ and valvular heart disease: the Loire Valley Atrial Fibrillation Project. Eur Heart J 2015;36:1822-1830 1238. Philippart R, Brunet-Bernard A, Clementy N, et al. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project. Thromb Haemost 2016;115:1056-1063 1239. Siontis KC, Yao X, Gersh BJ, Noseworthy PA. Direct oral anticoagulants in patients with atrial fibrillation and valvular heart disease other than significant mitral stenosis and mechanical valves: a meta-analysis. Circulation 2017;135:714-716 1240. Brennan JM, Edwards FH, Zhao Y, O’Brien S, Booth ME, Dokholyan RS, Douglas PS, Peterson ED, DEcIDE AVR Research Team. Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. J Am Coll Cardiol 2012;60:971-977 347 1241. Rafiq S, Steinbruchel DA, Lilleor NB, et al. Antithrombotic therapy after bioprosthetic aortic valve implantation: warfarin versus aspirin, a randomized controlled trial. Thromb Res 2017;150:104-110 1242. Russo A, Grigioni F, Avierinos JF, et al. Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications. J Am Coll Cardiol 2008;51:1203-1211 1243. Butnaru A, Shaheen J, Tzivoni D, Tauber R, Bitran D, Silberman S. Diagnosis and treatment of early bioprosthetic malfunction in the mitral valve position due to thrombus formation. Am J Cardiol 2013;112:1439-1444 1244. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206-1214. doi:10.1056/NEJMoa1300615 1245. Nijenhuis VJ, Brouwer J, Delewi R, et al. Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med 2020;382:1696-1707 1246. Maes F, Stabile E, Ussia GP, et al. Meta-analysis comparing single versus dual antiplatelet therapy following transcatheter aortic valve implantation. Am J Cardiol 2018;122:310-315 1247. Brouwer J, Nijenhuis VJ, Delewi R, et al. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med 2020;383:1447-1457 1248. Rodes-Cabau J, Masson JB, Welsh RC, et al. Aspirin versus aspirin plus clopidogrel as antith- rombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (Aspirin Versus Aspirin Clopidogrel Following Transcatheter Aortic Valve Implantation) randomized clinical trial. JACC Cardiovasc Interv 2017;10:1357-1365 1249. Dangas GD, Tijssen JGP, Wohrle J, et al, GALILEO Investigators. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med 2020;382:120-129 1250. Dewilde WJ, Oirbans T, Verheugt FW, et al, WOEST Study Investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013;381:1107-1115 1251. Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016;375:2423-2434 1252. Lopes RD, Heizer G, Aronson R, et al, AUGUSTUS Investigators. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019;380:1509-1524 1253. Fiedler KA, Maeng M, Mehilli J, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISARTRIPLE Trial. J Am Coll Cardiol 2015;65:1619-1629 1254. Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet 2019;394:1335-1343 1255. Lamberts M, Gislason GH, Lip GY, et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoa- gulant: a nationwide cohort study. Circulation 2014;129:1577-1585 348 1256. Yasuda S, Kaikita K, Akao M, et al, AFIRE Investigators. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med 2019;381:1103- 1113 1257. Collet JP, Thiele H, Barbato E, et al, ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021;42:1289- 1367 1258. Dewilde WJ, Janssen PW, Kelder JC, et al. Uninterrupted oral anticoagulation versus bridging in patients with long- term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial. EuroIntervention 2015;11:381-390 1259. Lip GYH, Collet JP, Haude M, et al, ESC Scientific Document Group. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or under- going percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), AsiaPacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace 2019;21:192-193 1260. Caldeira D, David C, Santos AT, Costa J, Pinto FJ, Ferreira JJ. Efficacy and safety of low molecular weight heparin in patients with mechanical heart valves: systematic review and meta-analysis. J Thromb Haemost 2014;12:650-659 1261. Spyropoulos AC, Turpie AG, Dunn AS, et al, REGIMEN Investigators. Perioperative bridging therapy with unfractionated heparin or low-molecularweight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry). Am J Cardiol 2008;102:883-889 1262. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in Nonsurgical Patients Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: 195–226 1263. Konstantinides SV, Meyer G, Becattini C, et al., ESC Scientific Document Group, 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020 Jan 21;41(4):543-603. https://doi.org/10.1093/eurheartj/ehz405 1264. Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ 2011;342:d3036 1265. Agnelli G, Prandoni P, Becattini C, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003;139:19-25 1266. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003;362:523-526 349 1267. Iorio A, Kearon C, Filippucci E, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med 2010;170:1710-1716 1268. Schulman S, Granqvist S, Holmström M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 1269. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 1998;104:332-338 1270. Couturaud F, Sanchez O, Pernod G, et al; PADIS-PE Investigators. Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: the PADIS-PE randomized clinical trial. JAMA 2015;314:31-40 1271. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-2510 1272. Weitz JI, Lensing AWA, Prins MH, et al; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017;376:1211-1222 1273. Agnelli G, Buller HR, Cohen A, et al; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013;368:699- 708 1274. Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012;367:1979—1987 1275. Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012;366:1959-1967 1276. Andreozzi GM, Bignamini AA, Daví G, et al; SURVET Study Investigators. Sulodexide for the prevention of recurrent venous thromboembolism: the Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) study: a multicenter, randomized, double-blind, placebo-controlled trial. Circulation 2015;132:1891-1897 1277. Steffel J, Verhamme P, Potpara TS, et al.; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of nonvitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018;39:1330-1393 1278. Lee AY, Kamphuisen PW, Meyer G, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015;314:677-686 1279. Deitcher SR, Kessler CM, Merli G, et al. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006;12:389-396 1280. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153 1281. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002;162:1729-1735 350 1282. Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018;36:2017-2023 1283. Napolitano M, Saccullo G, Malato A, et al. Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study. J Clin Oncol 2014;32:3607-3612 1284. den Exter PL, Hooijer J, Dekkers OM, Huisman MV. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol 2011;29:2405-2409 1285. Dentali F, Ageno W, Becattini C, et al. Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis. Thromb Res 2010;125:518- 522 1286. World Health Organization. Adherence to long-term therapies: evidence for action. WHO Library Cataloguing-in-Publication Data, Geneva, WHO 2003 – 211 рр. 1287. Бойцов С.А., Марцевич С.Ю., Гинзбург М.Л., и соавт. Люберецкое исследование смертности больных, перенесших мозговой инсульт или транзиторную ишемическую атаку (ЛИС-2). Дизайн и оценка лекарственной терапии. Рациональная фармакотерапия в кардиологии. 2013;9(2):114-122 1288. Chowdhury R, Khan H, Heydon E. et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J, 2013, 34: 2940-2948 1289. Журавская Н. Ю., Кутишенко Н. П., Марцевич С. Ю., Лукина Ю. В., Гинзбург М. Л. от имени рабочей группы исследования “ЛИС-2” Изучение приверженности врачебным рекомендациям пациентов, перенесших мозговой инсульт. Роль тревоги и депрессии (результаты регистра ЛИС-2). Кардиоваскулярная терапия и профилактика, 2015; 14(2): 46-51 1290. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009;119:3028–3035 1291. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353: 487– 497 1292. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006;333:15 1293. Марцевич, С.Ю., Навасардян А.Р., Кутишенко Н.П., Захарова А.В. Оценка приверженности к приему новых оральных антикоагулянтов у пациентов с фибрилляцией предсердий по данным регистра ПРОФИЛЬ. РФК, 2014, 10(6): 625-30 1294. Morisky D. E., Green L. W., Levine D. M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24(1): 67-74 1295. Лукина Ю.В., Кутишенко Н.П., Марцевич С.Ю., Драпкина О.М. Разработка и валидизация новых опросников в медицине на примере шкалы приверженности лекарственной терапии. Рациональная фармакотерапия в кардиологии 2020; 17 (4): 576-583 1296. Лукина Ю.В., Гинзбург М.Л., Смирнов В.П., и соавт. Изучение факторов, формирующих отношение пациента к лечению, предшествовавшему госпитализации по поводу острого коронарного синдрома (данные 351 анкетирования в рамках регистра ЛИС). Рациональная фармакотерапия в кардиологии 2013;9(5):472-481 1297. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419 1298. Laufs U, Retting-Ewen V, Bohm M. Strategies to improve drug adherence. Eur Heart J, 2011, 32: 264-268 1299. Burroughs Pena MS, Rollins A. Environmental Exposures and Cardiovascular Disease: A Challenge for Health and Development in Low- and Middle-Income Countries. Cardiol Clin 2017;35:71-86 1300. Ревич Б.А. Мелкодисперсные взвешенные частицы в атмосферном воздухе и их воздействие на здоровье жителей мегаполисов. Проблемы экологического мониторинга и моделирования экосистем. 2018;29(3):53-78. DOI: 10.21513/0207-2564-2018-3-53-78 1301. Argacha JF, Mizukami T, Bourdrel T, Bind MA. Ecology of the cardiovascular system: Part II - A focus on non-air related pollutants. Trends Cardiovasc Med 2019;29:274-282 1302. Heat and health in the WHO European Region: updated evidence for effective prevention. Copenhagen: WHO Regional Office for Europe; 2021. Licence: CC BYNC-SA 3.0 IGO 1303. Haines A, Ebi K. The Imperative for Climate Action to Protect Health. N Engl J Med 2019;380:263-273 1304. WHO. Quantitative risk assessment of the effects of climate change on selected causes of death, 2030s and 2050s. Geneva: World Health Organization, 2014 1305. Ревич Б.А. Волны жары в мегаполисах и пороги их воздействия на смертность населения. Гигиена и санитария. 2017; 11: 1073–1078. DOI: http://dx.doi.org/10.18821/0016-9900-2017-96-11-1073-1078 1306. Hausfater Р., Megarbane B., Dautheville S. et al. Prognostic factors in nonexertional heat stroke. Intensive Care Med. 2010; 36 (2): 272–280 1307. Ревич, Б.А., Шапошников Д.А., Подольная М.А., Харькова Т.Л., Кваша Е.А. Волны жары как фактор риска преждевременной смертности населения. Проблемы прогнозирования. 2015;2: 56–67 1308. O'Riordan M., Barclay L. Traffic Exposure, Air Pollution Biggest Population-Level Triggers for MI. From Heartwire. Published online Feb 25, 2011. www.medscape.com/viewarticle/738001 1309. Huang C., Barnett A.G., Wang X., Tong S. Effects of extreme temperatures on years of life lost for cardiovascular deaths: a time series study in brisbane, Аustralia // Circ Cardiovasc Qual Outcomes. 2012; Vol. 1, №5(5): 609–614 1310. Смирнова М.Д., Фофанова Т.В., Яровая Е.Б., Агеев Ф.Т. Прогностические факторы развития сердечно-сосудистых осложнений во время аномальной жары 2010 г. (когортное наблюдательное исследование). Кардиологический вестник. 2016; 1 (9): 43–51. https://readera. ru/14334763 1311. Планы действий по защите здоровья населения от воздействия аномальной жары. Под редакцией Matthies F., Bickler G., Marin N. C., Hales S. – Копенгаген: Всемирная организация здравоохранения, Европейское региональное бюро, 2011.–66 c 1312. Смирнова М.Д., Свирида О.Н., Виценя М.В., Михайлов Г.В., Агеев Ф.Т. Эффективность российских медико-санитарных рекомендаций по 352 саногенному поведению в условиях аномальной жары. Кардиология. 2015; 5: 66–71. DOI: https://dx.doi.org/10.18565/cardio.2015.5.66-71 1313. O’Connor M., Kosatsky T. Systematic review: How efficacious and how practical are personal health protection measures recommended to reduce morbidity and mortality during heat episodes? For Ouranos (the Consortium on Regional Climatology and Adaptation to Climate Change) and the National Collaborating Centre for Environmental Health (NCCEH), 2008. – 76 pp 1314. Постановление Правительства РФ от 28 декабря 2021 г. N 2505 "О Программе государственных гарантий бесплатного оказания гражданам медицинской помощи на 2022 год и на плановый период 2023 и 2024 годов" (с изменениями и дополнениями) 1315. Приказ Министерства здравоохранения РФ от 1 июля 2021 г. N 698н "Об утверждении Порядка направления граждан на прохождение углубленной диспансеризации, включая категории граждан, проходящих углубленную диспансеризацию в первоочередном порядке" 1316. "Методическое пособие по проведению профилактического медицинского осмотра и диспансеризации определенных групп взрослого населения, углубленной диспансеризации для граждан, перенесших новую коронавирусную инфекцию (COVID-19)" (утв. Минздравом России), 2021 1317. Salzwedel A, Jensen K, Rauch B, et al. Effectiveness of comprehensive cardiac rehabilitation in coronary artery disease patients treated according to contemporary evidence based medicine: Update of the Cardiac Rehabilitation Outcome Study (CROS-II). Eur J Prev Cardiol. 2020; 27(16): 1756–1774 1318. Anderson L, Thompson DR, Oldridge N, Zwisler AD, Rees K, Martin N, Taylor RS. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2016:CD001800. 1319. van Halewijn G, Deckers J, Tay HY, van Domburg R, Kotseva K, Wood D. Lessons from contemporary trials of cardiovascular prevention and rehabilitation: A systematic review and meta-analysis. Int J Cardiol 2017;232:294-303 1320. Santiago de Araujo Pio C, Marzolini S, Pakosh M, Grace SL. Effect of Cardiac Rehabilitation Dose on Mortality and Morbidity: A Systematic Review and Metaregression Analysis. Mayo Clin Proc 2017;92:1644-1659 1321. Santiago de Araujo Pio C, Chaves GS, Davies P, Taylor RS, Grace SL. Interventions to promote patient utilisation of cardiac rehabilitation. Cochrane Database Syst Rev 2019;2:CD007131 1322. Jorstad HT, von Birgelen C, Alings AM, et al. Effect of a nurse-coordinated prevention programme on cardiovascular risk after an acute coronary syndrome: main results of the RESPONSE randomised trial. Heart 2013;99:1421-1430 1323. Jennings C, Kotseva K, De Bacquer D, et al, EUROACTION PLUS Study Group. Effectiveness of a preventive cardiology programme for high CVD risk persistent smokers: the EUROACTION PLUS varenicline trial. Eur Heart J 2014;35:1411-1420 1324. Wood DA, Kotseva K, Connolly S, et al, EUROACTION Study Group. Nursecoordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, clusterrandomised controlled trial. Lancet 2008;371:1999-2012 1325. Anderson L, Sharp GA, Norton RJ, et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database Syst Rev 2017;6:CD007130 353 1326. Jin K, Khonsari S, Gallagher R, et al. Telehealth interventions for the secondary prevention of coronary heart disease: A systematic review and meta-analysis. Eur J Cardiovasc Nurs 2019;18:260-271 1327. Anderson L, Oldridge N, Thompson DR, et al. Exercise based cardiac rehabilitation for coronary heart disease. J Am Coll Cardiol 2016; 67(1): 1–12 1328. Martin BJ, Hauer T, Arena R, et al. Cardiac rehabilitation attendance and outcomes in coronary artery disease patients. Circulation 2012; 126(6): 677–687 1329. Аронов Д.М., Красницкий В.Б., Бубнова М.Г. и др. Физические тренировки в комплексной реабилитации и вторичной профилактике на амбулаторнополиклиническом этапе у больных ишемической болезнью сердца после острых коронарных осложнений. Российское кооперативное исследование. Кардиология 2006; 9: 33-38 1330. McMahon SR, Ades AA, Thompson PD. The role of cardiac rehabilitation in patients with heart disease. Trends Cardiovasc Med 2017;27(6):420–426 1331. Sadeghi M, Shabib G, Gholamreza Masoumi G, et al. A Systematic Review and Meta-analysis on the Prevalence of Smoking Cessation in Cardiovascular Patients After Participating in Cardiac Rehabilitation. Curr Probl Cardiol 2021; 46(3):100719 1332. Rauch B, Davos CH, Doherty P, et al. The prognostic effect of cardiac rehabilitation in the era of acute revascularisation and statin therapy: A systematic review and meta-analysis of randomized and non-randomized studies – The Cardiac Rehabilitation Outcome Study (CROS). EJPC 2016; 23(18) 1914– 1939 1333. Shields GE, Wells A, Doherty P., et al. Cost-effectiveness of cardiac rehabilitation: a systematic review. Heart. Sep;104(17):1403-1410. doi: 10.1136/heartjnl-2017- 312809. Epub 2018 Apr 13. 1334. Hansen TB, Zwisler AD, Berg SK et al. Cost-utility analysis of cardiac rehabilitation after conventional heart valve surgery versus usual care. Eur J Prev Cardiol. 2017 May;24(7):698-707. doi: 10.1177/2047487317689908. Epub 2017 Jan 25. 1335. Bjarnason-Wehrens B, McGee H, Zwisler AD, et al. Cardiac rehabilitation in Europe: results from the European Cardiac Rehabilitation Inventory Survey. Eur J Cardiovasc Prevention & Rehabilitation 2010; 17(4): 410–418 1336. Benzer W, Rauch B, Schmid J-P, et al. Exercise-based cardiac rehabilitation in twelve European countries results of the European cardiac rehabilitation registry. Int J Cardiol. 2017. Feb 1;228:58-67. doi: 10.1016/j.ijcard.2016.11.059. Epub 2016 Nov 11 1337. Abreu A, Frederix I, Dendale P, et al. Standardization and quality improvement of secondary prevention through cardiovascular rehabilitation programmes in Europe: The avenue towards EAPC accreditation programme: A position statement of the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol. 2020. Jun 1;2047487320924912. doi: 10.1177/2047487320924912 1338. Приказ Министерства здравоохранения РФ от 31 июля 2020 г. N 778н "О Порядке организации медицинской реабилитации взрослых" Зарегистрировано в Минюсте РФ 25 сентября 2020 г. Регистрационный № 60039 354 1339. Аронов Д.М., Бубнова М.Г., Погосова Н.В. Реабилитация больных ишемической болезнью сердца на диспансерно-поликлиническом этапе. Кардиология 2006; 46(2): 86–99 1340. Аронов ДМ, Бубнова МГ, Иванова ГЕ. Организационные основы кардиологической реабилитации в России: современный этап. Кардиосоматика 2012; 4:46-54 1341. Hansen D, Abreu A, Ambrosetti M, et al. Exercise intensity assessment and prescription in cardiovascular rehabilitation and beyond: why and how: a position statement from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology, Eur J Prev Cardiol. 2022. Feb 19;29(1):230-245. doi: 10.1093/eurjpc/zwab007 1342. Hansen D, Dendale P, Coninx K, et al. The European Association of Preventive Cardiology Exercise Prescription in Everyday Practice and Rehabilitative Training (EXPERT) tool: A digital training and decision support system for optimized exercise prescription in cardiovascular disease. Concept, definitions and construction methodology. Eur J Prev Cardiol 2017;24:1017-1031 1343. Abell B, Glasziou P, Hoffmann T. The Contribution of Individual Exercise Training Components to Clinical Outcomes in Randomised Controlled Trials of Cardiac Rehabilitation: A Systematic Review and Metaregression. Sports Med Open 2017;3:19 1344. Ambrosetti M, Abreu A, Cornelissen V, et al. Delphi consensus recommendations on how to provide cardiovascular rehabilitation in the COVID-19 era. Eur J Prev Cardiol. 2021 May 14;28(5):541-557. doi: 10.1093/eurjpc/zwaa080. PMID: 33624042; PMCID: PMC7717287 1345. Moulson N, Bewick D, Selway T, et al. Cardiac Rehabilitation During the COVID19 Era: Guidance on Implementing Virtual Care. Can J Cardiol. 2020 Aug;36(8):1317-1321. doi: 10.1016/j.cjca.2020.06.006. Epub 2020 Jun 14. PMID: 32553606; PMCID: PMC7293761 1346. Thomas RJ, Beatty AL, Beckie TM, et al. Home-Based Cardiac Rehabilitation: A Scientific Statement From the American Association of Cardiovascular and Pulmonary Rehabilitation, the American Heart Association, and the American College of Cardiology. Circulation 2019;140(1):e69-e89 1347. Kraal JJ, Van den Akker-Van Marle ME, Abu-Hanna A, Stut W, Peek N, Kemps HMC. Clinical and cost-effectiveness of home-based cardiac rehabilitation compared to conventional, centre-based cardiac rehabilitation: Results of the FIT@Home study. EJPC 2017; 24(12) 1260–127 1348. Chong MS, Sit JWH, Karthikesu K, Chair SY. Effectiveness of technology-assisted cardiac rehabilitation: A systematic review and meta-analysis. Int J Nurs Stud 2021; 124: 104087 1349. Погосова Н.В., Салбиева А.О., Соколова О.Ю. и соавт. Эффективность программ вторичной профилактики с дистанционной поддержкой у пациентов с ишемической болезнью сердца и абдоминальным ожирением. Кардиология 2019; 59 (11): 21–30 1350. Ades PA, Keteyian SJ, Wright JS, et al. Increasing cardiac rehabilitation participation from 20% to 70%: a road map from the Million Hearts Cardiac Rehabilitation Collaborative. Mayo Clin Proc 2017; 92(2):234–242 355 1351. Giannuzzi P, Temporelli PL, Marchioli R, et al., GOSPEL Investigators. Global secondary prevention strategies to limit event recurrence after myocardial infarction: results of the GOSPEL study, a multicenter, randomized controlled trial from the Italian Cardiac Rehabilitation Network. Arch Intern Med 2008;168:2194- 2204 1352. Owolabi M.O., Thrift A.G., Mahal A. et al. Primary stroke prevention worldwide: translating evidence into action. Lancet Public Health 2022; 7: e74–85 1353. Arena R, Guazzi M, Lianov L et all «Healthy Lifestyle Interventions to Combat Noncommunicable Diseased - A Novel Nonhierarchical Connectivity Model for Key Stakeholders: A Policy Statement From the American Heart Association, European Society of Cardiology, European Association for Cardiovascular Prevention and Rehabilitation, and American College of Preventive Medicine. Mayo Clinic Proceedings 2015) Eur Heart J. 2015 Aug 14;36(31):2097-2109. https://pubmed.ncbi.nlm.nih.gov/26138925/ 1354. Паспорт национального проекта “Демография” от 24 декабря 2018 г. №16. URL: http://government.ru/info/35559 (20.03.2021). 1355. Шальнова С. А., Баланова Ю. А., Деев А. Д. и др. Интегральная оценка приверженности здоровому образу жизни как способ мониторинга эффективности профилактических мер. Профилактическая медицина. 2018;21(4):65-72. https://doi.org/10.17116/profmed201821465. 1356. Концевая А.В., Шальнова С.А., Драпкина О.М. Исследование ЭССЕ-РФ: эпидемиология и укрепление общественного здоровья. Кардиоваскулярная терапия и профилактика. 2021;20(5):2987. https://doi.org/10.15829/1728- 8800-2021-2987 1357. Федеральный закон о государственном регулировании производства и оборота этилового спирта, алкогольной и спиртосодержащей продукции и об ограничении потребления (распития) алкогольной продукции. 22 ноября 1995 года N 171-ФЗ. URL: http://www.consultant.ru/document/cons_doc_LAW_8368/. (23.10.2021). 1358. Федеральный закон “О внесении изменений в статью 16 Федерального закона “О государственном регулировании производства и оборота этилового спирта, алкогольной и спиртосодержащей продукции и об ограничении потребления (распития) алкогольной продукции” от 24.04.2020 N 145-ФЗ. [Электронный ресурс] URL: http://www.consultant.ru/document/cons_doc_ LAW_351160/. (23.10.2021) 1359. Постановление Правительства РФ от 27 сентября 2007 года № 612. [Электронный ресурс] URL: http://pravo.gov. ru/proxy/ips/?docbody=&nd=102116923. (15.06.2021). 1360. Мырзаматова А.О., Концевая А.В., Горный Б.Э. и др. Меры популяционной профилактики, направленные на снижение потребления алкоголя: международный опыт и перспективы усиления мер в Российской Федерации. Кардиоваскулярная терапия и профилактика. 2020;19(3):2566. doi:10.15829/1728-8800-20202566 1361. Муканеева Д.К., Концевая А.В., Анциферова А.А., Rippin H., Wickramasinghe K., Драпкина О.М. Исследование маркировки и продвижения готовых продуктов питания для детей до 3 лет в Российской Федерации. Профилактическая медицина. 2022;25(1):54-62 356 1362. Mozaffarian D, Afshin A, Benowitz NL, et al. Population approaches to improve diet, physical activity, and smoking habits: a scientific statement from the American Heart Association. Circulation 2012; 126: 1514–1563 1363. Chisholm D, Moro D, Bertram M, et al (2018). Are the “best buys” for alcohol control still valid? An update on the comparative cost-effectiveness of alcohol control strategies at the global level. J Stud Alcohol Drugs. 2018;79:514– 22. doi:10.15288/jsad.2018.79.514 1364. Wagenaar A, Tobler A, Komro K. Effects of alcohol tax and price policies on morbidity and mortality: a systematic review. Am J Public Health. 2010;100;11:2270-8. doi:10.2105/ AJPH.2009.186007 1365. Scarborough P, Adhikari V, Harrington RA. (2020) Impact of the announcement and implementation of the UK Soft Drinks Industry Levy on sugar content, price, product size and number of available soft drinks in the UK, 2015-19: A controlled interrupted time series analysis. PLoS Med 17(2): e1003025. https://doi.org/10.1371/journal.pmed.1003025 1366. Fiscal policy options with potential for improving diets for the prevention of noncommunicable diseases (NCDs). Geneva: World Health Organization. Accessed November 18, 2021. https://www.who.int/dietphysicalactivity/publications/fiscal-policiesdietprevention/en 1367. Lucan SC, Maroko AR, Jin Aet al Change in an urban food environment within a single year: Considerations for food-environment research and community health. Prev Med Rep. 2020;19:101-102. https://doi.org/10.1016/j.pmedr.2020.101102 1368. Marsh L, Vaneckova P, Robertson L, et al. Association between density and proximity of tobacco retail outlets with smoking: A systematic review of youth studies. Health Place. 2021 Jan;67:102-275. doi: 10.1016/j.healthplace.2019.102275 1369. Zhao X. Health communication campaigns: A brief introduction and call for Dialogue. International Journal of Nursing Sciences 7 (2020) S11eS15 1370. Crosby K. How the food and drug administration convinced teens to rethink their relationship with cigarettes. Am J Prev Med 2019 Feb 1;56(2):S1e4